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Abstract
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) 
are two devastating neurological disorders that share clinical, genetic and 
pathological overlap. The discovery of a hexanucleotide G4C2 repeat ex-
pansion in the chromosome 9 open reading frame 72 (C9ORF72) gene as a 
major cause of FTD and ALS confirmed the genetic link between these two 
neurodegenerative diseases, collectively referred to as C9FTD/ALS. Many 
different hypotheses about the possible pathogenic mechanisms of this 
repeat have been proposed, including haploinsufficiency leading to partial 
loss of function of the endogenous C9ORF72 protein product, RNA toxicity 
caused by RNA molecules or RNA foci that bind and sequester RNA-bind-
ing proteins or production of toxic dipeptide repeat proteins (DPR) by re-
peat-associated non-AUG initiated (RAN) translation of the repeat. In this 
introduction, we review both clinical and functional studies that support 
one or more of these possibilities. Identification of the pathological path-
ways underlying neurodegeneration could guide future research and lead 
to new treatments and is therefore of great importance for the FTD/ALS 
field.
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1. Clinical and genetic factors in the FTD/ALS spectrum
1.1 General clinical introduction
In 1892 the neuropsychiatrist Arnold Pick (1851-1924) described several cases 
of patients with FTD-like clinical features[1]. This was the basis of Pick’s Disease 
(PiD) but also of the entire spectrum of FTD[1]. FTD is a form of neurodegen-
erative presenile dementia with predominant frontal and anterior temporal lobe 
involvement[1]. The clinical picture consists of two different types of manifes-
tations: behavioral-variant FTD (bvFTD) or predominant language impairment 
variant, also called primary progressive aphasia (PPA)[2]. bvFTD is character-
ized by progressive behavioral and personality changes and executive dysfunc-
tion[2]. PPA can be further divided into fluent speech with impaired word find-
ing and comprehension, so-called semantic variant PPA (svPPA)[3]. PPA can 
also manifest in two forms of non-fluent speech: with agrammatism and some-
times apraxia of speech (nonfluent variant nfvPPA) or with word-finding prob-
lems and repetition (logopenic variant lvPPA)[3]. In all FTD forms, perception 
and memory are relatively preserved[4]. FTD is the second most common cause 
of dementia after Alzheimer’s disease (AD) for people younger than 65 years 
of age[5]. The prevalence of FTD is estimated at 15-22 in 100.000 people and 
the incidence at 2.7–4.1 in 100.000 people[6]. The survival time after symp-
toms start is very variable between patients and ranges from 3 to 14 years[6]. 
 ALS was first described by Jean-Martin Charcot in 1869 and is the most 
common form of motor neuron disease (MND) in which patients display signs 
of both upper and lower motor neuron (UMN and LMN) degeneration[7]. Other 
forms of motor neuron disease include primary lateral sclerosis (PLS), progres-
sive muscular atrophy (PMA) or progressive bulbar palsy (PBP)[7]. Symptoms 
include muscular spasticity, weakening, hyperreflexia, muscular atrophy, fascicu-
lations, speech and swallowing difficulties[8]. Patients with ALS can also develop 
psychological and cognitive difficulties, including depression, impaired executive 
functions, and problems with social behavior[8]. The prevalence of ALS is 5 per 
100.000 people and it has an incidence of 1.7 per 100.000 people[8]. The aver-
age life expectancy is two to five years and death is usually caused by respiratory 
failure[8, 9]. Two FDA approved drugs are available for ALS patients: Riluzole 
and Edaravone. Riluzole prolongs survival with a few months by decreasing glu-
tamate levels and delaying motor neuron damage[10]. However, Riluzole does 
not reverse neuronal damage nor halt the disease progress[10]. For Edaravone, 
the exact mechanism is unknown but it has antioxidant properties that could pro-
tect against oxidative stress in motor neurons in ALS[11].
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 FTD and ALS may seem very distinct diseases at first sight, but they are 
part of a disease spectrum. About 15% of FTD patients develop MND and about 
50% of MND patients show some signs of cognitive impairment[12]. The neuro-
psychological deficits in ALS can be extremely heterogeneous and impact patient 
survival[13]. The cognitive profile of FTD and ALS shows similarities, including 
deficits in social cognition, verbal memory, fluency and executive functions[14]. 
When specified for C9ORF72 repeat expansion carriers, 30% of FTD patients 
develop ALS symptoms and 27% of ALS patients show symptoms of FTD[15].
1.2 Genetic factors in the FTD and ALS spectrum
Family history is observed in up to 50% of FTD patients and in about 10% of 
ALS patients, implying a role for genetic factors in the development of both dis-
eases[16]. There are some ‘pure’ FTD and ‘pure’ ALS genes, including micro-
tubule-associated protein tau (MAPT) and progranulin (GRN) for FTD and su-
peroxide dismutase 1 (SOD1) for ALS[17]. Next to these ‘pure’ genes, the list of 
‘shared’ genes between FTD and ALS has become quite extensive in the past 10 
years (reviewed in [16, 18]). Trans-activation response element DNA-binding pro-
tein 43 encoding gene (TARDBP) and fused in sarcoma (FUS) are thought to be 
major ALS genes but are occasionally found in FTD patients as well[17, 19]. The 
other way around, the charged multivesicular body protein 2B gene (CHMP2B) 
is seen as FTD gene but there are some rare occurrences in ALS patients[20]. 
Mutations in C9ORF72, valosin-containing protein (VCP), P62/sequestosome-1 
(SQSTM1), ubiquilin 2 (UBQLN2), Optineurin (OPTN), Coiled-coil-helix-coiled-
coil-helix domain containing 10 (CHCHD10), TANK-binding kinase 1 (TBK1) and 
heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) and A2/B1 (HNRNPA2/
B1) are found in both disorders[16-20]. Variants in transmembrane protein 106 
B (TMEM106B) can modify the disease penetrance of FTD in GRN carriers and 
protects C9ORF72 repeat carriers from developing FTD, but not from developing 
MND[21].
 Linkage to a locus on chromosome 9 in the 9p21.2–p13.3 region for FTD 
and ALS was already found in 2006[20]. In 2011, the hexanucleotide G4C2 repeat 
expansion in the C9ORF72 gene was discovered as cause of FTD and ALS[22, 
23]. The C9ORF72 mutation accounts for 26% of FTD, 34% of ALS and 88% 
of familial FTD-ALS patients worldwide[15, 24]. In sporadic ALS, it accounts for 
about 6-9% and in sporadic FTD it is found in 5-10% of all cases[25, 26]. The 
C9ORF72 repeat expansion is thus the most common genetic cause of FTD 
and ALS[15, 25, 27]. The highest mutation frequencies were observed in Cauca-
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sian populations of Europe and North America with a peak in Finland, Sweden 
and Denmark[28]. The existence of a common northern European founder has 
been suggested[25, 29, 30], but haplotype analysis on Swedish C9ORF72 ex-
pansion mutation carriers indicates that the C9ORF72 expansion mutation arose 
on at least two risk haplotypes[31] and screening of Ashkenazi and North Africa 
Jews indicates the existence of two founder populations with the same risk hap-
lotypes[32].
1.3 Clinical phenotype of C9FTD/ALS
Patients harboring the C9ORF72 repeat expansion can develop FTD, ALS or both 
and are therefore associated with wide clinical diversity[24, 33-36]. C9ORF72 re-
peat expansion mutations leading to motor neuron disease symptoms is almost 
always classified as ALS (C9ALS) and only rarely with PLS, PMA or PBP[33, 37]. 
Around 70% of C9ALS cases display a spinal onset[23, 37]. C9ORF72 caused 
FTD (C9FTD) was in almost all of the cases enriched in the behavioral vari-
ant with most common symptoms being disinhibition, forgetfulness, anxiety and 
compulsive or stereotyped behavior[33, 34]. PPA is a fairly rare phenotype of 
C9ORF72 expansions[34]. Although FTD patients sometimes show Parkinson-
ism, the prevalence of the C9ORF72 repeat expansion in patients with Parkin-
son’s disease (PD) is lower than 1%[33, 34]. Also AD patients only rarely harbor a 
repeat expansion[33]. The mean age of onset of C9FTD/ALS is 57 years[35, 36]. 
Survival is longer in C9ORF72 patients diagnosed with FTD compared to ALS 
diagnosis and overall disease duration ranges from 1 to 22 years[24, 35, 36]. At 
the start of ALS symptoms, survival is dramatically reduced to an average of 1.8 
years[15, 36]. Neuronal loss and gliosis in the frontal and temporal cortical re-
gions of the brain are the major pathological changes in FTD patients[34, 38]. For 
ALS patients, motor neuron loss in the brainstem and spinal cord are observed in 
post-mortem brain sections[34, 37]. In addition to predominant atrophy in frontal 
and temporal areas, C9FTD patients show more thalamic, posterior insula and 
cerebellar atrophy than non-C9ORF72 FTD patients in imaging studies[34].
1.4 Effect of the C9ORF72 repeat size on clinical phenotype
The exact number of repeats that causes C9FTD/ALS has not been determined, 
but repeat sizes of 30 – 4400 have been reported so far[39]. Healthy individu-
als often carry alleles with 2, 8 or 24 repeats[39], but some controls have been 
identified with longer repeats[40], which might be explained by reduced pene-
trance that is reported for C9FTD/ALS[41]. Repeat sizes vary a lot between fam-
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ily members, even between monozygotic twins and different tissues of the same 
person[42-46]. Patients often have longer repeats in brain tissue than in DNA 
isolated from blood samples[42-46] and the repeat expansions in the cerebellum 
seem to be smaller and more stable[43]. There have been some reports of ALS 
and FTD cases with 20-30 repeats in blood[47, 48], but their repeat size could be 
longer in brain due to somatic mosaicism[42-46]. Associations between repeat 
size and FTD or ALS clinical diagnosis have not resulted in a clear picture[42-46], 
only intermediate allele sizes appear to specifically associate more frequently 
with neuropsychiatric phenotypes[49]. The age of onset is highly variable, rang-
ing from 27 to 83 years and is considered fully penetrant around the age of 80[25, 
41]. Genetic anticipation could play a role, based on the instability of expanded 
repeats that have the tendency to further increase in size with each generation 
and may lead to a younger age of onset. But so far, multiple studies indicate that 
the repeat size can both extend or shorten over generations[42, 44, 50]. Correla-
tions between repeat size and age of onset, disease progression or survival have 
been reported[42-46]. However, repeat sizes measured in blood are very variable 
and correlations could rely on the confounding factor age at collection[42]. Thus, 
the exact repeat size that triggers disease onset and the influence of repeat size 
on many clinical characteristics is unknown and seems to be personal and highly 
variable.
2. Pathological features of C9FTD/ALS
Post-mortem brain and spinal cord tissue of patients with C9FTD/ALS harbors 
some characteristic pathological features such as RNA foci and protein aggre-
gates containing: dipeptide repeats (DPRs), autophagy protein p62/sequesto-
some 1 (p62) and phosphorylated 43kDa TAR DNA-binding protein (pTDP-43). In 
this section, we describe their amount, cellular localization pattern and spreading 
throughout the central nervous system (CNS). We shortly introduce the mecha-
nism of RAN translation and more specific the production of DPRs. Information 
about possible correlation with clinical features, neurodegeneration or co-local-
ization between pathological features are discussed in chapter 6 (general dis-
cussion).
2.1 RNA foci
The presence of RNA foci in postmortem brain tissue from C9FTD/ALS patients 
was first described by DeJesus-Hernandez at the discovery of the C9ORF72 
G4C2 repeat expansion[22]. This initial report has been confirmed and quantified 
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by multiple studies since then[51]. The precise content of RNA foci is unclear. 
They might contain only G4C2 repeat RNA, the spliced intron 1 or the complete 
C9ORF72 (pre-)mRNA. Increased levels of sense and antisense C9ORF72 
mRNA containing intron 1 were found in frontal cortex of C9FTD cases[52, 53]. 
Downstream introns seem to be correctly spliced out[54]. Intron 1 retention of 
polyadenylated C9ORF72 mRNA in the cytoplasm and nucleus has also been 
identified in frontal cortex of C9FTD/ALS cases[54]. However, it remains unclear 
if these intron 1-containing mRNA molecules can form RNA foci. In the rest of 
this thesis and in most studies, probes were used to visualize sense G4C2 or 
antisense C4G2 repeats.
 Both sense and antisense foci are observed throughout the CNS (figure 
1): in frontal cortex (average 25% of cells containing sense foci, 15% antisense)
[22, 55-58], hippocampus dentate gyrus (average 30% sense, 17% antisense)
[56, 59, 60] and cornu ammonis (average 60% sense, 43% antisense, only 1 
study[60]), spinal cord (average 44% sense, 72% antisense)[22, 51, 60, 61] and 
cerebellum granular layer (average 35% sense, 4% antisense)[56, 58, 60, 61] 
and Purkinje cells (average 63% sense, 80% antisense)[58, 60]. Foci were also 
observed in the cingulate cortex, striatum, inferior temporal gyrus, entorhinal 
cortex, pre- and post-central gyrus, medial pulvinar thalamus and calcarine cor-
tex[59]. Sense foci seem to be more common than antisense foci in most brain 
areas, only Purkinje cells and spinal cord motor neurons contain more antisense 
foci[51]. Foci are sometimes also found in astrocytes, oligodendrocytes, microg-
Figure 1: Distribution of RNA foci over several brain areas. A) Both sense and antisense RNA foci 
(red dots) are present in nuclei (blue) of C9FTD post-mortem frontal cortex but not in non-demented 
controls. Scale bars are 10µm. B) Quantification of the number of cells harboring sense and antisense 
RNA foci in several brain areas. Error bars are standard error of the mean (SEM). Values are based 
on data from publications [22, 51, 55-61]. 
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lia and peripheral blood leukocytes[55, 56]. Motor and cortical neurons generated 
from induced pluripotent stem cells (iPSCs) also contain foci[62]. Fibroblasts from 
symptomatic and asymptomatic C9ORF72 repeat carriers contain foci as well[61, 
63]. In general, foci are predominantly localized in the nucleus and only sparsely 
in the cytoplasm[56, 58]. The number of foci per nucleus is usually low (1-3) but 
occasionally higher, especially for antisense foci[56, 58]. Sense and antisense 
foci can sometimes be found together in the same nucleus, but not necessary 
in the same spot. Around 14% of all nuclei in the frontal cortex, 7% of nuclei in 
the hippocampus and 3% of nuclei in the cerebellum contained both sense and 
antisense foci[56]. Co-localization of sense and antisense foci occurred for less 
than 15% nuclei in frontal cortex, hippocampus and cerebellum[56] and for 18% 
in spinal cord[51]. Any correlations between clinical features and the number of 
foci or their abundance in certain brain areas have not yet been determined. Cor-
relation studies with other pathological features are also not yet performed. 
2.2 RAN translation and DPR proteins
Repeat-associated non-AUG (RAN) translation was first described by Zu et al. 
in 2011 for spinocerebellar ataxia type 8 (SCA8) and myotonic dystrophy type 
1 (DM1)[64]. By now, RAN proteins have also been reported in fragile X-asso-
ciated tremor/ataxia syndrome (FXTAS), Huntington’s disease (HD), DM type 2 
(DM2) and SCA type 31 and 37 (SCA31/37)[65]. In 2013, it was shown that RAN 
translation also occurs in cases with the C9ORF72 repeat expansion[57, 66, 67]. 
RAN translation occurs in all reading frames of sense and antisense transcripts 
resulting in 6 different DPRs: poly-glycine-alanine (GA), poly-glycine-proline (GP) 
and poly-glycine-arginine (GR) from the sense strand and poly-proline-alanine 
(PA), poly-proline-arginine (PR) and poly-proline-glycine (PG) from the antisense 
strand. Note that poly-GP and -PG contain similar repeated amino acids but can 
have a different N- and C-terminus. All RAN products were shown to be pres-
ent in post-mortem brain tissue of C9FTD/ALS cases (figure 2)[52, 55, 57, 66, 
67]. C-terminal specific antibodies were produced for almost all DPR, except for 
the antisense poly-PG DPR that harbors a stop codon immediately after the re-
peat[52, 55]. Expression of FMRpolyG (one of the RAN product of FXTAS) with 
its C-terminus in primary mouse cortical neurons and Drosophila models was 
more toxic than expression of FMRpolyG without C-terminus[68]. The possible 
toxicity of N- or C-termini of RAN products in C9FTD/ALS is yet unknown but 
might also influence DPR toxicity.
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Figure 2: DPR pathology in C9FTD cases. 
Frontal cortex post-mortem brain sections from 
C9FTD patients shows perinuclear DPRs stained 
with DAB (brown). Non-demented control fron-
tal cortex did not contain any DPRs. Slides were 
counterstained with mayers heamatoxylin to visu-
alize cell nuclei (blue). All scale bars are 20µm.
 Ash et al. were the first to quantify the presence of DPR inclusions in 24 
brain regions of 30 cases of C9FTD/ALS and found widespread neuronal cyto-
plasmic and small round intranuclear inclusions[67]. Since then, the presence of 
DPRs has been confirmed many times[51, 69]. For a detailed overview of the pa-
thology, see the recent review of Vatsavayai who made a list of all 17 studies that 
have investigated DPR pathology so far[51]. In general, DPRs are most abun-
dant in cortexs, hippocampus (especially cornu ammonis), amygdala, thalamus 
and cerebellum granular layer. DPRs are less often observed in basal ganglia, 
brain stem nuclei and spinal cord[51]. To date, no DPRs have been found in as-
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trocytes, microglia and oligodendrocytes[51], but they are present in ependymal 
and subependymal cells of the lateral ventricle[70]. Sense products are more fre-
quent than antisense products and the order of abundance is poly-GA, -GP and 
–GR, -PA and –PR[51]. Several studies quantified absolute numbers of DPRs in 
several brain areas, but use different methods which makes it hard to combine 
results[69-73]. Furthermore, reported numbers of poly-GA aggregates vary from 
averages of 7 to 82 per mm2 in the frontal cortex[69, 73]. Poly-GP and –GR vary 
from 11-23 and 4-14 aggregates per mm2 in the frontal cortex[69, 73]. Absolute 
numbers of DPRs in spinal cord anterior horn are consistently low[69, 71]. Most 
DPRs are round or star-like neuronal cytoplasmic (NCI) inclusions, but can also 
be found as neuronal intranuclear inclusions (NII), dystrophic neurites (DNs) and 
diffuse cytoplasmic staining[51]. 
 Different DPRs can be produced in the same cell and have been found 
to co-localize in hippocampal and cerebellar neurons[52]. Poly-GR neuronal 
cytoplasmic inclusions in these areas co-localized with poly-PR or poly-PA for 
about 5-18%[52]. Poly-GA has been reported to sequester poly-GR into aggre-
gates[74]. The different DPRs all have different biophysical properties, which can 
influence their localization and aggregation pattern. Poly-GA is very hydrophobic, 
insoluble and aggregation prone and can form filamentous structures[75] In con-
trast poly-GP is very soluble[76]. Poly-GR and -PR are positively charged, which 
could influence their interactions with other proteins[77]. The possible toxicity of 
DPRs is discussed in part 5 of the introduction.
 The mechanism of RAN translation and factors needed to evoke this 
newly identified translation mechanism are largely unknown. Known factors influ-
encing RAN translation are the upstream human flanking region that may contain 
some AUG-like start codons, repeat length and expression levels, but these fac-
tors can be different per reading frame[55, 57, 66, 78]. Poly-GA expression has 
been detected in constructs with repeat sizes of 38 or higher, suggesting that the 
translation mechanism has a certain repeat length threshold[66, 79]. Poly-GP 
products were only detected at very long repeat sizes (~145 repeats)[66]. Fur-
thermore, frame shifting can produce combined DPRs in one product[80]. Sev-
eral reports show that RAN translation is cap- and eIF4A-dependent[81, 82] but 
cap-independent translation initiation can also cause DPR expression[83]. More 
insight into the mechanism of RAN translation may provide suggestions for new 
therapeutic strategies, as new drugs that target this process could lower the ex-
pression levels of DPRs and thereby limit the impact of DPRs.
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2.3 pTDP-43 and p62 pathology
TDP-43 is an RNA-binding protein involved in many cellular functions includ-
ing splicing regulation and translational repression[93, 94]. Patients carrying the 
C9ORF72 repeat expansion display pTDP-43 inclusions, which can be neuronal 
cytoplasmic and/or intranuclear[51, 84]. pTDP-43 is predominantly found in ar-
eas that are known to display substantial neurodegeneration[85-87]. In C9FTD 
patients, pTDP-43 aggregates are present in the frontal and temporal regions 
of the cerebral cortex and also in subcortical structures, including striatum, hip-
pocampus, basal ganglia, and substantia nigra[84, 90]. pTDP-43 pathology in 
C9FTD is usually categorized as type B, with moderate amount of NCI and a few 
DNs in all layers[51, 84, 90]. However, pTDP-43 inclusion load is variable and 
sometimes even undetectable[27, 91]. C9ALS patients present with NCI pTDP-
43 in the spinal cord and extensive microglial pathology in the medulla and motor 
cortex[51, 92]. Almost all neurons with cytoplasmic pTDP-43 aggregates show 
nuclear clearing of TDP-43[88, 89].Knock-out of mouse homologue TAR DNA 
binding protein (TARDBP) causes embryonic lethality and partial knock-down of 
TDP-43 causes motor neuron loss and a motor phenotype in mice[93, 94], indi-
cating the importance of TDP-43.
 In addition to pTDP-43-positive neuronal and glial inclusions, C9FTD/
ALS patients exhibit ubiquitin- and p62-positive, pTDP-43-negative neuronal and 
cytoplasmic inclusions[51]. Binding of ubiquitin to a substrate protein can cause 
degradation via the proteasome, but can also affect cellular location, activity and 
protein interactions. P62, also called sequestosome 1, has multiple functions in-
volved in the degradation of proteins. Once the polyubiquitin chain of a substrate 
protein binds to p62, it is transported to the proteasome for degradation. P62 is 
also involved the autophagic/lysosomal pathway by binding aggregated proteins 
prior to their inclusion in autophagosomes[95]. P62 pathology in C9FTD/ALS has 
a wider distribution than pTDP-43 pathology, extending to the pyramidal cell layer 
of the hippocampus, cortex, thalamus, basal ganglia, and cerebellum, where they 
far exceeded the number of pTDP-43 inclusions[36, 37]. After the identification 
of DPRs in aggregates in the brain of C9FTD/ALS patients, it became evident 
that DPRs were present in p62-positive/p-TDP-43-negative inclusions[51]. Dou-
ble immunolabeling revealed co-localization of p62 and poly-GA in 75% of the 
inclusions and about 10% of all p62 inclusions were also positive for poly-AP and 
-PR staining[52].
 The role of pTDP-43 and ubiquitin inclusions in the pathogenesis of the 
C9ORF72 repeat expansion is not clear; they are believed to be harmful but 
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Figure 3: The C9ORF72 gene with the G4C2 repeat expansion, its RNA transcripts and protein 
isoforms. The G4C2 repeat expansion is shown as red diamond and is located between two non- 
coding exons of the C9ORF72 gene (exon 1a and exon 1b, light blue). RNA variant 1 is predicted to 
result in a short C9ORF72 protein of 222 amino acids (exons 2–5, isoform B), whereas RNA variants 
2 and 3 encode a long C9ORF72 protein of 481 amino acids (exons 2–11, isoform A). Image adjusted 
with permission from Gendron et al., 2017[98] Copyright @ Cold Spring Harbor Press.
could also be a protective cell mechanism that has been proposed to cope with 
protein toxicity[96]. The co-localization with RNA foci and the relationship be-
tween DPRs and pTDP-43 is unknown and needs further investigation. Knowl-
edge about the order of pathological events might give new insight in the patho-
genesis of C9FTD/ALS.
Pathological mechanisms of C9FTD/ALS
Three possible pathological mechanisms have been proposed to explain the 
pathogenic effect of C9ORF72 repeat expansions; first, haploinsufficiency may 
lead to a partial loss of function of the endogenous C9ORF72 protein product 
(part 3 of the general introduction). Secondly, RNA toxicity can be caused by the 
sequestration of RNA-binding proteins (RBPs) (part 4). Finally, production of t 
DPRs by RAN translation of the G4C2 repeat can be toxic(part 5). In these parts of 
the introduction, we will focus on functional studies that could tell us more about 
the pathological mechanisms implicated in C9FTD/ALS.
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3. Loss of function
3.1 Expression pattern of the C9ORF72 gene
The C9ORF72 gene is located on chromosome 9p21 and consists of 11 exons. 
Pre-mRNA transcript variants 2 and 3 encode C9ORF72-long protein (isoform 
A, 481 amino acids, exons 2-11), and transcript variant 1 encodes C9ORF72-
short protein (isoform B, 222 amino acids, exons 2-5). The hexanucleotide ex-
pansion is located between exon 1a and 1b. This is part of the promoter region 
of transcript variant 2 or in the first intron of transcripts 1 and 3 (figure 3). All 
three transcript variants of the C9ORF72 mRNA are present in a large variety of 
tissues; kidney, lung, liver, heart, testis, lymphoblasts, brain; cerebellum, fron-
tal cortex, hippocampus[22], temporal cortex, hypothalamus, medulla, occipital 
cortex, putamen, spinal cord, thalamus, white matter and substantia nigra[23]. 
Expression of C9ORF72 is also high in CD14+ myeloid cells, involved in immuni-
ty[97]. Especially variant 2 is highly expressed in the CNS[97].
 Xi et al. detected two cytosine-phosphate-guanine (CpG) islands imme-
diately flanking the hexanucleotide repeat of C9ORF72, but only the region 5’ of 
the repeat revealed evidence of hypermethylation[99]. This 5’ CpG island was 
significantly more methylated in C9ALS expansion carriers versus non-C9ORF72 
ALS cases and healthy controls[77]. Another study found that hypermethylation 
extended into the repeat expansion and is associated with reduced expression of 
C9ORF72 mRNA[100]. Demethylation by 5-aza-2-deoxycytidine (5-AZA) or bro-
modomain-inhibitor treatment of patient derived fibroblasts increased C9ORF72 
mRNA expression[101, 102]. Histone methylation can also reduce gene expres-
sion and can be influenced by age[101] and oxidative stress[103]. Histones that 
are trimethylated at lysine residues strongly bind to C9ORF72 expanded repeats 
in frontal cortex and cerebellum tissue, but not to control length repeats[101]. Hy-
permethylation has been associated with reduced RNA foci, DPR levels and re-
duced neuronal and gray matter loss in patients with C9FTD/ALS[104, 105]. But 
the effect of hypermethylation is still under debate, as it has been linked to later 
age-of-onset and a longer survival of C9FTD/ALS patients in some studies[44, 
106] but reduced disease duration before death in another study[99]. 
 The reduction of C9ORF72 mRNA transcripts has been validated by 
multiple studies and occurs in blood lymphocytes, iPSC derived neurons, frontal 
cortex, motor cortex, cerebellum and spinal cord of C9ORF72 carriers[77]. The 
reduction in mRNA levels is on average 50% compared with controls[27, 107]. 
Sense and antisense pre-mRNA transcripts upstream of the repeat and tran-
scripts that contain intron 1 are elevated[53, 77, 98], and seem to terminate in the 
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repeat[55]. Higher levels of transcript 1 in the frontal cortex and cerebellum are 
associated with increased survival[53], which might implicate a role for the short 
isoform of the C9ORF72 protein in neuronal survival.
 Next to mRNA levels, C9ORF72 protein levels also seem to be reduced 
in the cerebellum of C9ORF72 repeat carriers[108]. However, no associations 
between cerebellar protein levels and clinical phenotypes were observed[108]. 
Some studies found almost 50% reduction in the frontal cortex, occipital cortex 
but not in the motor cortex nor cerebellum[72, 109]. The long isoform (C9-L) 
seems to be the predominant expressed isoform, but expression levels are very 
low[108]. An antibody against C9-L shows a diffuse cytoplasmic staining in neu-
rons and labeled large speckles in cerebellar Purkinje cells[110]. In human iPSC 
derived motor neurons, C9-L localized to lysosomes and pre-synapses[108]. The 
short isoform (C9-S) is more difficult to detect but a localization along the nuclear 
membrane has been reported[110]. Aberrant localization of C9-S to the plasma 
membrane was observed in diseased motor neurons of post-mortem spinal cord 
sections of C9ALS patients[110]. The different localization of the two C9ORF72 
protein isoforms could implicate that they have different cellular functions.
3.2 Cellular function of the C9ORF72 protein
The C9ORF72 gene is highly conserved between vertebrate species[111]. The 
hexanucleotide expansion itself is only conserved within primates but the genom-
ic site is also conserved between mouse and human (58.3%)[111]. This could in-
dicate an important regulatory function of this genomic area[111]. The C9ORF72 
protein is a homologue of ‘differentially expressed in normal and neoplastic cells’ 
(DENN) proteins, which are Rab-GDP/GTP exchange factors (GEFs)[112]. GEFs 
interact with the GDP-bound, inactive form of Rabs and exchange GDP for GTP 
to activate the Rab. Rabs are small GTPases, important in signal transduction, 
endo- and exocytosis and intracellular (vesicle) trafficking. Membrane trafficking 
can be fine-tuned by the modulation of Rab activity[113]. Some DENN domains 
interact with one Rab while mediating GEF activity of a second Rab, so DENN 
domains may be the link between different Rab cell signaling pathways[114]. Im-
portantly, several DENN domain proteins have been linked to neurodegenera-
tion[115, 116]. 
 Knock-down of C9ORF72 protein in HeLa, HEK295 and SY5Y cells and 
primary murine neurons inhibits autophagy and causes p62 and pTDP-43 ag-
gregation[117, 118]. Overexpression of C9ORF72 protein in the same cell lines 
increases the amount of autophagosomes[117]. Especially the long isoform of 
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C9ORF72 protein seems to be implicated in autophagy[118]. C9ORF72 protein 
binds SMCR8 and WDR41 and together with these proteins exchanges GDP for 
GTP of several Rabs (Rab1a, 3, 5, 7, 8a, 11 and 39b have all been implicated)
[108, 117-121]. In this way, C9ORF72 protein regulates Rab-dependent traffick-
ing of the ULK1 autophagy initiation complex to the phagophore [117, 118, 120]. 
SMCR8 is phosphorylated by TBK1, which might enhance C9ORF72 GEF activ-
ity and autophagy[118]. Loss-of-function mutations in TBK1 are also associated 
with FTD and ALS[122]. Impaired autophagy and enhanced sensitivity to auto-
phagy inhibitors is also observed in iPSC derived neurons from C9FTD/ALS pa-
tients[117, 123, 124], which was rescued by increasing autophagy with an SRC-
ABL pathway inhibitor[125].
 Next to its function in autophagy, C9ORF72 protein also plays a role in 
endosomal and lysosomal trafficking. Reduced endocytosis and reduced traf-
ficking of endosomal vesicles was observed after knock-down of C9ORF72 pro-
tein in neuronal cell cultures[121] and in patient fibroblasts and iPSC derived 
neurons[124]. C9ORF72 protein interacts with endosomes and was required for 
normal intracellular vesicle trafficking in iPSC derived motor neurons of C9ALS 
patients[126]. These motor neurons also showed reduced number of lysosomes 
compared with motor neurons of controls[126]. Furthermore, motor neurons also 
show accumulation of glutamate receptors and enhanced sensitivity to excitotox-
icity[126, 127].
3.3 Animal models of C9ORF72 loss-of-function
To study loss of C9ORF72 in vivo, Therrien et al. created a null mutation in the 
C. elegans C9ORF72 orthologue F18A1.6, also called alfa-1[128]. Alfa-1 null mu-
tants are morphologically normal but develop age-dependent paralysis, similar 
to ALS models expressing TDP-43 and FUS proteins in C. elegans motor neu-
rons[129]. The motor phenotype is probably caused by the loss of GABAergic 
motor neurons, which coordinate body movement in worms[128]. Alfa-1 mutants 
were highly sensitive to osmotic stress, which led to increased motor neuron 
degeneration[128].
 Knockdown of the zebrafish orthologue of C9ORF72 (zC9ORF72) by two 
specific antisense morpholino oligonucleotides causes locomotion deficits and 
results in major morphological abnormalities[130]. Similar to previous genetic 
models of ALS in zebrafish (TDP-43, FUS and SOD1)[131, 132], knockdown of 
zC9ORF72 resulted in shortened and disturbed arborization of motor neuron ax-
ons[130]. Touch-evoked escape response and spontaneous swimming was also 
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deficient in a large percentage of the morpholino-injected zebrafish (morphants)
[130]. All phenotypes were rescued by the introduction of human C9ORF72 
mRNA long transcript, illustrating specificity of the knockdown[130].
 Next to the research in worms and fish, 10 C9ORF72 knock-out mouse 
models have been published to date. For a list and overview of these studies, 
please see the recent review of Balendra & Isaacs[77]. In all studies, hetero-
zygous mice are completely normal, only homozygous knock-out mice have a 
reduced live span[77]. Homozygous knock-out mice show immune system dys-
regulation, enlarged spleen and lymph nodes, increased levels of cytokines and 
changes in the number of myeloid and lymphoid cells[77]. Transcriptomics con-
firmed changes in immune pathways, also observed in the CNS of C9FTD/ALS 
patients[133]. Interestingly, C9FTD/ALS patients show an increased prevalence 
of autoimmune disease[134, 135]. None of the mouse models show neuronal 
loss and FTD or ALS phenotypes[77], only some mild late-onset motor and cogni-
tive defects have been found in two models[136, 137]. This suggests that haplo-
insufficiency is not sufficient to cause C9FTD/ALS symptoms. The function of the 
C9ORF72 protein in both autophagy and endosome and lysosome function and 
trafficking might influence disease progression. Future research will be needed to 
elucidate interactions between loss- and gain-of-function mechanisms in C9FTD/
ALS.
4. RNA gain of function
The possibility of a RNA toxic gain of function mechanism was already proposed 
at the discovery of the C9ORF72 repeat expansion by DeJesus-Hernandez et 
al.[22] and Renton et al.[23] in 2011. The mechanism of RNA gain-of-function 
is well known from other repeat disorders[62]. In myotonic dystrophy 1 the ex-
panded CUG repeat sequesters muscleblind-like 1 (MBNL1), causing abnormal 
splicing of key transcripts in muscle and brain. The resulting toxicity can be sup-
pressed by boosting MBNL protein expression[138]. The G4C2 expansion in the 
C9ORF72 gene might work in a similar manner. It can form multiple secondary 
structures that can bind and sequester several proteins, summarized below.
4.1 Secondary structures of the G4C2 repeat
The sense strand of the G4C2 repeat is capable of forming G-quadruplexes (a 
stack of G-quartets on a square configuration) both on DNA and RNA level[78, 
139-141]. A graphic interpretation of the secondary structures are shown in figure 
4. G-quadruplexes have been known to occur in telomeric regions, but have now 
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Figure 4: Schematic representation of secondary structures formed by the G4C2 repeat ex-
pansion on DNA and RNA level. Hairpins and G-quadruplexes (a stack of G-quartets on a square 
configuration) can be present on both DNA and RNA level. Transcribed repeat RNA can bind to repeat 
DNA and form R-loops, a three-strand structure formed by a DNA:RNA hybrid plus a displaced DNA 
strand. The C-rich antisense sequence might also be able to form I-motifs, a four-stranded second-
ary structure, on DNA and RNA level. Secondary structures can lead to genomic and transcriptional 
instability and cause DNA damage. Image adjusted with permission from Haeusler et al., 2017.[62] 
Copyright @ Nature reviews neuroscience.
also been shown to occur in promotor and intronic regions of more than hundred 
genes[142]. G-quadruplexes can influence multiple biological processes includ-
ing transcription, alternative splicing, translation regulation, genetic instability, 
telomere regulation and RNA transport and degradation[140, 143]. Interestingly, 
G-quadruplexes located in the 3’ UTR of mRNAs can alter the localization of 
mRNAs to dendrites via interaction with the FMRP protein[144]. However, the 
presence of G-quadruplexes in vivo is not confirmed yet due to the lack of vi-
sualization techniques[142]. Transcribed G4C2 repeat RNA can bind to C4G2 re-
peat DNA or vice versa and form R-loops, a three-strand structure formed by a 
DNA:RNA hybrid plus a displaced DNA strand[139, 145]. Formation of R-loops 
can cause transcription disruption and genome instability[62, 139, 145]. The 
C-rich antisense sequence might also be able to form I-motifs, a four-stranded 
secondary structure, on DNA and RNA level[146, 147]. G4C2 repeat-containing 
RNA may even form more structures, like hairpins[78, 139], stem-loops and RNA 
duplexes[62, 77]. 
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4.2 Sequestration of proteins by RNA foci
Repeat-containing RNA or secondary RNA structures can be bound by sever-
al RNA-binding proteins. The secondary structure of the C9ORF72 repeat can 
influence the binding affinity to several proteins, for example nucleolin and Ran-
GAP preferentially bind G-quadruplexes but hnRNP-H binds both hairpins and 
G-quadruplexes[62]. Several studies using pull-down or proteomic arrays have 
delivered large lists of G4C2 repeat RNA-binding proteins, which sometimes show 
overlap[62]. Binding of important cellular proteins to C9ORF72 repeat RNA or 
their sequestration in RNA foci can cause depletion of these proteins and subse-
quent dysfunction of cellular processes. We summarized proteins that specifically 
have been shown to co-localize with RNA foci in table 1. Some proteins have 
been validated to co-localize with RNA foci in C9FTD/ALS patient iPSC derived 
neurons or in post-mortem brain sections of C9FTD/ALS patients. We will shortly 
introduce these proteins.
 ADARB2 was found to interact with 5’Cy5-labeled 6.5x G4C2 repeat RNA 
hybridized to a protein array and co-localizes with sense foci in C9ALS iPSC 
derived neurons[107]. Knockdown of ADARB2 leads to a 50% reduction of sense 
RNA foci in iPSC derived neurons, which might indicate that ADARB2 enables 
the formation or stabilization of RNA foci[107]. C9ALS iPSC derived neurons 
show enhanced sensitivity to glutamate, and knock-down of ADARB2 in control 
iPSC derived neurons causes the same phenotype[107]. This suggests that the 
sequestration of ADARB2 in RNA foci of C9ALS patients could lead to enhanced 
vulnerability to glutamate of C9ALS iPSC derived neurons[107]. ADARB2 is part 
of the RNA editing family which performs post-transcriptional deamination of ad-
enosine to inosine (A-I) of mRNAs and one of the targets of ADAR proteins is the 
Q/R site of the GluR2 AMPA receptor[156]. 
 ALYREF was found to bind 5x G4C2 biotinylated RNA in a pull-down ex-
periment using whole cell and nuclear extract of SH-SY5Y cells and extract of 
dissected human cerebellum[61]. Cooper-Knock found 26% co-localization of 
sense RNA foci with ALYREF in cerebellar granule cells and 29% co-localiza-
tion in motor neurons of C9ALS cases[61]. In another study they showed 7.8% 
co-localization with antisense foci in cerebellar Purkinje neurons of C9ALS pa-
tients[60]. ALYREF is a nuclear protein that functions as a molecular chaperone 
and is involved in the nuclear export of spliced RNAs[157].
 By far the biggest group of RNA-binding proteins known to bind G4C2 re-
peat RNA is the heterogeneous nuclear ribonucleoprotein group (hnRNP). Exam-
ples are hnRNP-A1[150, 151], -A2/B1[123, 150], -A3[150], -H[152, 158], -F[139], 
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-K[139], -L[150] and –U[139]. Sequestration of these proteins can lead to splicing 
alterations of many genes[62]. hnRNP-A1 and -A3 are known to shuttle between 
nucleus and cytoplasm and function in pre-mRNA splicing, nuclear import and cy-
toplasmic trafficking of mRNA, mRNA stability and turnover and translation[150]. 
Cooper-knock found 27% co-localization of sense RNA foci with hnRNP-A1 in 
cerebellar granule cells[61] and 21% with antisense foci in cerebellar Purkinje 
neurons in post-mortem brain tissue of C9ALS patients[60]. C9FTD/ALS cas-
es show a reduction in nuclear staining of hnRNP-A3 and the appearance of 
dot-like nuclear and cytoplasmic inclusions in neurons[150]. About 20 percent 
of p62-positive inclusions co-localized with hnRNP-A3 staining in hippocampus 
dentate gyrus (DG) of both C9FTD and C9FTD/ALS[150]. Lee et al. (2013) found 
hnRNP-H in pull-down experiments with biotinylated 48x G4C2 repeat RNA[152]. 
hnRNP-H co-localized with about 70% of sense RNA foci in C9ALS/FTD patient 
cerebellum[152]. hnRNP-H is a splicing factor that is necessary to include exon 
7 into the mature TARBP2 RNA, it strongly binds to G-rich intronic sequences to 
enhance exon skipping and it can also bind G-rich RNA quadruplexes[152]. Sa-
reen et al. (2013) found that RNA foci frequently co-localized with hnRNP-A1 and 
Pur-alpha in C9ALS iPSC derived neurons, but could not confirm involvement of 
hnRNP-A3 and -A2/B1[151]. The hnRNP protein family contains an RNA recog-
nition motif also present in pTDP-43 and FUS[62]. HnRNP-A1 and –A2/B1 are 
known binding partners of TDP-43[159] and were recently linked to ALS[160]. In 
conclusion, the involvement of the hnRNP protein family seems obvious, but the 
contribution of each individual protein it is not clear yet.
 Pur-alpha is another G4C2 RNA binding protein that was found to co-lo-
calize with RNA foci in C9ALS iPSC-derived motor neurons[151] and in a ze-
brafish model for C9ORF72 repeat toxicity[154]. Pur-alpha was also found in 
intranuclear inclusions in the molecular layer of the cerebellum of C9FTD cases, 
although these were sometimes also observed in non-demented controls[153]. 
Pur-alpha is a DNA- and RNA-binding protein implicated in the initiation of DNA 
replication, DNA repair, control of transcription, mRNA translation and cell cycle 
regulation[161]. Moreover, it is critical for postnatal brain development and is in-
volved in the transport of specific mRNAs to the synapse[161]. 
 Nucleolin was found to bind the G4C2 G-quadruplex structure and co-lo-
calized with foci in motor cortex of C9FTD/ALS patients[139]. C9ALS iPSC de-
rived neurons[139] and C9-BAC primary mouse neurons showed dispersion of 
nucleolin from the nucleolus[162]. Lymphoblastoid cell lines, fibroblasts and iPSC 
derived neurons from C9ALS patients showed a disturbed nucleolus and more 
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processing-bodies, indicative of nucleolar stress[139]. Some studies have shown 
that RNA foci sometimes surround the nucleolus and form a so called ‘peri-nu-
cleolar’ studding pattern[51, 59, 163, 164]. Especially antisense foci were found 
to surround the nucleolus, and did so more often in disease relevant brain ar-
eas[164]. Neurons with sense foci positioned around their nucleoli exhibited larg-
er nucleoli than cells without peri-nucleolar localization of sense foci[163]. How-
ever, another study investigated hippocampus cornu ammonis (CA) and frontal 
cortex of C9FTD cases and healthy controls and did not find any difference in 
the size of the nucleoli[70]. Thus, peri-nucleolar studding remains an enigmatic 
phenomena that awaits further study.
 G4C2 repeat RNA associates with paraspeckle proteins and RNA like 
SFPQ and hLinc-p21[165]. Paraspeckles are ribonuclear bodies with unknown 
function, but they could affect post-transcriptional processes and cause nuclear 
retention of RNA’s[165]. An increase in paraspeckle bodies has been reported 
in the early phase of motor neuron degeneration in ALS[166]. Ran-GAP is also 
capable of binding G4C2 RNA[107] and is found to co-localize with G4C2 RNA foci 
in C9ALS iPSC derived neurons and mis-localizes in C9ALS motor cortex[155]. 
Expression of Ran-GAP rescued repeat toxicity in Drosophila eyes and motor 
neurons[155]. This indicates the involvement of nucleocytoplasmic transport in 
C9FTD/ALS pathogenesis[155].
 Finally, serine-arginine-rich splicing factor 2 (SRSF2, alternative name 
SF2) and serine-arginine-rich splicing factor 35 (SC35) are both found to co-local-
ize with G4C2 RNA foci in SH-SY5Y cells transfected with 48x G4C2 repeat[152], 
but rarely (<5%) co-localized with G4C2 RNA foci in cerebellum of C9FTD/ALS 
patients[152]. In another study, SRSF2 showed a higher percentage (33%) of 
co-localization with RNA foci in cerebellar granule cells and in motor neurons 
(30%) of C9ALS patients[61]. SRSF2 also co-localizes with antisense foci, for 
34% in Purkinje neurons of C9ALS cases[60]. SRRSF2 and SC35 ensure the 
accuracy of splicing and regulating alternative splicing, which again indicates that 
important splicing factors can be sequestered by RNA foci.
 All of the above and in table 1 mentioned proteins that are known to 
bind RNA foci have a function in RNA processing. This can be at the initiation of 
transcription (eIF2α and β), chromatin remodeling (nucleolin) and transcription 
control (pur-alpha, FUS). Next are factors involved in splicing of mRNAs (FUS, 
hnRNP-A1, -A3, ILF2/3, SC35, SRSF2, SF2), exon skipping (hnRNP-H, SRSF2, 
SF2) or other modifications (ADARB2). Also mRNA transport (FUS, hnRNP-A1, 
-A3) and export out of the nucleus (ALYREF, Ran-GAP) can be affected by pro-
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teins that are sequestered in RNA foci. Finally, proteins that function in cytoplas-
mic trafficking of mRNAs (hnRNP-A1, -A3), mRNA stability (hnRNP-A1, -A3) and 
translation (hnRNP-A1, -A3, pur-alpha) can also be sequestered by RNA foci. 
Analyses of transcriptome changes in iPSC derived neurons[107, 151] and dif-
ferent brain areas of C9FTD/ALS cases[107, 158, 167] revealed aberrant gene 
expression and splicing. Together, this could implicate that RNA toxicity of the 
G4C2 repeat expansion mainly works via the sequestration of factors involved in 
RNA processing.
5. DPR toxicity
The impact of DPRs on cellular functioning has been studied extensively. In this 
part of the introduction, we first describe studies that examine DPR toxicity and 
later focus on downstream mechanism underlying their toxicity. To complete the 
picture of gain-of-function mechanisms, we will also summarize all gain-of-func-
tion mouse models.
5.1 Direct toxicity of different DPRs
To study the toxicity of DPRs without the relative contribution of RNA gain-of-
function mechanisms, Mizielinska was the first to change the G4C2 repeat se-
quence into alternative codons that contain A or T nucleotides but encode the 
same dipeptides[168]. Multiple cell and animal models have now indicated the 
detrimental effect of expression of the arginine-containing DPRs, poly-GR and 
poly-PR[77, 168] and the slightly less toxic poly-GA[75, 77]. Synthetic poly-GA, 
-GR and –PR are toxic to primary neurons and cultured human astrocytes[169, 
170]. Transfection of constructs encoding DPRs into different cell lines indicates 
that of all DPRs, especially poly-GR and poly-PR are toxic[171-174]. Not all of 
these studies found an effect of poly-GA, but some others focused only on po-
ly-GA and confirmed its toxicity in vitro[75, 175]. When expressed in Drosophila 
models, poly-GR and –PR caused reduced survival, a locomotor phenotype and 
severe eye degeneration[74, 168, 171, 176-178]. Poly-GA only caused a mild re-
duction in survival in one of these studies[168], and poly-PA and poly-GP did not 
show toxic effects in Drosophila[168, 171, 177]. In zebrafish, expression of po-
ly-GR caused developmental abnormalities and reduced locomotor activity and 
survival[179]. Also expression of poly-GA evoked toxic effects in zebrafish[180].
 Even though these studies clearly show a toxic effect of DPRs, caution 
is required with interpretation, as they often use overexpression systems which 
might not reflect the endogenous mechanisms that occur in C9FTD/ALS patients.
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5.2 Downstream mechanisms
DPRs can bind many proteins and molecules in the cell and thus affecting multiple 
molecular pathways. To date, an overwhelming amount of different downstream 
mechanisms implicated in the pathogenesis of DPRs have been reported. We will 
summarize these processes and will mainly focus on the effect of poly-GR, – GA 
and -PR, since they are considered to be the most toxic dipeptides (as discussed 
above).
 Poly-GR and poly-PR are capable of binding to proteins that contain 
low-complexity domains (LCDs)[176, 181]. Many RNA-binding proteins, such as 
TDP-43 and FUS, contain LCDs[182]. LCD proteins can form droplets by liq-
uid-liquid phase separation. In this way, LCD proteins can form membrane-less 
organelles, such as nucleoli, the nuclear pore complex and stress granules. 
DPRs can disturb this process and have been shown to alter the dynamics of 
stress granules[173, 176, 183]. Nucleolar stress can also lead to splicing and 
mRNA translation defects[173, 176]. Nucleocytoplasmic transport (NCT) defects 
are often found in Drosophila models of C9ORF72[155, 177, 178]. Knock-down 
of several LCD proteins rescues the eye phenotype in Drosophila that express 
poly-GR[176].
 Interactome studies indicate that poly-GR and poly-PR can bind many 
RNA-binding proteins, nucleolar proteins, hnRNPs and spliceosome components 
and thereby disrupt splicing[173, 174, 184]. Especially the U2 small nuclear ri-
bonucleoprotein (snRNP) is found in many interactome studies[176, 181, 184] 
and is mis-localized in the cytoplasm of C9FTD and C9ALS iPSC derived motor 
neurons[184]. Splicing alterations are found in postmortem brain tissue of C9ALS 
patients[158] and 50% of these are U2 snRNP-dependent[184]. Poly-GR and 
–PR accumulated in the nucleolus in cultured cells, primary neurons, astrocyte 
cultures, C9FTD/ALS iPSC derived neurons and Drosophila, leading to altered 
nucleolar morphology[70, 163, 169, 171, 173, 185]. Nucleolar changes have also 
been observed in C9FTD/ALS patients[163], that is, overall smaller neuronal nu-
cleoli were observed but nucleoli were larger in neurons that contained poly-GR 
aggregates[163]. 
 The aberrant formation of RNA-binding protein complexes and altered 
splicing processes due to expression of poly-GR and –PR may affect ribosomal 
RNA maturation and ribosome biogenesis[169]. Poly-GR and -PR can also di-
rectly bind to mRNAs, ribosomal proteins and translation initiation factors and as 
a consequence block translation[174]. Translation inhibition and accumulation 
of poly-A mRNA have been shown in both NSC34 and HeLa cell lines[149, 174, 
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176]. Poly-GR co-localized with hnRNP-A1, an RNA-binding protein, in post-mor-
tem brain sections of C9ALS patients[174] and altered the biophysical properties 
of hnRNP-A1 in vitro[176]. Furthermore, overexpression of poly-GR and poly-PR 
caused stress granule formation in HeLa cells[149, 176, 183] and primary neu-
rons[171]. Stress granules are cytoplasmic aggregates of RNAs and proteins 
with stalled translation pre-initiation complexes and are a marker of translation 
arrest. 
 Next to affecting RNA metabolism, poly-GR and –PR also affect nucleo-
cytoplasmic transport. This can occur in multiple ways. First, splicing of Ran-GAP 
was found to be altered[169]. Second, importins, NUPs and the lamin B receptor 
can bind to poly-GR and –PR which might reduce their functionality[176, 186, 
187]. Poly-PR can even directly bind to the nuclear pore and reduce traffick-
ing through the pore[187]. Third, NCT factors can localize to stress granules, 
which can disrupt nucleocytoplasmic transport[188]. Inhibition of stress granule 
assembly rescued NCT defects and neurodegeneration in C9ALS iPSC derived 
neurons and a Drosophila model[188]. iPSC derived neurons of C9ALS patients 
show reduced nucleocytoplasmic Ran gradient and the nuclear import of proteins 
and export of RNAs was reduced[155, 177]. Ran-GAP, Nup107 and Nup205 were 
also found as perinuclear aggregates and showed nuclear retention in the motor 
cortex of C9ALS patients[155]. Finally, several screens have identified NCT as 
modifier of poly-GR and poly-PR toxicity in yeast[189] and Drosophila[178].
 To date, mitochondrial and DNA damage are only linked to poly-GR. Po-
ly-GR can directly bind to mitochondrial proteins[186]. DNA damage and oxida-
tive stress were higher in iPSC derived motor neurons from C9FTD and C9ALS 
patients compared with controls[186]. Expression of poly-GR in control derived 
iPSC motor neurons was sufficient to cause DNA damage, which was rescued 
by reduction of oxidative stress using antioxidant treatment[186]. An increase 
in DNA damage has also been reported in spinal cord neurons of C9ALS pa-
tients[145, 190].
 Poly-GA toxicity probably acts via the ubiquitin-proteasome system 
(UPS). Poly-GA interacts with proteasomal subunits, ubiquitin related proteins 
ubiquilin 1 and 2 and Unc119[175]. Unc119 is a transport factor linked to neu-
romuscular and axonal function[175]. Unc119 overexpression partially rescues 
poly-GA toxicity in primary neurons and co-localizes with 9.5% of poly-GA in-
clusions in the frontal cortex, but only with 1.6% of poly-GA inclusions in the 
cerebellum of C9FTD/ALS patients[175]. Expression of poly-GA in HEK293T and 
neuro2a cells[172] and primary mouse cortical neurons caused increased p62 
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expression and accumulation of ubiquitinated proteins[75]. In these cell models, 
proteasome activity was decreased and ER stress induced[75]. Neuro2a cells 
expressing poly-GA were more sensitive to UPS inhibition[172]. Interestingly, ER 
stress inhibitors provided protection against poly-GA toxicity[75]. The other way 
around, iPSC derived neurons of C9ALS patients were more sensitive to ER 
stress inducers[139].
 Thus, DPRs probably affect multiple cellular pathways simultaneously. 
Poly-GR and –PR bind many proteins involved in splicing and the translational 
machinery. Furthermore, they seem to impact nucleocytoplasmic transport by 
direct binding to importins, nups and the nuclear pore itself. Next to these direct 
effects, DPRs also influence the formation of membrane-less organelles, which 
further impairs the function of the nucleolus, the nuclear pore and stress gran-
ules. The role of poly-GR in mitochondrial and DNA damage is recently being 
recognized and not completely understood yet. Finally, poly-GA mainly impacts 
the UPS, which further enhances the involvement of aberrant cellular stress 
response. Further research is needed to complete the picture of downstream 
mechanisms involved in the pathogenesis of C9FTD/ALS and to identify possible 
targets for drug development.
5.3 Mouse models of C9ORF72 gain-of-function 
In 2015, Chew et al. published the first gain-of-function mouse model[191] (mouse 
models are summarized in table 2). This model was generated by AAV-virus 
driven expression of 66x pure G4C2 repeats injected in the ventricle of wildtype 
C57BL/6J mice. After 6 months, about 50% of neurons contained sense RNA foci 
and sense DPRs were present in cortex and hippocampus. Both foci and DPRs 
were less frequent in cerebellum and spinal cord. Mice developed a behavioral 
and motor phenotype in the open field test and on the rotarod. When sacrificed 
at 6 months, brain weight was reduced and neurodegeneration was observed in 
the whole cortex and in Purkinje cells specifically. pTPD-43 pathology was also 
sparsely observed. This mouse model was the first to recapitulate the symptoms 
seen in C9FTD/ALS patients and has proven that expression of 66 pure G4C2 
repeats is enough to evoke this phenotype, thereby supporting a gain-of-function 
mechanism. 
 Next, four BAC mouse models have been published in which both ex-
pression levels and expression pattern of the C9ORF72 repeat expansions re-
flect the human situation[136, 162, 192, 193]. All of the BAC mouse models con-
tain sense and antisense RNA foci and sense DPRs, however antisense DPRs 
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have not been observed. Interestingly, two out of four mouse models did not 
show any behavioral and motor phenotype, nor showed any neurodegenera-
tion or pTPD-43 neuropathology[162, 192]. The third mouse model only showed 
some memory and anxiety deficits and some mild neurodegeneration in the hip-
pocampus, which only became apparent after 12 months[136]. Expression levels 
might be too low to cause a phenotype. The last BAC mouse model did show 
a very strong C9FTD/ALS phenotype, complete with locomotor abnormalities, 
grip strength loss, paralysis and decreased survival. Neuronal loss is observed 
in cortical areas and in the spinal cord, including the presence of reduced ChAT 
neurons. In addition, neuromuscular junctions were disrupted[193]. This model 
differs from the first three by the genetic background and some different flanking 
regions[193]. It will be interesting to compare expression levels between the BAC 
mice or to back-cross these models into the same genetic background. 
 Finally, the effect of long pure and interrupted (TCGAG sequence without 
stop codons) G4C2 repeats were investigated in vivo[194, 195]. AAV-virus medi-
ated expression of both short (10x) and long (102x) interrupted G4C2 C9ORF72 
repeat expansions cause the formation of abundant RNA foci in mice[194]. But 
only the mice expressing the long (interrupted) repeat expansion developed DPR 
and p62 pathology, Purkinje cell apoptosis, neuromuscular junction abnormalities 
and gait and cognitive defects[194]. AAV-149x pure repeat mice developed sense 
and antisense RNA foci, sense and antisense DPRs, p62 and pTDP-43 patholo-
gy[195]. This is the first mouse model that clearly shows nucleocytoplasmic inclu-
sions of DPRs and pTDP-43[195]. Also these mice show neurodegeneration and 
behavior abnormalities (see table 2). This indicates that repeat length also plays 
an important role in the development of a phenotype and pathological features 
such as antisense DPRs and clear pTDP-43 pathology. Still, one must be cau-
tious with comparing mouse models, as it remains difficult to compare expression 
levels between mice and between pure and interrupted repeats. 
 All of these mouse models show the impact of G4C2 repeat expression 
in vivo and support a toxic gain-of-function mechanism underlying the pathogen-
esis of C9FTD/ALS. Administration of an AON that targets the repeat sequence 
has proven to prevent the formation of RNA foci, DPRs and the development of 
a phenotype in one of the BAC models of C9FTD/ALS[136], which further high-
lights expression of the G4C2 repeat as toxic gain-of-function mechanism. Mouse 
models that express the G4C2 repeat interrupted with stop codons or DPRs only 
(made by alternative codons) might further disentangle the contribution of RNA 
and DPR protein gain-of-function.
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6. Remaining open questions in the research field of C9FTD/ALS
Despite the enormous amount and pace of published research articles on C9FTD/
ALS, there are still some remaining open questions. In the following section, we 
identify important questions (summarized in box 1), set the aim for this thesis and 
explain how our research may address some of the knowledge gaps.
 The most outstanding open question in the field is the determination of 
the contribution of the different proposed molecular mechanisms underlying neu-
rodegeneration observed in C9FTD/ALS. The toxicity of DPRs has been studied 
extensively and expression of DPRs seems to be sufficient to cause cell death. 
On the other hand, RNA foci have been proven to sequester important proteins 
involved in splicing and depletion of these proteins could contribute to cellular 
toxicity. Loss-of-function does not cause FTD and/or ALS symptoms in mouse 
models of C9ORF72, but the function of the C9ORF72 protein in autophagy and 
endosomal and lysosomal function could still contribute to C9ORF72 pathogen-
esis. In order to be able to answer how these mechanisms all contribute to the 
pathogenesis of C9FTD/ALS, we need to understand the mode of action of the 
different components. 
 In the second chapter of this thesis, we study the effects of expression of 
either poly-GR and poly-PR in zebrafish embryos. Understanding the molecular 
pathways which are affected by these toxic peptides is important for elucidating 
the pathogenesis of C9FTD/ALS and might give new starting points for future drug 
development. In the third chapter of this thesis, we study the effect of expression 
of all sense DPRs in a murine model. DPRs were present as soluble peptides, 
which allows us to investigate another open question in the neurodegenerative 
field; is the soluble or aggregated state of certain proteins the most toxic form or 
could they also be protective? DPRs could also influence the aggregation of each 
other[74, 196], but the way that they affect availability for other binding partners 
and downstream mechanisms is still unclear.
 So far, there has been an overwhelming number of studies investigating 
downstream molecular pathways involved in the pathogenesis of C9FTD/ALS. 
The main problem with these studies is that the identified pathways are probably 
all dysfunctional, but it is hard to distinguish primary from secondary effects. We 
try to address this problem by using a pharmacological approach in chapter 2. 
Drugs or compounds that show a full rescue of poly-GR and poly-PR toxicity in-
dicate a primary or prominently affected pathway. Importantly, potential aberrant 
pathways are validated from in vitro and/or in vivo studies using post-mortem 
brain sections of C9FTD/ALS patients as described in chapter 4. The validation 
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Box 1: Open questions in the research field of C9FTD/ALS.
1. What is the toxic culprit? Many studies highlight the toxicity of (arginine-contai-
ning) DPRs in models for C9FTD/ALS. On the other hand, evidence of sequestration 
of several proteins into RNA foci and consequent cellular depletion has been put 
forward as pathological mechanism. In addition, the function of the C9ORF72 protein 
in autophagy could modify pathogenesis and should also be taken into account. The 
relative contribution of all of these mechanisms and their interactions to neurodege-
neration is unknown.
 
2. What molecular pathways are primary affected? Both DPRs and G4C2 
RNA seem to influence the function of several cellular processes. It is impor-
tant to distinguish primary from secondary effects in order to design drugs or 
compounds that prevent the major effects of DPRs or G4C2 repeat RNA mole-
cules. Drugs that prevent binding of DPRs or G4C2 repeat RNA to important cel-
lular proteins might reduce toxicity and prevent subsequent neurodegeneration. 
3. Is the aggregation of DPRs needed for their toxicity? DPRs seem to differ in 
their mode of action depending on their conformational state and could possible also 
influence each other on solubility, aggregation, interaction partners and downstream 
effects. It is unclear if aggregation of DPRs is causative or protective for neuronal 
death.
 
4. How does RAN translation work? As RAN translation is a relatively new concept, 
many questions are still unanswered. Minimal repeat size, necessary sequences and 
expression levels needed for the initiation of RAN translation are unknown. Mecha-
nisms like frame shifting could produce chimeric DPRs, but we are still to discover 
what the contribution of all of these processes is to the final pool of DPRs in a cell.
 
5. What is the possible time-window for treatment? Administration of an AON has 
proven to prevent the formation of RNA foci, DPRs and the development of a pheno-
type in a BAC mouse model of C9FTD/ALS[136]. Is it also possible to block or reverse 
disease progression in the symptomatic phase? It is important to identify possible 
time-windows for treatment.
 
6. Can we develop specific biomarkers for the C9FTD/ALS field? Pathological 
hallmarks of C9FTD/ALS, including RNA foci and DPRs, might provide information on 
disease onset and progression. Their levels in blood, CSF and brain might be linked 
to certain clinical characteristics. As they are the targets of many new drugs, they 
could also be used as pharmacodynamics markers of target engagement in clinical 
trials.
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of pathology in human neurons can be used as selection criteria to filter out any 
side effects or artifacts from overexpression models. We perform an extensive 
characterization of one of these identified new protein pathologies (HR23B) in 
chapter 4. We include HR23B co-localization patterns with DPRs, which can pro-
vide more information on the order of events and the differential effect of DPRs in 
the pathogenesis in the human brain.
 Another main theme is RAN translation. This newly identified translation 
mechanism is subject of many studies investigating minimal requirements for 
RAN translation. The necessary flanking regions and repeat length can be differ-
ent per reading frame and might also depend on expression levels. Each reading 
frame can contain different AUG-like start codons or Kozak sequences that en-
able translation. Frame shifting could also happen and might produce chimeric 
DPRs. The contribution of each of these mechanisms to the final proportion of 
DPRs in the cell is still a major gap of knowledge. We overexpress 36x G4C2 re-
peats in a mouse model (chapter 3) to investigate if this repeat number is enough 
to evoke RAN translation and production of DPRs in vivo. Compounds that are 
capable of binding the G4C2 RNA sequence or upstream start-like sites might 
block RAN translation and prevent the formation of toxic DPRs. Possibilities for 
drugs development are therefore increasing with every step made in understand-
ing the mechanisms of RAN translation.
 The last important step to make is the transition from many pre-clinical 
drug development studies to human clinical trials. In order to facilitate this pro-
cess, it is important to investigate the time-window of treatment in an appropriate 
model. So far, some drugs have proven to prevent the formation of RNA foci or 
DPRs, but their effects in the symptomatic phase of the disease are unknown. We 
can use our mouse Tet-on model to turn expression of the C9ORF72 repeat on 
and off at several time-points and investigate the contribution of timing of expres-
sion to evoke the development and regression of disease symptoms. Another 
important tool for the successful assessment of clinical trials is the identification 
of reliable biomarkers that provide information on disease onset and progression. 
DPRs could be perfectly suited for this goal, as they are very specific for C9FTD/
ALS and can be directly targeted by drugs. Poly-GP levels are found to be stable 
over time in CSF of C9ORF72 repeat carriers, but do not correlate with disease 
status, progression or other clinical characteristics[197]. In this thesis, we inves-
tigate the possibility of using poly-GR as fluid biomarker in chapter 5. The devel-
opment of biomarkers is essential to gain information about disease onset and 
progression and to select and monitor patients in clinical trials.
Introduction
1
45
Aim of this thesis
In summary, the aim of this thesis is to study the molecular mechanisms underly-
ing the pathogenesis of C9FTD/ALS. In addition, these results will be essential for 
the development of new therapeutic strategies and to facilitate clinical research.

Chapter 2
Reduction of oxidative stress and inhibition of the 
integrated stress response rescues poly-GR and 
poly-PR mediated toxicity in zebrafish embryos
F.W. Riemslagh1*, R.F.M. Verhagen1, D. Smits1, W. Quint1, H. van der Linde1, 
A.M. Isaacs2, T. van Ham1, R. Willemsen1
1Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Rotterdam, 
The Netherlands.
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Abstract
The G4C2 hexanucleotide repeat expansion in the C9ORF72 gene is the 
most common known pathogenic mutation linked to both frontotemporal 
dementia (FTD) and amyotrophic lateral sclerosis (ALS). This repeat can be 
translated into dipeptide repeat proteins (DPRs) via repeat-associated non-
AUG (RAN) translation. DPRs are found throughout the brain of C9ORF72-
linked FTD and ALS (C9FTD/ALS) patients. Especially the arginine-con-
taining DPRs, poly-glycine-arginine (GR) and poly-proline-arginine (PR), 
are reported to be toxic in cell and animal models. In addition, poly-GR 
distribution correlates with neurodegeneration in postmortem C9FTD/ALS 
brains. Here, we report zebrafish models for poly-GR and -PR toxicity, using 
the Sec-A5 YFP fluorescent transgenic line that allows for easy detection 
and quantification of apoptosis in vivo. Microinjection of poly-GR or -PR 
encoding RNA into the yolk-sac of fertilized one-cell stage embryos was 
sufficient to evoke abundant apoptosis in the brain and abnormal motor 
neuron morphology in the tail of embryos at 1-4 days post fertilization (dpf). 
Poly-GR expression evoked elevated MitoSOX and yH2AX levels, indicative 
of oxidative stress and DNA damage. Both poly-GR and -PR expression 
caused inhibition of protein translation in cell culture. Inhibition of cellular 
stress pathways using either Trolox (reactive oxygen species inhibitor) or 
ISRIB (integrated stress response inhibitor) showed a full rescue of po-
ly-GR and -PR toxicity, respectively. Our study indicates that poly-GR and 
-PR exert their toxicity via activation of cellular stress pathways. These 
zebrafish models can further elucidate molecular mechanisms underlying 
neurodegeneration in C9FTD/ALS and allow for (unbiased) drug screens. 
Keywords
C9ORF72, ALS, FTD, poly-GR, poly-PR, neurodegeneration, ISR
Poly-GR and -PR mediated toxicity in zebrafish embryos
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Introduction
FTD and ALS are two neurological disorders that are characterized by degenera-
tion of cortical neurons in the frontal and temporal cortices and motor neurons in 
the motor cortex and spinal cord[12]. The G4C2 hexanucleotide repeat expansion 
in the C9ORF72 gene is a shared genetic factor that has been linked to both 
FTD and ALS[22, 23]. Patients carrying this mutation can develop symptoms of 
both disorders[12]. How the G4C2 repeat expansion causes neurodegeneration is 
currently unknown. Possible hypotheses include both loss- and gain-of-function 
mechanisms or a combination of both. Methylation of the repeat and surrounding 
CpG islands can silence the C9ORF72 gene leading to haploinsufficiency[77]. 
Sense and antisense RNA containing the repeat accumulate in RNA foci and se-
quester multiple RNA binding proteins[77]. Furthermore, DPRs are produced by 
unconventional RAN translation of the repeat sequences in both sense and anti-
sense direction, creating different DPRs: poly-glycine-alanine (GA), -glycine-pro-
line (GP), -glycine-arginine (GR), -proline-arginine (PR), –proline-alanine (PA) 
and -proline-glycine (PG) [55, 57, 66, 67]. These DPRs are found throughout 
postmortem brain tissue of patients[198] but only poly-GR pathology correlates 
with neurodegeneration[72, 73]. 
 The arginine-containing DPRs, poly-GR and –PR, have been reported to 
be very toxic in both cell and animal models[168, 171, 173, 174, 176, 179, 199]. 
Poly-GR and -PR interact with ribosomal proteins, heterochromatin, nucleolar 
proteins, RNA-binding proteins and proteins containing low-complexity domains 
(LCDs)[173, 174, 176, 181, 199, 200]. LCD proteins can form membrane-less 
organelles such as nucleoli, the nuclear pore and stress granules. Poly-GR and 
-PR have been shown to alter the dynamics and assembly of these organelles, 
leading to reduced mRNA translation, ribosomal stress, endoplasmatic reticulum 
(ER) stress and aberrant nucleocytoplasmic transport (NCT)[176, 177, 183, 188, 
199]. Poly-PR also disrupts the liquid phase of HP1α, binds heterochromatin and 
causes abnormal histone H3 methylation, leading to repetitive element expres-
sion and accumulation of double-stranded RNA in a mouse model[200]. Overex-
pression of poly-PR in primary murine cortical neurons leads to an increase in 
stress granule formation[171]. In addition, overexpression of either poly-GR and 
-PR resulted in reduced translation in NSC34 and HeLa cells[149, 174], and in a 
mouse model for poly-GR[199]. Poly-GR and -PR can accumulate in the nucleus 
and co-localize with nucleoli in NSC24 and HEK293 cells[173], and nucleolar vol-
ume changes have been observed in C9FTD patient brain tissue[163]. Disrupted 
nucleolar function can lead to impaired ribosomal RNA maturation as observed 
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in HEK293T cells and C9ORF72 iPSC-derived motor neurons[169, 184]. Fur-
thermore, poly-GR can interact with mitochondrial ribosomal proteins and conse-
quently impair mitochondrial function in C9FTD/ALS iPSC-derived neurons[186, 
201]. Finally, poly-GR increases the amount of oxidative stress which can cause 
DNA damage in motor neurons differentiated from iPSCs[186]. Importantly, since 
all these processes can influence each other and lead to general cellular dys-
functioning, the primary start of the toxicity cascade is still unknown and warrants 
further investigation[169, 188]. 
 To study poly-GR and -PR toxicity in a vertebrate in vivo system, we 
used zebrafish (Danio rerio). Zebrafish have been extensively used in (neuro)
toxicity studies for multiple reasons (reviewed in[202, 203]). First, their genome 
can be easily manipulated using CRISPR-CAS9 technique or by injection of RNA 
encoding a protein of interest. Second, they are transparent and develop rapid as 
external embryos, allowing for easy detection of body and organ abnormalities. 
Fluorescent transgenic reporter zebrafish lines that label structures or cell types 
are readily available worldwide. In order to visualize apoptosis, we make use of 
the fluorescent Sec-A5 model that labels apoptotic clusters with YFP[204]. Third, 
basic (neuro)biological processes are conserved between vertebrates, making 
identification of aberrant cellular and molecular pathways in the pathogenesis of 
human disorders feasible[202, 205]. Fourth, zebrafish produce many offspring 
which are easily injected, allowing for medium-throughput experiments. Finally, 
they are perfectly suited for drug screens because they readily take up small 
molecules from the water[203].
 Here, we inject RNA transcribed in vitro from DNA constructs encoding 
ATG-mediated codon-optimized 100xGR or 100xPR. High concentrations led to 
deceased and malformed fish, while low concentrations of only 10pg RNA encod-
ing poly-GR and 5pg RNA encoding poly-PR were sufficient to evoke apoptosis 
in the brain and caused aberrant motor neuron morphology at 1-4 dpf. These 
models allow to screen for drugs that modify poly-GR and -PR toxicity, and we 
identified Trolox and ISRIB that show a full rescue for poly-GR and –PR, respec-
tively. Trolox is an antioxidant that reduces reactive oxygen species (ROS), which 
are free radicals that can evoke oxidative stress and cause mitochondrial and 
DNA damage and are linked to many neurodegenerative diseases[206]. ISRIB is 
a known inhibitor of the cellular integrated stress response (ISR). The ISR can be 
activated by amino acid deprivation, viral infection, iron deficiency, and misfolding 
of proteins within the ER. The accumulation of misfolded proteins in the ER caus-
es ER stress and activation of the ISR and the unfolded protein response (UPR)
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[207]. Oxidative stress can worsen ER stress by reducing the efficiency of protein 
folding pathways and thereby increasing the amount of misfolded proteins[208]. 
The other way around, ER stress can cause ROS production[209]. In this study, 
we investigate the involvement of these cellular stress pathways in the pathogen-
esis of C9ORF72-linked ALS and FTD.
Methods
Constructs
DNA plasmids containing the pcDNA3.1+Peredox-mCherry-NLS (addgene cat. 
Nr 32384), pcDNA3.1+100xGlycine-Arginine and pcDNA3.1+100xProline-Argi-
nine (Isaacs lab) were transformed into Top10 competent cells followed by DNA 
isolation with NucleoBond®Xtra maxi kit (BioKé). DNA constructs were linear-
ized by digestion with Apal (NEB) and/or NheI (NEB), purified by phenol-chlo-
roform extraction and quantified on Nanodrop (Thermofisher). To obtain con-
trol constructs for injection of RNA, we performed site directed mutagenesis to 
mutate the ATG initiation codon using the QuickChange Lightning Site-Directed 
mutagenesis Kit (ThermoFisher, Waltham, Massachusetts, USA). The following 
primers were used to obtain the mutated start codons: for PR: forward 5’-CGAG-
GACGAGGCACGGTGGGATCCGAG-3’. reverse 5’-CTCGGATCCCACCGTG-
CCTCGTCCTCG-3’ for GR: forward: 5’-CTCGTCCACG TCCCTAGGTGGGATC-
CG – 3’ reverse: 5’-GCTCGGATCCCACCTAGGGACGTGGAC– 3’. To denature 
the DNA template and anneal the mutagenic primers containing the desired mu-
tation we used a thermal cycling protocol (1x(2min at 95◦C), 18x (20sec at 95◦C, 
10 sec at 60◦C, 3 min at 68◦C), 1x (5min at 68◦C)). After mutant strand synthesis 
the template DNA was digested by adding 1µl of the Dpn1 enzyme, mixtures 
were incubated for 5 minutes at 37◦C. Mutated DNA constructs were transformed 
and isolated as described above.
RNA synthesis
For the production of RNA the mMessage mMachine T7 transcription kit (Invi-
trogen) was used. 400 ug of linear template DNA was mixed with 2uL reaction 
buffer, 10ul NTP/CAP, 0.1ul RNAse out and nuclease free water. The mixture was 
incubated at 37°C for 2 hours. After incubation 1ul TURBO DNase was added to 
remove template DNA at 37°C for 15 minutes. 30ul lithium chloride and 30 ul nu-
clease free water was added for precipitation and mixtures were placed at -20°C 
for at least 30 minutes. RNA was subsequently centrifuged at 4°C , washed with 
70% ethanol, re-centrifuged, dried to air and dissolved in DEPC water and quan-
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tified using Nanodrop (ThermoFisher). Samples were stored at -80°C in aliquots.
Injections and fish maintenance
For all experiments one cell stage zebrafish embryos of the AB wildtype or Sec-A5 
YFP zebrafish reporter line[204] were injected in the yolk sac within 30 minutes 
after egg fertilization. Injection mixtures contained a standard amount of 400pg/
nl mCherry-mRNA and 10% phenol red. The RNA encoding poly-GR and -PR 
constructs was added to these mixtures with a final concentration of 1 to 100 pg/
nl. All zebrafish embryos were injected with 2 nl of injection mix. After injection, 
embryos were kept in a 28ᵒC incubator for 1 till 4 days in E3-water and on the 
first day with additional methylene blue as antifungal aid. Propylthiouracil (PTU) 
(1:40) was added to E3-water to prevent pigmentation and keep the fish optically 
transparent. At 24 hours post fertilization (hpf) the embryos underwent visual in-
spection for dysmorphic features. Morphologically abnormal embryos and unfer-
tilized eggs were excluded from all further experiments. Embryos were selected 
at 1 dpf time point based on their mCherry signal intensity in order to select only 
correctly injected embryos. The non–mCherry fluorescent embryos and mosaic 
embryos were disposed.
 
Apoptotic cluster count
The apoptotic cluster quantification study was performed in the Sec-A5 YFP ze-
brafish reporter line[204] at 1 – 4 dpf with 3 separate injection rounds for each 
time point and minimal 10 fish per group per time point were imaged. Prior to im-
aging embryos were dechorionated, anesthetized with 10% tricaine in E3-water 
and embedded in 1.8% low melting point agarose in E3-water. The Leica SP5 
AOBS confocal microscope and a HCX L 20.0x1.00 water dipping objective were 
used for the apoptotic cluster count. A z-stack step size of 4.2 micron was used 
ranging from the first till the last YFP+ cell on the Z-axis. Automatic quantification 
of apoptotic cells was done using Fiji software with the 3D object counter appli-
cation with automated threshold and a minimum of 3 voxols. 1-way ANOVA with 
Barlett’s test for equal variances showed a significant difference in the variance 
per group, so we performed a Kruskal-Wallis test that does not assume equal 
variances and post Dunn’s multiple comparison test to compare groups.
TUNEL assay
Wildtype AB strain fish injected with 5pg RNA encoding poly-PR, 10 pg RNA en-
coding poly-GR or 400pg RNA encoding mCherry were used for TUNEL assay 
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analysis. Fish were fixed at 2 dpf for 4h in 4% paraformaldehyde (PFA) in 0.1M 
PBS followed by washing in 0.1MPBS. Subsequently, fish were washed and kept 
in 100% MeOH at -20°C until further processing. Rehydration was obtained by in-
cubating fish in decreasing concentrations of MeOH: 75% - 50% - 25% MeOH fol-
lowed by PBS. After washing in PBS-T (0.2% Triton X-100; Sigma in 0.1M PBS) 
fish were treated with 10µg/ml Proteinase K in PBS-T for 15 minutes and refixed 
with 4% PFA for 20 min. After washing fish three times in PBS-T for 10 min, fish 
were incubated for 30 minutes with 100 µl TdT buffer (Click-iT Plus TUNEL Assay 
647 dye; Invitrogen). Following initial incubation, fish were incubated overnight 
with 100µl TdT reaction mix (94µl TdT buffer; 2µl EdUTP; 4µl TdT enzyme). After 
incubation fish were washed with 3% bovine serum albumin (BSA; Sigma) in 
PBS-T three times followed by incubation with 100µl Click-iT reaction mix for 3h 
and washed three times with 3% BSA in PBS-T. Fish were mounted in 1.8% low 
melting point agarose (Invitrogen) in E3-water. Imaging was performed using a 
SP5 Intravital microscope equipped with HCX-APO L 20x/100W objective (Leica) 
for 10 fish per group.
Synaptic Vesicle 2 whole mount staining
At 48h post injection with 5pg RNA encoding poly-PR, 10pg RNA encoding po-
ly-GR or 400pg RNA encoding mCherry, Sec-A5 YFP zebrafish were fixed over-
night in 4% PFA in 0.1M PBS. Fish were permeabilized with acetone for 1h at 
-20°C and blocked with 1% BSA / 1% DMSO / PBS-T (0.2% Triton X-100; Sigma 
in 0.1M PBS)  for 1 h at room temperature. Subsequently, fish were immunos-
tained overnight at 4◦C with the anti-mouse SV2 antibody (1:200, AB231587, 
Developmental Studies Hybridoma Bank, University of Iowa). After incubation 
fish were washed 10 times in 0.5% Triton X-100 (Sigma) in PBS and incubated 
overnight with the secondary antibody Anti-mouse-Cy5 (1:200, Sigma Aldrich). 
The following day the fish were washed 6 times in 0.5% Triton X-100 and mount-
ed with 1.8% low melting point agarose (ThermoFisher) in E3-water. Imaging was 
done with Leica SP5 AOBS confocal microscope and a HCX L 20.0x1.00 water 
dipping objective for 10 fish per group.
Fluorescent immunohistochemistry
For immunohistochemical analysis fish from the AB wildtype strain were injected 
with 5pg RNA encoding poly-PR, 10pg RNA encoding poly-GR or 400pg RNA 
encoding mCherry only. Fish were fixed at 1-4 dpf (n = 30 per group) overnight in 
4% PFA and subsequently embedded in paraffin. Tissues were cut into 6um thick 
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sections using a rotary microtome. Sections were deparaffinized using xylene 
and rehydrated in an alcohol series (100%-96%-90%-80%-70%-50%). Antigen 
retrieval was done in 0.01M sodium citrate, pH6.0 using pressure cooker treat-
ment. Endogenous peroxidase activity was blocked with 3% H2O2 and 1,25% so-
diumazide in 0.1M PBS. Immunostaining was performed overnight at 4°C in PBS 
block buffer (0.1M PBS / 0.5% protifar / 0.15% glycine) and with primary antibod-
ies (anti-PR 1:500 LifeTein, anti-GR 1:5000 LifeTein, yH2AX 1:750 GeneTEX) 
at 4◦C. After incubation with the primary antibody, sections were washed with 
PBS block buffer and incubated with secondary anti-mouse/rabbit Cy2/3 linked 
antibodies (Jackson). To remove background staining, a 10 min incubation with 
Sudan Black (Sigma, 0.1 gr in 100ml 70% ethanol, filtered) was performed. To vi-
sualize nuclei, slides were incubated for 10 min with Hoechst 33342 (Invitrogen). 
Slides were mounted with ProLongGold (Invitrogen) and kept at 4°C until imaging 
at a Zeiss LSM700 Confocal microscope. 
Enzyme Linked Immuno Sorbent Assay (ELISA)
Poly-GR sandwich ELISA was performed at 1 – 4 dpf with 3 separate experiments 
for each time point and 30 SecA5 fish per group per time point. Prior to lysing, 
fish were dechorionated and euthanized. Mechanical lysis of fish was performed 
in RIPA buffer containing 0.05% protease inhibitors (Roche) and 0.3% 1M DTT 
(Invitrogen). After 30 min incubation, mechanical lysis was repeated and samples 
were centrifuged at 13.000xg for 15 min at 4°C, followed by 3x 1 min sonication. 
After sonication, samples were centrifuged at 13.000xg for 20 min at 4°C. Whole 
protein content was determined using BCA assay (Thermo Fisher Scientific). 
MaxiSorp 96 well F-bottom plates (Thermo Fisher) were coated for 2h with 5.0 
µg/ml monoclonal GR antibody (LifeTein Services) followed by overnight blocking 
with 1% BSA in PBS-Tween (0.05% Tween-20 in 0.1M PBS) at 4°C. After wash-
ing, samples were added at 300µg total protein in one well and 2-fold diluted in 
PBS in a second well. Standard curve made with 15x GR synthetic peptide was 
added in duplo. All samples were incubated for 1h on the plate. After washing, 
all wells were incubated for 1h with biotinylated monoclonal anti-GR antibody 
(LifeTein Services) at a final concentration of 0.25 µg/ml in PBS-Tween/1% BSA. 
After washing, samples were incubated for 20 min with Streptavidin-HRP conju-
gate (R&D Sciences) diluted 1:200 in PBS-Tween/1% BSA. Following extensive 
washing, samples were incubated with substrate reaction mix (R&D Sciences) 
for 15 min and stopped using 2N H2SO4. Read-out was performed at 450nm and 
570nm (Varioscan). We performed a two-way ANOVA with post Bonferroni test 
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for differences between groups over time.
Rescue experiments
ISRIB (Sigma) was dissolved in 100% DMSO and diluted in E3-water to a final 
concentration of 2μM. Trolox (Sigma) was dissolved in 100% DMSO and diluted 
in E3-water to a final concentration of 50μM. Dissolved ISRIB, Trolox, or similar 
volumes of DMSO as a control, were added to the E3 water directly after mi-
cro-injections and refreshed every day. The amount of apoptotic clusters was 
determined at 1-4 dpf as described above. We used 30 Sec-A5 YFP zebrafish 
per group per time point. 1-way ANOVA with Barlett’s test for equal variances 
showed a significant difference in the variance per group, so we performed a Kru-
skal-Wallis test that does not assume equal variances and post Dunn’s multiple 
comparison test to compare groups.
MitoSOX Assay
Wildtype AB strain fish injected with 10pg RNA encoding poly-GR or 400pg RNA 
encoding mCherry only were used for MitoSOX (Invitrogen) assay analysis. Fish 
were collected at 2 dpf, dechorionated and washed once with pre-warmed HBSS 
(HBSS Calcium Magnesium; Gibco) at 28°C. All fish were stained with 5µM Mi-
toSOX reagent diluted in HBSS at 28°C for 20 min. Following incubation, all fish 
were washed 3 times with HBSS (28°C) and anesthetized with 1x Tricaine for 5 
min. Fish were mounted in 1.8% low melting point agarose (Invitrogen). Imaging 
was performed using a SP5 Intravital microscope equipped with HCX-APO L 
20x/100W objective (Leica) for 8 fish per group. F-test for equal variances p=0.91 
so variances are not significantly different so we performed a students’t-test.
ATF4b qPCR
Expression of the ATF4b gene in zebrafish larvae was determined using SYBR 
Green fluorescence (iTaq Universal SYBR Supermix; BioRad). Wildtype AB strain 
fish injected with 5pg RNA encoding poly-PR or 400pg RNA encoding mCherry 
only were used, with n = 30 fish per group. All samples were run in triplicate. 
Primers for ATF4b gene: FW primer: 5’- GGA GCT CAT TGC TTC TCT GG– 3’; 
RV primer: 5’- GAC AGA GGC TGA TGG AGA GG – 3’ and β-actin gene: FW 
primer: 5’- GCT GTT TTC CCC TCC ATT GTT – 3’; RV primer: 5’- TCC CAT GCC 
AAC CAT CAC T – 3’. Analysis was performed using the 2-ΔΔCt method with data 
normalized to β-actin. F-test for equal variances p=0.29 so variances are not 
significantly different so we performed a students’t-test.
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Puromycin experiment
COS7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gib-
co) supplemented with 10% fetal calf serum (FCS), 1% Penicillin/Streptomycin 
(P/S) and 1% non-essential amino acids (NEAA, Sigma-Aldrich) at 37°C in a 
5% CO2 humidified incubator. COS7 cells were plated at 150.000 cells/well in a 
6-wells plate and transfected with 3 ul GeneJuice (Novagen) for 1ug DNA. The 
same DNA constructs were used for COS7 transfection as we used for RNA gen-
eration and injection of zebrafish embryos. The next day, cells were washed with 
0.1M PBS and incubated with puromycin (1ug/ml) dissolved in supplemented 
DMEM medium for 1 hour. Afterwards, cells were washed with 0.1M PBS and 
fixed with 4% paraformaldehyde (PFA) for 20 min and permeabilized with 0.5% 
Triton X-100 in 0.1M PBS. Immunostaining was performed overnight at 4°C in 
0.1M PBS with 1.5% BSA and anti-puromycin antibody 1:10.000 (MABE343 Mer-
ck). The next day, cells were washed with 1.5% BSA in 0.1M PBS and incubated 
with secondary antibody anti-mouse Cy3 (Jackson) 1:200 at room temperature 
for 1 hour. After washing with PBS, cells were shortly incubated with Hoechst 
33342 (Invitrogen) and mounted with ProLong Gold (Invitrogen).
Results
Injection of poly-GR or –PR encoding RNA evokes apoptosis and aberrant 
motor neuron axon morphology in 1-4 dpf zebrafish embryos. 
We started with assessing the toxicity of poly-GR and -PR at the systemic level 
using a dosage-dependent approach. RNA was transcribed in vitro from ATG-
100xGR or ATG-100xPR constructs, using alternative codons without the G4C2 
repeat sequence. Concentration series ranging from 1-200pg RNA were injected 
into the yolk-sac of fertilized oocytes at the one cell stage. Both Poly-GR and -PR 
encoding RNA showed a dose-dependent toxicity (supplementary figure 1), with 
high concentrations leading to deceased and undeveloped embryos and lower 
concentrations leading to malformations including heart edema and tail twists. 
For further experiments we chose a concentration that resulted in a robust and 
reproducible phenotype, without causing severe malformations. Amounts of 10pg 
poly-GR and 5pg poly-PR encoding RNA were used for all further experiments. 
These amounts still resulted in about 30% malformations, but all malformed fish 
were discarded and not used for further analyses. Lower concentrations did not 
show a clear and reproducible phenotype on apoptotic cluster count (data not 
shown). To determine the effect of poly-GR and -PR at the cellular level, we used 
the Sec-A5 reporter zebrafish line that fluorescently labels apoptotic clusters in 
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Figure 1: Injection of poly-GR or –PR encoding RNA evokes apoptosis and aberrant motor 
neuron axon morphology in 1-4 dpf zebrafish embryos. A) Upper panel shows max projection of 
z-stack images of the Sec-A5 YFP (green) fluorescent reporter line embryos 48 hours after injection 
with 10pg RNA encoding poly-GR, 5pg RNA encoding poly-PR or 400pg RNA encoding mCherry 
only. Scale bar is 100 µm. Lower panel shows max projection of z-stack images of TUNEL assay in 
wildtype AB embryos 48 hours after injection with 10pg RNA encoding poly-GR, 5pg RNA encoding 
poly-PR or 400pg RNA encoding mCherry only. TUNEL positive signal is magenta, cell nuclei are 
stained with DAPI in blue. Scale bar is 50 µm. n = 10 per group. B) Quantification of z-stack images 
of the Sec-A5 YFP fluorescent reporter line embryos after injection with 10pg RNA encoding poly-GR, 
5pg RNA encoding poly-PR or 400pg RNA encoding mCherry only at 1-4 dpf. N = 30 fish/group/day. 
Kruskal-Wallis test (p = <0.0001). Post Dunn’s multiple comparison test * = p <0.05, ** = p < 0,001 
and *** = p < 0.0001 differences of poly-GR and –PR RNA injected fish compared to mCherry only at 
1-4 dpf. C) Synaptic vesicle (SV2) staining visualizes aberrant axonal protrutions in the tail of 2 dpf old 
embryos of the Sec-A5 YFP fluorescent reporter line after injection with 10pg RNA encoding poly-GR, 
5pg RNA encoding poly-PR compared to 400pg mCherry only. n = 10 per group. Scale bar is 50 µm.
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vivo[204]. As injections by themselves already cause a slight increase of cell 
death (data not shown), we used RNA from a mCherry-only construct as control. 
This marker was also used to select for correctly injected fish. Co-injection of 
mCherry RNA together with low concentrations of either poly-GR or -PR encod-
ing RNA evoked massive apoptosis in zebrafish embryos at all stages (1-4 dpf) 
(figure 1A upper panel). Apoptosis was confirmed by TUNEL staining (figure 1A 
lower panel). To quantify the amount of apoptotic clusters, we made z-stack im-
ages of whole zebrafish heads in vivo. The YFP clusters in z-stack images were 
automatically quantified using FIJI software for 3D cluster counting. Both 10pg 
of poly-GR encoding RNA and 5pg of poly-PR encoding RNA was sufficient to 
cause a significant increase in the amount of apoptotic clusters in the brain of 
zebrafish embryos at 1-4 dpf compared to mCherry control injected fish (figure 
1B, Kruskal-Wallis test with post Dunn’s multiple comparison test p = < 0.0001) 
without other gross morphological abnormalities. To further characterize our ze-
brafish model, we stained embryos for SV2, a marker for neuronal axons that la-
bels presynaptic vesicles. This revealed that both poly-GR and -PR RNA injected 
fish display aberrant morphology with less axonal protrusions of the motor neuron 
axonal structure in the tail (figure 1C).
 To study the specificity of our observed protein-toxicity, we used site-di-
rected mutagenesis to mutagenize the ATG-start codon to a GTG-codon or a 
TAG-stop codon. This mutation disables translation of the RNA molecules into 
DPRs and can be considered as a control for RNA toxicity per se. Injection of high 
concentrations (50-200 pg) of RNA of TAG-100xGR or GTG-100xPR constructs 
caused an increase in deceased and malformed embryos (supplementary figure 
1). Apparently, high concentration of non-coding RNA can have a small toxic ef-
fect on its own, even though this RNA does not contain a G4C2 repeat sequence. 
Low concentrations (2-10 pg) of TAG/GTG-mediated poly-GR and -PR RNA were 
only slightly toxic compared to mCherry only (supplementary figure 1), while low 
concentrations of ATG-mediated poly-GR and -PR RNA evoked abundant apop-
tosis (figure 1). This shows the specificity of the detrimental effect of expressing 
poly-GR and -PR peptides. For further studies we used mCherry-only construct 
as a valid control.
 Next, poly-GR and -PR peptides were visualized using immunofluores-
cent (IF) staining of whole body zebrafish at 1-4dpf.  Poly-GR and -PR peptides 
were detected both diffusely and as nuclear and perinuclear puncta in embry-
os injected with a high concentration (20pg poly-PR and 40pg poly-GR), while 
embryos injected with low concentration (5pg poly-PR and 10pg poly-GR) only 
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showed some (peri)nuclear puncta dispersed throughout the body (figure 2A). 
Presence of poly-GR and -PR at these low concentrations was very difficult to 
detect with whole mount or IF staining on sections. We therefore performed a 
newly developed Enzyme-Linked Immuno Sorbent Assay (ELISA) to confirm the 
presence of poly-GR peptide in 1-4 dpf zebrafish embryos (figure 2B). Zebrafish 
embryos injected with 10pg of RNA encoding poly-GR showed a signal of 10-20 
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Figure 2: Poly-GR and poly-PR peptides are detected as (peri)nuclear puncta in zebrafish em-
bryos at 1-4dpf. A) Immunofluorescence staining for poly-GR and poly-PR (red) in 2 dpf wt AB em-
bryos after injection with high concentrations of RNA encoding poly-GR and –PR (40pg RNA poly-GR 
/ 20pg RNA poly-PR) or low concentrations (10pg RNA poly-GR / 5pg RNA poly-PR) or 400pg RNA 
mCherry only. N = 30 per group. C9FTD patient frontal cortex sections were used as positive control. 
Poly-GR and –PR peptides are detected as nuclear or perinuclear (red) puncta in poly-GR and –PR 
RNA injected fish and in C9FTD patient frontal cortex. Nuclei were stained with Hoechst (blue). Scale 
bars are 20 µm. B) ELISA for the detection of poly-GR shows a signal of 10-20pg peptide in 1-4 dpf 
wt AB embryos injected with 10pg RNA encoding poly-GR. Two-way ANOVA p = 0.0003 with post 
Bonferroni test indicating that all time points were significantly different from mCherry-only injected 
fish. N = 90 fish per group per time point divided over 3 independent experiments (30 fish per group 
x 3 experiments per time point). 
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pg/ml peptide in our ELISA that was significantly different from mCherry-only in-
jected fish (2-way-ANOVA p = 0.0003). Unfortunately, we were unable to set-up 
a sensitive ELISA for the detection of the poly-PR peptide. In summary, ATG-me-
diated poly-GR and -PR encoding RNA is translated and detectable as (peri)
nuclear puncta throughout the zebrafish body. Expression of poly-GR and –PR 
peptides causes abundant apoptosis in the developing zebrafish.
Inhibition of cellular stress responses, using Trolox and ISRIB, rescues po-
ly-GR and –PR mediated toxicity.
Poly-GR and -PR DPRs have been shown to disturb many cellular processes 
and pathways, but their main target is still unknown. To discriminate between 
primary and secondary effects, we used a pharmacological approach. Trolox, an 
antioxidant that reduces ROS, partially rescued toxicity in an iPSC-induced motor 
neuron model of C9FTD/ALS[186]. Also in our in vivo study, Trolox significantly 
reduced poly-GR-mediated apoptosis in 1-4 dpf embryos of the Sec-A5 zebrafish 
line (figure 3A and B) (Kruskal-Wallis test that does not assume equal variances 
p = <0.0001. Post Dunn’s multiple comparison test showed *** = p < 0.0001 dif-
ference between DMSO vs Trolox treated  fish at 2-4 dpf). TUNEL staining con-
firmed the reduction of apoptotic cells in zebrafish embryo’s treated with Trolox 
(figure 3A lower panel). 
 ISRIB, a small molecule that inhibits the cellular response to ER stress, 
was shown to prevent PR-mediated toxicity in cell culture[188, 210]. ISRIB sig-
nificantly rescued poly-PR-mediated apoptosis at 1-4 dpf in vivo (figure 3C and 
D) (Kruskal-Wallis test that does not assume equal variances p = <0.0001. Post 
Dunn’s multiple comparison test showed *** = p < 0.0001 difference between 
DMSO vs ISRIB treated  fish at 1-4 dpf). The observed rescue of Sec-A5 apop-
totic clusters was confirmed by TUNEL staining in zebrafish embryo’s treated with 
ISRIB (figure 3C lower panel). Unexpectedly, we observed a full rescue for both 
Trolox and ISRIB; apoptotic clusters were reduced to baseline level of mCher-
ry-only injections. This underscores the significance and central role of the cellu-
lar stress response in the toxicity caused by these two DPRs.
 Next, we wanted to further investigate the activation of these pathways. 
As Trolox is known to inhibit the formation of ROS, we used a whole-mount proto-
col to quantify the ROS in alive zebrafish by MitoSOX staining. Indeed, 10pg RNA 
encodng poly-GR injected fish showed an increase in MitoSOX staining com-
pared to mCherry-only injected fish (figure 4A and B) (Students’ t-test p=0.0002. 
F-test for equal variances p=0.914 so variances are not significantly different). 
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Figure 3: Trolox and ISRIB reduce the number of apoptotic clusters in SecA5 zebrafish embry-
os injected with 10pg RNA encoding poly-GR or 5pg RNA encoding poly-PR. A) Upper panel: 
max projection of z-stack images of the Sec-A5 fluorescent reporter line embryos 48 hours after injec-
tion with 10pg RNA encoding poly-GR and treated with 50uM Trolox or DMSO. A) Lower panel: max 
projection of TUNEL staining of the same treatment groups in wt AB fish at 2dpf. Scale bars are 100 
µm. B) Quantification of Sec-A5 z-stack images. N = 30 fish per group per day. Kruskal-Wallis test p 
= <0.0001. Post Dunn’s multiple comparison test *** = p < 0.0001. C) Upper panel: max projection of 
z-stack images of the Sec-A5 fluorescent reporter line embryos 48 hours after injection with 5pg RNA 
encoding poly-PR and treated with 2uM ISRIB or DMSO. C) Lower panel: max projection of TUNEL 
staining of the same treatment groups in wt AB fish at 2 dpf. Scale bar are 100 µm. D) Quantification 
of Sec-A5 z-stack images. N = 30 fish per group per day for 1 and 2 dpf, n = 20 fish per group for 3 dpf 
and n= 10 fish per group for 4 dpf. Kruskal-Wallis test p = <0.0001. Post Dunn’s multiple comparison 
test *** = p < 0.0001.
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As ROS can also evoke DNA damage, we stained for yH2AX, a marker for DNA 
double strand breaks. 10pg RNA encoding poly-GR injected embryos showed 
yH2AX nuclear puncta, while mCherry-only RNA injected embryos did not (figure 
4C). This indicates that poly-GR evokes ROS and DNA damage in vivo. 
 For poly-PR, we assessed the induction of the integrated stress re-
sponse. Activation of the ISR results in down regulation of general protein syn-
thesis and the induction of transcription factors ATF4 and CHOP, that normally 
A
poly-GR
M
ito
SO
X 
he
ad
mCherry only
yH
2A
X
C
B
M
ito
SO
X 
ta
il
poly-GR mCherry only
mCherry only 10pg GR + mCherry
0
10
20
30
40
***
MitoSOX
# 
M
ito
SO
X 
cl
us
te
rs
Figure 4: Poly-GR increases oxidative stress and DNA damage in vivo. A) MitoSOX red staining 
in 2 dpf wildtype AB embryos after injection with 10pg RNA encoding poly-GR or mCherry-only RNA. 
MitoSOX signal in magenta is seen as clusters in the brain and in spinal cord in the tail. Scale bars 
are 100 µm. B) MitoSOX signal is significantly higher in 10pg RNA encoding poly-GR compared 
to mCherry-only RNA injected zebrafish embryos at 2 dpf. N = 8 fish per group. Students’ t-test 
p=0.0002. F-test for equal variances p=0.914 so variances are not significantly different. C) yH2AX 
immunostaining (red) in brain sections of 2 dpf embryos of the Sec-A5 fluorescent reporter line was 
detected after injection with 10pg RNA encoding poly-GR but not in mCherry-only RNA fish. Nuclei 
were stained with Hoechst (blue). Scale bars are 20 µm.
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promote cellular recovery. Under prolonged or severe stress, activation of ATF4 
and CHOP can lead to apoptosis[211] (figure 5A). However, ATF4-b RNA levels 
were not significantly different between 5pg RNA encoding poly-PR injected vs 
mCherry-only RNA injected fish (figure 5B) (Students’t-test p =0.693. F-test for 
equal variances p = 0.29). As the activation of the ISR may also result in inhibition 
of translation (figure 5A), we assessed the effect of poly-GR and –PR peptides on 
the incorporation of puromycin in newly synthesized peptides. For this purpose 
we used COS7 cells co-transfected with DNA encoding GFP and either poly-GR 
or poly-PR peptides. In these co-transfection studies we could not detect posi-
tive puromycin staining (figure 5C). In contrast, untransfected cells or cells trans-
fected with GFP-only stained positive for puromycin, illustrating normal protein 
synthesis (figure 5C). These results suggest that overexpression of poly-GR and 
–PR peptides causes inhibition of protein translation.
Discussion
In this study, we use a zebrafish model to readily visualize and quantify apoptosis 
in brain tissue evoked by injection of RNA encoding poly-GR and -PR DPRs. Po-
ly-GR and -PR peptides were detectable as small (peri)nuclear puncta through-
out the body and by an ELISA for poly-GR. Poly-GR evoked formation of reactive 
oxygen species and DNA damage, and both poly-GR and –PR inhibited transla-
tion in an overexpression COS7 cell model. We were able to fully rescue poly-GR 
by Trolox and poly-PR toxicity by ISRIB, inhibitors of oxidative stress and the 
integrated stress response, respectively. Our study indicates the importance of 
these cellular stress pathways in the pathogenesis of C9FTD/ALS.
 Our model only focusses on single DPR-induced toxicity and does 
not take effects of G4C2 repeat RNA-toxicity, haploinsufficiency of the normal 
C9ORF72 protein or simultaneous expression of different DPRs into account. 
Our constructs are ATG-mediated and use alternative codons to encode DPRs to 
circumvent G4C2-RNA toxicity. As an extra control for specificity, we used side-di-
rected mutagenesis to change the start site of our constructs to TAG/GAG-co-
dons to prevent translation and study non-coding RNA toxicity. Injection of ex-
tremely high RNA concentrations of TAG/GAG-constructs was toxic in embryos, 
showing that high expression of RNA molecules has a toxic effect. However, low 
concentrations of non-coding RNAs did not show an additional toxic effect com-
pared with our control construct, mCherry-only. Swinnen et al. showed toxicity 
of RNA molecules containing 35-90x G4C2 in a zebrafish model for C9ALS/FTD 
[154]. DPRs were undetectable in these fish, but interrupting the RNA constructs 
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Figure 5: Both poly-GR and –PR reduce translation in cell culture. A) Activation of the integrated 
stress response (ISR) or the unfolded protein response (UPR) causes phosphorylation of eIF2α. 
ISRIB inhibits downstream signaling of phosphorylated eIF2α, which normally activates activating 
transcription factor 4 (ATF4) and subsequent transcription of pro-apoptotic C/EBP homologous pro-
tein (CHOP). Phosphorylation of eIF2α can also inhibit protein translation. Chronic activation of this 
pathway ultimately leads to apoptosis. B) Q-PCR assessing the levels of ATF4-b mRNA in 2 dpf old 
wt AB zebrafish embryos injected with 5pg RNA encoding poly-PR or mCherry-only RNA. n = 30 per 
group. Students’t-test p =0.693. F-test for equal variances p = 0.29. 
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with stop codons reduced toxicity[154], indicating a combined effect of RNA and 
DPR toxicity. In Drosophila models, even high-level expression of RNA molecules 
containing 160x and 288x G4C2 repeats with RNA foci but no DPRs caused little 
or no toxicity, supporting the importance of DPRs in C9ORF72 pathology[168, 
212]. The TAG/GAG-constructs used in our study do not provide any informa-
tion about RNA toxicity of the pure G4C2 repeat structure. Thus, our models only 
provide information about poly-GR and –PR peptide toxicity, which was clearly 
higher than the sole effect of injections of the TAG/GAG-constructs.
 Poly-GR and poly-PR peptides were mainly detected as nuclear puncta 
in the brain of RNA-injected zebrafish embryos. Immunofluorescence staining 
was not sensitive enough to robustly detect these DPRs and poly-GR expression 
was therefore confirmed by ELISA. Injection with very low amount of RNA may 
create a mosaic effect, which may explain why only some cells show nuclear 
poly-GR and –PR puncta throughout the zebrafish body. In addition, GR and 
PR aggregation can be influenced by co-expression of poly-GA[74], that is not 
expressed in our model. For poly-GA, toxicity was directly linked to its cytoplas-
mic aggregation in a mouse model and neuronal cell culture[213]. For poly-GR, 
cytoplasmic aggregation does not seem to be necessary to exert its toxic effect in 
our model and in a recently published mouse model[199]. Aggregation processes 
and consequences of the presence of solid aggregates may vary between indi-
vidual DPRs. 
 Apoptosis is a normal event in the development of embryos from all spe-
cies, and it plays a major role in proper (embryonic) development and organiza-
tion of all tissues including the nervous system. However, in the adult brain apop-
tosis is linked to neurodegeneration[214]. Signs of apoptosis have been shown 
in spinal cord motor neurons of ALS patients[215, 216] and in neurons and astro-
cytes in brain tissue from FTD patients[217]. We observed increased apoptosis 
in zebrafish brain tissue upon expression of poly-GR and –PR peptides. The 
involvement of these DPRs in neuronal cell death may also be underlying the 
neurodegeneration observed in C9FTD/ALS patients. Next to apoptosis in brain 
tissue, overexpression of poly-GR and -PR in zebrafish models has been report-
Figure 5 continued: C) Co-transfection of COS7 cells with DNA constructs encoding 100x poly-GR 
or 100x poly-GR peptides and GFP-only. One day after transfection, cells were treated with 1ug/ml 
puromycin for 1 hour, fixed and stained for puromycin to visualize translation (red). Poly-GR and –PR 
DNA transfected cells (in green) do not show any puromycin staining, while GFP-only DNA transfect-
ed cells (in green) show normal puromycin staining. Nuclei were stained with DAPI (blue). Scale bars 
are 20 µm.
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ed to cause motor axon outgrowth defects such as shorter axons and aberrant 
branching[154, 179]. Our study confirms these findings and also shows similari-
ties to motor axonal phenotypes in zebrafish models for other genetic causes for 
FTD and ALS[218, 219]. Interestingly, overexpression of poly-GA did evoke tox-
icity but no defects in motor neurons or motility in zebrafish[154, 180], indicating 
that this phenotype can not be generalized to all DPRs.
 Our results show that inhibition of oxidative stress rescues poly-GR tox-
icity while inhibition of the ISR is sufficient to prevent apoptosis caused by po-
ly-PR. Previous studies indicate that poly-GR and –PR share similar cellular tar-
gets, including mitochondrial and ribosomal proteins[174, 186, 201, 220]. It might 
therefore be interesting to test Trolox and ISRIB on both DPRs. ER stress and 
oxidative stress have been linked to each other in the pathophysiology of several 
diseases[208]. ROS and oxidative stress can cause a redox imbalance and re-
duce the efficiency of protein folding pathways[208]. Accumulation of misfolded 
proteins in the ER activates the ISR and the UPR[207]. Furthermore, activation 
of the ISR causes a (temporarily) stop on translation, and both poly-GR and –PR 
inhibit translation in our cell culture experiment, which has been described be-
fore[174, 199, 220]. Recent reports on mouse models for poly-GR and –PR show 
a downregulation of genes involved in ribosome biogenesis[200] and reduced 
translation[199]. Enhanced phosphorylation of eIF2α, increased levels of ER fol-
dase PDIA1 and upregulation of CHOP have been found in post mortem brain 
sections of ALS patients[221-224], indicating activation of the ISR. Furthermore, 
the ER membrane protein complex and ER-resident proteins such as TMX2 and 
CANX can modify poly-PR toxicity[210]. Dysregulation of the ER can also lead 
to disruptions in the membrane of mitochondria, since the two organelles are 
interconnected[225]. In C9ORF72 iPSC-derived motor neurons that express both 
poly-GR and -PR, decreased cell survival is correlated with dysfunction in Ca2+ 
homeostasis, increased ER stress, and reduced mitochondrial membrane poten-
tial[201]. The effect of poly-GR and -PR on mitochondrial function can also be 
direct via their binding to mitochondrial ribosomal proteins[186, 201]. Thus, po-
ly-GR and -PR DPRs can evoke oxidative stress and activate the ISR via multiple 
ways.
 Another point of interest is the effect of ISRIB on RAN translation. Activa-
tion of the ISR and phosphorylation of eIF2α, either by DPRs or through neuronal 
excitation and stress, can enhance RAN translation[82, 83, 226]. Upregulation of 
RAN translation results in the formation of more DPRs, which in turn activate the 
ISR. Inhibition of this positive feed-forward loop by ISRIB might decrease neuro-
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toxicity by reduction of stress granule formation and restoring translation levels 
while at the same time prevent the formation of new toxic proteins. ISRIB might 
therefore have a double impact on cell viability.
 The ability of poly-GR and -PR to induce massive apoptosis in the ab-
sence of the other DPRs, G4C2 repeat RNA toxicity and haploinsufficiency illus-
trates the importance of these two DPRs in neuronal loss. Our toxicity model for 
poly-GR and -PR DPRs in zebrafish is perfectly suited for drug screens. To date, 
the effect of ISRIB and Trolox on the toxicity of DPRs has only been investigated 
in cell culture[186, 188, 210], and we are the first – to our knowledge – to confirm 
these rescue properties in vivo. Our study indicates a central role of oxidative 
stress and the integrated stress response in the pathogenesis of C9FTD/ALS. 
Additional drug screens can help to further identify and elucidate aberrant path-
ways involved in the neurodegeneration of C9FTD/ALS.
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Supplementary figure 1: Concentration series of poly-GR and –PR ATG-mediated and TAG/
GAG-mediated constructs. RNA of ATG and TAG/GAG constructs was injected in the yolk sac of 
fertilized oocytes in concentrations ranging from 1-200pg/nl. The amount of dead and malformed fish 
were assessed 24 hours after injection. Malformed embryos were defined as: severely undeveloped, 
having no head, a smaller head or only 1 eye. Fish with heart edema and/or tail twists were also 
scored as malformed. The average amount in mCherry injected fish is about 20% dead and only a 
few (1-5%) malformed fish. All malformed fish were taken out of any further analysis. N = 50 fish per 
construct per concentration.
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Abstract
The hexanucleotide G4C2 repeat expansion in the first intron of the C9ORF72 
gene explains the majority of frontotemporal dementia (FTD) and amyo-
trophic lateral sclerosis (ALS) cases. Numerous studies have indicated the 
toxicity of dipeptide repeats (DPRs) which are produced via repeat-associ-
ated non-AUG (RAN) translation from the repeat expansion and accumulate 
in the brain of C9FTD/ALS patients. Mouse models expressing the human 
C9ORF72 repeat and/or DPRs show variable pathological, functional and 
behavioral characteristics of FTD and ALS. Here, we report a new Tet-on in-
ducible mouse model that expresses 36x pure G4C2 repeats with ~100bp up-
stream and downstream human flanking regions. Brain specific expression 
causes the formation of sporadic sense DPRs aggregates within 6 months 
but no apparent neurodegeneration. Ubiquitous expression evokes abun-
dant sense DPRs in multiple organs, leading to weight loss, neuromuscular 
junction disruption, myopathy and a locomotor phenotype within the time 
frame of four weeks. We did not observe any RNA foci nor pTDP-43 pa-
thology. Two weeks of expression followed by two weeks of wash-out (no 
expression) reduced but did not completely clear DPRs. This short time pe-
riod was not enough to reverse the myopathy phenotype. Thus, expression 
of 36x G4C2 repeats, including 100bp human flanking regions, is sufficient 
for RAN translation of sense DPRs. In addition, expression of sense DPRs 
is sufficient to evoke a functional locomotor phenotype. Further research 
on this inducible mouse model is necessary to establish reversibility pos-
sibilities and time-windows to prevent cellular toxicity.
Keywords
C9ORF72, ALS, FTD, mouse model, inducible, DPRs, RAN translation
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Introduction 
FTD is a neurological disease characterized by neuronal loss in the frontal and 
temporal lobes leading to behavior and personality changes and language defi-
cits[1, 2]. The prevalence of FTD is approximately 15-20 cases per 100.000 peo-
ple and the age of onset is usually between 45 to 65 years[1]. FTD is part of 
a disease spectrum that also comprises ALS[13, 227]. ALS is a rapid progres-
sive motor neuron disorder which affects the upper motor neurons in the motor 
cortex and the lower motor neurons in the anterior horn of the spinal cord[8, 
9]. ALS patients develop muscle weakness, spasticity, atrophy and eventual-
ly paralysis[8, 9]. The prevalence of ALS is about 5 in 100.000 people and the 
age of onset is between 50 and 60 years of age[8, 9]. The hexanucleotide G4C2 
repeat expansion in the C9ORF72 gene explains almost 90% of the families 
presenting with both FTD and ALS symptoms[22, 23] (referred to as C9FTD/
ALS). Patients can be mosaic for repeat size and often have longer repeats in 
brain tissue than in DNA isolated from blood samples[42, 43, 46]. So far, re-
peat sizes of 30 – 4400 have been reported[39]. Associations between repeat 
size and FTD or ALS clinical diagnosis have not resulted in a clear picture 
[42-44]. Thus, the exact repeat size that triggers disease onset is not known. 
 Three mechanisms for the C9ORF72 repeat expansion have been pro-
posed to cause C9FTD/ALS[77]: 1) Hypermethylation of the repeat and surround-
ing CpG islands can lead to reduced levels of the normal C9ORF72 protein[101, 
109]. C9orf72 knock-out mice have shown its essential function in immunity, 
but do not present with FTD or ALS symptoms[77]. However, haploinsufficiency 
can still modify the effects of gain-of-function mechanisms via the function of 
C9ORF72 protein in autophagy and lysosomal biogenesis[118, 126]. 2) Repeat 
containing RNA from both sense and antisense direction can form secondary 
structures[78, 146] and RNA foci[56, 57]. Repeat–containing RNA or RNA foci 
can sequester RNA-binding proteins and prevent their normal functioning in the 
cell[62]. 3) The G4C2 repeat can also be translated into dipeptide repeats (DPRs) 
via repeat-associated non-ATG (RAN) translation [57, 66, 67]. RAN translation 
occurs in all reading frames of sense and antisense transcripts and results in 
the formation of poly-glycine-alanine (GA), poly-glycine-proline (GP), poly-gly-
cine-arginine (GR), poly-proline-alanine (PA) and poly-proline-arginine (PR). 
DPRs have been found throughout the brains of C9FTD/ALS patients[69] and 
especially poly-GR has been associated with neurodegeneration[72, 73]. Multi-
ple cell and animal models have indicated the detrimental effect of expression of 
both arginine-containing DPRs poly-GR and poly-PR and the slightly less toxic 
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poly-GA[74, 77, 168, 169, 171-174, 178, 179, 189]. DPRs have been studied 
extensively (reviewed in [77]), but possible reversibility and the exact number 
of repeats needed for RAN translation in vivo are still not determined[65, 79]. 
 So far, several mouse models of C9ORF72 have been published, includ-
ing 11 loss-of-function models and 10 gain-of-function models (reviewed in [77, 
228]), and 4 DPR-only mouse models investigating the role of poly-GA[213, 229], 
poly-GR[199] and poly-PR[200]. All mouse models support a gain-of-function hy-
pothesis in C9FTD/ALS, although not all BAC mouse models show neurodegen-
eration or a motor phenotype associated with ALS[77,228]. Here, we describe 
the generation and characterization of a mouse model that expresses human 
C9ORF72 36x pure G4C2 repeats with 100bp upstream and downstream human 
flanking regions under the expression of an inducible Tet-on promotor. This sys-
tem allows for temporal and spatial expression of the repeat expansion. We study 
both brain specific expression using a Ca2+/calmodulin-dependent protein kinase 
II linked reverse tetracycline-controlled trans-activator (Camk2-alpha-rtTA) driver 
and ubiquitous expression using a heterogeneous nuclear ribonucleoprotein 2B1 
(hnRNP-rtTA) driver. Expression of 36x pure G4C2 repeats was sufficient to pro-
duce low levels of sense DPRs and a locomotor phenotype upon four weeks after 
induction of expression.
Material and Methods
Cloning
DNA obtained from a C9FTD patient was assessed for the C9ORF72 repeat 
expansion by Asuragen kit according to manufacturer’s protocol and contained 
at least 54 repeats. DNA was amplified in three consecutive rounds of PCR with 
primers flanking the C9ORF72 repeat expansion (forward primer 5’-CCACG-
GAGGGATGTTCTTTA-3’ and reverse primer 5’-GAAACCAGACCCAAACACA-
GA-3’) and a PCR mix containing 50% betaine. The PCR program started with 
10 min at 98 °C, followed by 35 cycles of 35 sec at 98 °C, 35 sec at 58°C and 3 
minutes at 72°C and finished with 10 min at 72°C. The PCR product was cloned 
into TOPO vector PCR2.1 and restriction analysis with BsiEI (NEB) for 1 hour at 
60 °C revealed a G4C2 repeat expansion estimated around 50 repeats. Next, the 
TRE-90xCGG-GFP vector[230] was restricted with SacII (NEB) and the 90xCGG 
repeat expansion was replaced with the 50x G4C2 repeat expansion. This vector 
was sequenced using a primer in the tetracycline response element (TRE) se-
quence (5’-CGGGTCCAGTAGGCGTGTAC-3’) and revealed a repeat expansion 
of 36x G4C2. The final vector was cut with Aat II, PvuI and NdeI (NEB) and the 
C9ORF72 36x pure G4C2 hexanucleotide repeat mouse model
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band containing the TRE-36x G4C2-GFP construct was isolated from gel, dis-
solved in injection buffer (10 mM Tris-HCl, pH 7.4, 0.25 mM EDTA), and used 
to generate transgenic mice. Experiments on human material were done under 
informed consent and approved by the local Medical Ethical Test Committee 
(METC).
Animals
Pronuclei from oocytes of C57BL/6JRj wildtype (WT) mice were injected to create 
a new transgenic line harboring the TRE-36xG4C2-GFP construct. Genotyping was 
done 5’ of the repeat expansion with the following primers: forward 5’-GGTAC-
CCGGGTCGAGGTAGG-3’ and reverse 5’- CTACAGGCTGCGGTTGTTTCC-3’. 
Founder mice, F1 and F2 were screened in an animal welfare assessment by 
the local animal caretakers and scored normal for litter size and health charac-
teristics. All mice were housed in groups of 2 to 4 and were allowed to have free 
access to standard laboratory food and water. They were left on a 12h light/dark 
cycle. TRE-36xG4C2-GFP mice were crossed with hnRNP-rtTA[231] or Camk2-al-
pha-rtTA (kind gift of Rob Berman) on a C57BL/6JRj WT background. This gives 
25% of double transgenic mice (harboring both the TRE- and one of the rtTA-con-
structs), 50% of single transgenic littermates (harboring either the TRE- or the 
rtTA-construct) and 25% of WT littermates (having no transgene). At 6 weeks of 
age, mice were exposed to doxycycline (dox) (Sigma) (4 grams/L) combined with 
sucrose (50grams/L) dissolved in drinking water. Both single and double trans-
genic mice received dox water. To monitor the health and wellbeing mice were 
weighed every weekday while on dox water. TRE-36xG4C2-GFP x hnRNP-rtTA 
mice were sacrificed by cervical dislocation after maximal 4 weeks of dox admin-
istration. The TRE-36xG4C2-GFP x Camk2-alpha-rtTA mice were sacrificed by 
cervical dislocation after maximal 24 weeks of dox administration. As required by 
Dutch legislation, all experiments were approved in advance by the institutional 
Animal Welfare Committee (Erasmus MC, Rotterdam, The Netherlands). Project 
license: AVD1010020172224, protocol number 17-2224-01.
Erasmus Ladder  & Grip strength
The Erasmus Ladder is a fully automated test for detecting motor performance 
in mice[232]. It consists of a horizontal ladder between two shelters, which are 
equipped with a bright white LED spotlight and pressurized air outlets. These 
are used as cues for departure from the shelter box to the other shelter box. The 
ladder has 2 x 37 rungs for the left and right side. All rungs have pressure sen-
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sors, which are continuously monitoring and registering the walking pattern of the 
mouse. The mouse was placed in the starting box and after a period varying from 
9 to 11 seconds the LED light turned on and the mouse was supposed to leave 
the box. If the mouse left the box before the light turned on a strong air puff drove 
the mouse back into the box, and the waiting period restarts. If the mouse does 
not leave the box within 3 seconds after the light turned on a strong air puff drove 
the mouse out of the box. When the mouse arrived in the other box the lights 
and air puff turned off and the waiting period from 9 to 11 seconds starts and the 
cycle repeats again, making mice run back and forth on the ladder. Mice were 
trained on the Erasmus Ladder at the age of 5 weeks, every day for 5 days. The 
mice were trained to walk the ladder for 42 runs each day. At the age of 6 weeks 
the mice received dox/sucrose water and were tested on Monday, Wednesday 
and Friday the Erasmusladder. The average percentage of missteps, that were 
sensed by the descended rungs, was calculated over 42 runs in one test. Grip 
strength of the mice was measured after 4 weeks of dox treatment with a grip 
strength meter from Bioseb (Chaville, France). Measurements were performed 
on all four limbs together.
Neuromuscular Junction staining
Extensor digitorum longus (EDL) muscles were fixed in 1% paraformaldehyde 
(PFA) in 0.1M phosphate-buffered saline (PBS) overnight (o/n). The muscles 
were washed in 0.1M PBS and permeabilized in 2.5% Triton-X100 (Sigma) in 
0.1M PBS for 30 minutes and incubated in 1µg/ml α-bungarotoxin-TRITC (Invi-
trogen) in 1M NaCl for 30 minutes. Subsequently, muscles were  incubated for 
1 hour in a blocking solution (4% bovine serum albumin, 0.5% Triton-X100 in 
0.1M PBS). After blocking the muscles were incubated with a polyclonal chicken 
anti-neurofilament antibody (2Bscientific) 1:500 in blocking solution o/n at 4°C, 
followed by incubation for 4 hours with anti-chicken-alexa fluor 488 (Jackson Im-
muno Labs). Finally, the muscles were mounted on slides with 1.8% low-melting 
point agarose (ThermoFisher) in 0.1M PBS and images were taken with a Zeiss 
LSM700 confocal microscope.
Fluorescent In Situ Hybridization 
Brain and EDL muscle tissues of mice were fixed in 4% PFA in 0.1M PBS o/n. Tis-
sues were dehydrated and embedded in paraffin and cut into 6µm thick sections 
using a rotary microtome. Sections were deparaffinized using xylene and rehy-
drated in a standard alcohol series. Antigen retrieval was established in 0.01M 
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sodium citrate with pH 6 using microwave treatment of 1x 9min followed by 2x 
3min at 800W. The slides were then dehydrated in an alcohol series and shortly 
dried to air. Next, pre-hybridization was performed in hybridization solution (dex-
tran sulphate 10%w/v, formamide 50%, 2x SSC in diethyl pyrocarbonate (DEP-
C)-treated water) for 1 hour at 65°C. After pre-hybridization, hexanucleotide sense 
oligo (5’-Cy5-4xGGGGCC-3’) and hexanucleotide antisense oligo (5’-Cy5-4xC-
CCCGG-3’) probes (IDT) were diluted to 40nM in hybridization solution and heat-
ed to 95°C for 5 minutes. The slides were hybridized with probe mix o/n at 65°C. 
After hybridization the slides were washed once with 2xSSC/0.1%Tween-20 in 
DEPC-treated water and three times with 0.1x SSC in DEPC-treated water at 
65°C. Subsequently,  slides were stained with Hoechst (Invitrogen), washed with 
0.1M PBS and stained with Sudan Black (Sigma). Finally, slides were dehydrated 
and mounted using Pro-Long Gold mounting solution (Invitrogen) and images 
were taken with a Zeiss LSM700 confocal microscope.
Immunohistochemistry
Tissues of mice were fixed in 4% PFA in 0.1M PBS o/n, and  dehydrated and em-
bedded in paraffin. 6µm thick sections were cut using a rotary microtome. Sec-
tions were deparaffinized using xylene and rehydrated in an alcohol series. Anti-
gen retrieval was established in 0.01M sodium citrate with pH 6 using microwave 
treatment of 1x 9min followed by 2x 3min 800W. Endogenous peroxidase activity 
was blocked with 3% H2O2 and 1.25% sodiumazide in 0.1M PBS. Immunostain-
ing was performed overnight at 4°C in PBS block buffer (0.1M PBS / 0.5%protifar 
/ 0.15%glycine) and with the primary antibodies (see supplementary table 1 for 
all antibodies used in this study). The next day, sections were washed with PBS 
block buffer and antigen-antibody complexes were visualized by incubation with 
DAB substrate (DAKO) after incubation with Brightvision poly-HRP-linker (Im-
munologic) or anti-mouse/rabbit HRP (DAKO). Slides were counterstained with 
Mayer’s haematoxylin and mounted with Entellan (Merck Millipore International). 
The slides were imaged using a Olympus BX40 microscope (Olympus).
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Results
Generation and expression pattern of the human 36x G4C2 repeat mouse 
model
We generated our mouse model from DNA isolated from a C9FTD patient’s blood 
and amplified the repeat in three consecutive PCR rounds using primers that 
flanked the C9ORF72 repeat expansion (for primer sequences see materials and 
methods). The PCR product was cloned into a Tet-on vector with a GFP report-
er gene[230] (figure 1A). Sequencing of this DNA construct revealed a repeat 
size of 36x pure G4C2 repeats with 118 bp upstream and 115 bp downstream 
human flanking region (supplementary figure 1). The transgene (containing the 
TRE promotor, 36x G4C2 repeats and the GFP gene) was injected into pronu-
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Figure 1: Generation and expression of the 36x G4C2 repeat mouse model. A) Schematic of 
the Tet-on system. Mice either have a Camk2-alpha-rtTA or hnRNP-rtTA transgene that expres-
ses rtTA in a brain specific manner or in the whole body, respectively. Upon binding of doxycycli-
ne, rtTA can bind the TRE promotor and start transcription of the C9ORF72 G4C2 repeat expan-
sion and GFP gene, which has its own start site. B) DNA isolated from different tissues from the 
same mouse was analyzed with the Asuragen C9ORF72 PCR kit and shows a repeat length of 
36 in all tissues. C) Upper panel: GFP expression was detected in striatum and hippocampus cor-
nu ammonis (CA) and hippocampus dentate gyrus (DG) in double transgenic Camk2-alpha-rtTA/
TRE-36G4C2-GFP mice after dox administration. Lower panel; GFP expression in EDL muscle, 
kidney and liver of double transgenic hnRNP-rtTA/TRE-36xG4C2-GFP mice. Scale bars are 20 µm.
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clei of C57BL/6J mice. Founder mice were screened for the presence and size 
of the transgene  and transmission to their offspring. Genotyping for transgene 
presence was performed with primers 5’ of the repeat. Repeat size estimation 
was established using the Asuragen C9ORF72 repeat kit that is also used in rou-
tine diagnostics. Repeat size remained stable between generations and between 
multiple organs of the same mouse (figure 1B). Transgenic mice were born at 
Mendelian frequencies and showed normal viability. 
 Heterozygous tansgenic mice containing the TRE-36xG4C2–GFP trans-
gene were bred with two different heterozygous rtTA driver lines to evoke specific 
expression in the brain (CamK2-alpha-rtTA) or in all tissues (hnRNP-rtTA). Litters 
of this breeding consist of 4 different genotypes referred to in the rest of the 
paper as double transgenic (containing both the TRE-36xG4C2–GFP transgene 
and one of the rtTA transgenes) or single transgenic (containing only TRE or only 
an rtTA-driver transgene). WT littermates were not used in this study. Mice were 
administered doxycycline (dox) in their drinking water at 6 weeks of age to turn 
on expression, which revealed specific expression of GFP in the double trans-
genic (DT) mice only and no transgene expression in single transgenic (ST) mice 
(supplementary figure 2). Using the ubiquitous hnRNP-rtTA driver, we observed 
expression in almost all tissues, including extensor digitorum longus (EDL) mus-
cle, liver, kidney (figure 1C), heart and lung (supplementary figure 2), but not 
in brain and spinal cord (supplementary figure 2). Using the Camk2-alpha-rtTA 
driver, we observed GFP expression only in striatum and hippocampus dentate 
gyrus (DG) and cornu ammonis (CA) (figure 1C). GFP expression was detectable 
after 1 week of dox administration and remained detectable over 6 months (data 
not shown).
Human 36x G4C2 repeat mice show DPR expression but no RNA foci
To further characterize the expression of the transgene in our mouse model, we 
performed fluorescence in situ hybridization (FISH) to test for the presence of 
sense and antisense RNA foci. We were unable to detect RNA foci in multiple 
organs at multiple time points in none of the driver lines (supplementary figure 3). 
Despite the fact that our protocol was optimized to detect RNA foci in post-mortem 
human C9FTD/ALS frontal cortex paraffin tissue (supplementary figure 3), we 
could not detect any RNA foci in mouse paraffin tissue. Even though we could not 
detect any RNA foci, we were able to detect DPRs, illustrating that RNA contain-
ing the human 36x G4C2 repeat expansion is expressed in our in vivo model. Only 
sense transcribed DPRs (poly-GA, -GP and -GR) were present in all GFP-posi-
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tive tissues of the DT hnRNP-rtTA mice (figure 2). Poly-GA was visible as diffuse 
nuclear and cytoplasmic labeling, while poly-GP and –GR were only observed in 
the nucleus (figure 2 and supplementary figure 4). In the DT Camk2-alpha-rtTA 
mice, we could detect some small perinuclear aggregates in the striatum and hip-
pocampus after 24 weeks of dox administration (figure 2). However, the numbers 
of aggregates were very rare (about 1 aggregate per sagittal brain section). Lon-
ger follow-up of these mice is not possible, as administration of dox for more than 
6 months often leads to intestine problems. Also, both Camk2-alpha-rtTA and 
hnRNP-rtTA driven 36xG4C2 repeat mice show no abundant pathological hall-
marks of C9FTD/ALS, including p62 and pTDP-43 aggregates in brain and mus-
cle (supplementary figure 5). Nor did we observe any signs of neurodegeneration 
(cleaved caspase-3 staining, supplementary figure 5), astrogliosis or microgliosis 
(supplementary figure 6). As DPR inclusions were very rare in Camk2-alpha-rtTA 
mice and expression of DPRs was evident in the hnRNP-rtTA mice, we choose 
to focus on the DT hnRNP-rtTA mice for further assessment of the toxic effect of 
DPR expression in multiple organs in vivo.
36x G4C2 repeat mice develop a locomotor phenotype, rapid muscular dys-
trophy and NMJ abnormalities 
Ubiquitous expression of 36x G4C2 repeats in DT hnRNP-rtTA mice led to pro-
found toxicity. We started with dox treatment in 6 weeks old mice to avoid DPRs 
affecting normal development, which would complicate behavioral and functional 
read-out. A large proportion (45%) of DT mice quickly declined in body weight in 
the first 2-3 weeks after dox administration and had to be sacrificed (figure 3A). 
Mice that quickly lost weight after 2.5 weeks showed general sickness symptoms 
(weight loss, bad condition of the fur, reduced activity, shivering) and an enlarged 
bladder. The majority of mice survived longer and did not lose weight but devel-
oped a locomotor phenotype on the Erasmus ladder (figure 3B). This is a locomo-
tor test that counts the number of missteps of mice walking on a horizontal ladder. 
DT mice began to show more missteps after 2 weeks of dox treatment, while 
they were first trained and started at the same level as their ST littermates (fig-
ure 3B) (Two-way ANOVA analysis p=0.0001 for genotype and p<0.0001 for the 
interaction between genotype and time). DT mice sacrificed after 4 weeks of dox 
treatment displayed a white appearance of leg and back muscles macroscopical-
ly (figure 3C). At the histological level a massive distortion of muscle fibers could 
be observed (figure 3D). Histological analysis of other tissues revealed enlarged 
renal tubules in the kidney and hemorrhages in the bladder of mice that quickly 
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Figure 2: Expression of 36x G4C2 human repeats is enough to evoke sense DPR formation 
in vivo. TRE-36xG4C2-GFP/Camk2-alpha-rtTA double transgenic mice show some sparse peri-
nuclear aggregates of sense DPRs in the hippocampus dentate gyrus (pointed at by arrows). In 
TRE-36xG4C2-GFP/hnRNP-rtTA double transgenic mice, poly-GA shows both diffuse cytoplasmic 
and nuclear localization, while diffuse poly-GP and poly-GR are observed in the nucleus of the 
EDL muscle. Single transgenic littermates, consisting of either TRE-only or rtTA-only, are all nega-
tive for DPRs. Human post-mortem frontal cortex sections from C9FTD patients and non-demented 
controls was used as positive and negative control for DPR stainings. All scale bars are 20 µm.
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Figure 3: Expression of 36x G4C2 human repeats in vivo causes a locomotor phenotype 
and muscular dystrophy within 4 weeks. A) TRE-36xG4C2-GFP/hnRNP-rtTA double transgenic 
mice that receive dox show reduced survival after 1-3 weeks. B) Mice that survive develop a lo-
comotor phenotype on the Erasmusladder after 7 sessions (3 sessions/week). Two-way ANOVA 
p=0.0001 for genotype and p<0.0001 for the interaction between genotype and time. Error bars re-
present standard error of the mean (SEM) C) Sacrificed DT mice show white appearance of back 
and upper leg muscles. D) HE staining of the EDL muscle, kidney and bladder of DT mice. Scale 
bars of EDL and kidney images are 50 µm. Scale bar of bladder image is 200 µm. E) NMJ stai-
ning of the EDL muscle shows dissolving boutons (red, α-bungarotoxin) and disorganized axonal 
projections (green, neurofilament antibody). Scale bar 50 µm. F) The number of ChAT-positive 
motor neurons in the spinal cord does not differ between DT and ST mice. Scale bar is 20 µm.
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lost weight at 2.5 weeks (figure 3D). Analyses of the neuromuscular junctions 
(NMJ) by whole mount immunostaining of the EDL muscle showed distortion of 
the muscular boutons and projecting motor neuron axons after 4 weeks of dox 
treatment (figure 3E). The number of motor neurons assessed by choline acetyl-
transferase (ChAT) staining of the spinal cord was not different between DT mice 
and ST control littermates (figure 3F). Together, these data indicate that ubiqui-
tous expression of 36x pure G4C2 repeats in our mouse model causes multi-sys-
tem dysfunction, including urinary system problems and muscular dystrophy over 
the time course of one month. 
No reversibility of DPR expression and muscular dystrophy in mice with 2 
weeks expression followed by 2 weeks of wash-out
In order to investigate whether the phenotype could be reversed, we set-up a 
pilot experiment in which we administered 6 weeks old DT and ST mice with dox 
for 2 weeks and then changed them back to normal drinking water for 2 weeks 
(wash-out). After 4 weeks in total, mice were tested on grip strength and sacri-
ficed to assess pathology. Even though dox administration was stopped after 2 
weeks, about half of the DT mice still showed a fast reduction in body weight in 
the first 2-3 weeks after the start of the experiment and did not survive until the 
end of the experiment. For the reversibility experiments we applied a simple grip 
strength test for analyzing the muscular strength. Grip strength only showed a 
statistical significant difference between DT mice and ST control mice that both 
were exposed for a total of 4 weeks of dox treatment (figure 4A). Other groups 
were not significantly different (1-way ANOVA p=0.04 with post Bonferroni test). 
Haematoxyline-eosine (HE) staining of the EDL muscle from wash-out mice (2 
weeks dox treatments followed by 2 weeks normal water) still showed parts that 
displayed abnormal organization (figure 4B) and the NMJ still showed disrupted 
boutons and axonal projections (figure 4C). Immunostaining for GFP, poly-GA 
and -GP in muscles was clearly reduced but was still detectable, especially in nu-
clei (figure 5). Only poly-GR could not be detected anymore (figure 5). In kidney, 
GFP and all sense DPRs were cleared efficiently after dox reversal (supplemen-
tary figure 7). This indicates that DPR clearance is different per organ or cell type. 
Together, dox withdrawal for 2 weeks is not sufficient to completely clear DPRs 
and reverse muscular dystrophy in vivo.
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Figure 4: Two weeks of dox withdrawal is not enough to reverse the muscular dystrophy and 
NMJ phenotype of TRE-36xG4C2-GFP/hnRNP-rtTA double transgenic mice. A) Grip strength test 
shows a significant difference between TRE-36xG4C2-GFP/hnRNP-rtTA DT and ST control mice that 
received 4 weeks of dox. One-way ANOVA analysis p=0.04. Other groups are not significantly diffe-
rent. Error bars represent standard error of the mean (SEM). N=4 for DT groups and n=6 mice for ST 
groups. B) HE staining of the EDL muscle shows distortion in TRE-36xG4C2-GFP/hnRNP-rtTA DT mice 
that received 4 weeks dox or 2 weeks dox followed by 2 weeks of normal drinking water. Scale bars 
are 50 µm. C) NMJ of the EDL muscle shows collapsed boutons (red, α-bungarotoxin) and axonal pro-
jections (green, neurofilament antibody) in both groups of double transgenic mice. Scale bars 50 µm.
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Figure 5: GFP and sense DPRs are reduced but still visible after 2 weeks of dox withdrawal. 
A) GFP staining on EDL muscle of TRE-36xG4C2-GFP/hnRNP-rtTA double transgenic mice shows 
reduction in the intensity of staining when mice received 2 weeks of dox water followed by 2 weeks of 
normal drinking water compared to DT littermates that received 4 weeks of dox. B) Poly-GA staining of 
EDL muscle shows clearance of cytoplasmic poly-GA but retention of nuclear poly-GA after two weeks 
of dox withdrawal. C) Poly-GP staining is reduced in the nucleus of EDL muscle and D) Poly-GR staining 
is cleared from nuclei of EDL muscles after 2 weeks of dox withdrawal. Single transgenic littermates, 
consisting of either TRE-only or rtTA-only, are all negative for GFP and DPRs. All scale bars are 20 µm.
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Discussion
In this study, we show that ubiquitous expression of 36x pure G4C2 repeats in 
vivo is sufficient to cause NMJ abnormalities and muscular dystrophy leading 
to a specific locomotor phenotype within four weeks. In contrast, expression 
of 36x pure G4C2 repeats for 24 weeks in the murine brain, using a Camk2-al-
pha-rtTA driver, was not sufficient to result in pathology nor neurodegeneration. 
We speculate that expression levels of the 36x G4C2 repeat RNA and DPRs in 
our Camk2-alpha-rtTA driven model are not high enough in the brain. Alterna-
tively, the repeat length might not be long enough to evoke these abnormali-
ties. Other gain-of-function mouse models did show sense DPR pathology and 
a cognitive phenotype upon expression of longer repeats[136, 191, 193, 194], 
indicating that expression of C9ORF72 G4C2 repeat RNA is capable of evok-
ing these brain specific changes. Mice expressing 500 repeats show a severe 
phenotype compared with 29/36 repeat mice[193]. On the other hand, some 
C9ORF72 mouse models lack locomotor symptoms due to unknown factors [136, 
162, 192]. We do detect DPRs and a locomotor phenotype in DT hnRNP-rtTA 
mice, which might indicate a difference in vulnerability between tissues. Besides 
our model, neuromuscular junction abnormalities have only been described in 
one BAC mouse and one AAV-102x interrupted G4C2 mouse model [193, 194]. 
 Our mouse model shows similarities to the BAC 29/36 repeat mouse 
model published by Liu et al.[193], which carries the same repeat length, displays 
a motor phenotype, NMJ abnormalities and motor neuron loss in the spinal cord. A 
limitation of our mouse model is the lack of expression of our transgene, RNA foci 
and DPR pathology in the brain and spinal cord, which indicates that our observed 
locomotor phenotype might be driven by muscular dysfunction. Also, we use a 
different background (C57BL/6JRj) than Liu et al., (FVB/NJ)[193]. The phenotype 
in our mouse model develops faster (within four weeks after dox administration) 
than reported by Liu et al. (first symptoms started after 16 weeks of age)[193]. 
Differences in disease onset might be due to expression levels, as no phenotype 
was observed in a 37 repeat mouse with low expression levels[193]. Our hn-
RNP-driven model has only 36 repeats but expression levels might be higher than 
the model of Liu et al, which could explain the early onset of disease symptoms. 
 Sense DPRs were detected as cytoplasmic or nuclear diffuse and 
did not form aggregates in our hnRNP-driven mouse model. We did not de-
tect antisense DPRs, maybe because antisense C4G2 RNA is not transcribed 
in our mouse model or antisense DPR levels might be too low to detect. Re-
cent publications on poly-GR and -PR mouse models suggests that soluble 
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poly-GR and -PR are sufficient to cause neurodegeneration and behavioral 
deficits[199, 200]. On the other hand, the aggregation of poly-GA seems nec-
essary for its toxicity in another mouse model[213]. DPRs might differ in their 
abilities to aggregate, their molecular targets and their effects on several cel-
lular compartments and functions. Interestingly, poly-GA can influence the ag-
gregation of poly-GR and -PR[74, 196], and this is confirmed in AAV-66 and 
AAV-149x mice in which poly-GA and -GR co-aggregate in cells with poly-GA 
aggregates but poly-GR remains diffuse in cells devoid of poly-GA[195, 199]. 
Poly-GA expression can even partially suppress poly-GR induced cell loss at 
the wing in the Drosophila model[74]. Co-overexpression of poly-GA also abol-
ished cellular toxicity of low concentrations of poly-PR in NSC34 cells[196]. Oth-
er interactions between DPRs are still unknown and need further investigation. 
 Next to DPRs, we would expect to find RNA foci in our mouse mod-
el. Repeat length might influence RNA foci formation. A BAC mouse mod-
el of 110 repeats did not contain any RNA foci[136], while BAC mice with 
longer repeat sizes did present with RNA foci [136, 162, 192, 193]. On the 
other hand, AAV-mediated overexpression of 10 or 66 repeats did evoke RNA 
foci[191, 194], indicating that formation of RNA foci could also depend on ex-
pression levels. Even though we did not detect any RNA foci in our mouse 
model, we cannot exclude an effect of repeat RNA on the observed patho-
genesis. Repeat-containing RNA molecules might still be able to bind and se-
quester molecules or proteins and affect the function of cellular processes. 
 Another point of interest is the lack of apparent pTDP-43 pathology in our 
mouse model. pTDP-43 pathology is thought to be a late event in the pathogene-
sis of C9FTD/ALS[77]. TDP-43 cytoplasmic aggregation is also observed during 
muscle regeneration[233]. Several mouse models already show behavioral phe-
notypes and some mild neurodegeneration before the onset of pTDP-43 neuro-
pathology[136, 194, 199, 213, 229]. Changes in pTDP-43 solubility or cellular 
localization could already arise and contribute to cellular distress without the for-
mation of cytoplasmic aggregates per se. Indeed, several reports of C9FTD/ALS 
showed affected individuals with DPR pathology but mild or absent TDP-43 pa-
thology[27, 59, 66, 234, 235]. Together, our hnRNP-driven mouse model shows 
that ubiquitous expression of diffuse labeled sense DPRs is sufficient to evoke 
a locomotor phenotype without the need for RNA foci and pTDP-43 pathology. 
 The rapid translation of current knowledge into therapeutic intervention 
studies opens new avenues for drug discovery screens. So far, AON therapy has 
been tested in a BAC mouse model for C9ORF72 and successfully reduced the 
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amount of RNA foci and DPRs[136]. However, it remains unknown if this AON can 
also functionally reduce motor symptoms associated with the C9ORF72 repeat. 
New therapies are under development, including small molecules targeting RAN 
translation[78, 155, 236-239]. These can be easily tested in our mouse model, as 
it develops a quick and robust phenotype. Our model is suited to study DPR toxic-
ity in vivo but has the limitation of lack of expression and absence of neurodegen-
eration in the brain and spinal cord. We demonstrated that two weeks of expres-
sion followed by two weeks of wash-out (expression turned off) is not sufficient to 
prevent mice from developing muscular dystrophy. This indicates that transgene 
RNA or DPRs that were already produced during the first two weeks of dox admin-
istration continue to exercise their toxic effects. A recent publication estimated the 
half-time of most DPRs to be >200 hours[226]. Half time was longer for poly-GA 
puncta than for diffuse poly-GA and increased for poly-GR when localized in the 
nucleus[226]. Earlier intervention might be able to halt or reverse symptoms, but 
the preferred time-window for treatment is probably before the onset of symptoms. 
 Together, we provide evidence that expression of human 36x pure G4C2 
repeats is sufficient to evoke RAN translation and a locomotor phenotype in 
vivo. Due to high expression of sense DPRs driven by hnRNP-rtTA, a rapid pro-
gression of muscular dystrophy and NMJ disruption phenotype developed. This 
mouse model allows for determination of time-windows for treatment and for fast 
in vivo screening of new drugs and compounds that act on systemic toxicity of 
sense DPRs.
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Supplementary table 1: antibodies
Ab name Host Company Cat.nr Dilution
GA mouse Millipore, clone 5E9 MABN889 1:500
GP rabbit Bio Connect Life 
Sciences
24494-1-AP 1:250
GR mouse LifeTein Services n.a. (costum 
-made)
1:4000
PR mouse LifeTein Services n.a. (costum 
-made)
1:500
PA mouse Gift from Petrucelli n.a. 1:2500
pTDP-43 mouse Cosmo bio CAC-TIP-
PTD-M01
1:1000
p62 mouse BD Biosciences 610833 1:100
Neurofilament chicken 2B Scientific Ltd. CPCA-NF-H 1:500
GFAP rabbit Sigma G-9269 1:100
Iba1 rabbit Wako 019-19741 1:200
ChAT goat Chemicon AB144P 1:500
Poly-HRP anti 
Ms/Rb IgG
goat Immunologic DPV055HRP undiluted
anti-mouse HRP goat DAKO P0260 1:100
anti-rabbit HRP  goat DAKO P0217 1:100
anti-mouse Cy2 goat Jackson 715-255-150 1:100
anti-rabbit Cy3 goat Jackson 711-165-152 1:100
anti-chicken 488 goat Jackson 303-545-006 1:100
anti-goat HRP rabbit DAKO P0449 1:100
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Mouse
Human
Supplementary figure 1: Alignment of DNA sequence of mouse transgene (upper text line, lo-
wer case letters) and human C9ORF72 sequence  (lower text line with capital letters) surroun-
ding the repeat expansion. NCBI Reference Sequence: NG_031977.1. Our mouse model contains 
118 bp upstream and 115 bp downstream human flanking region around the G4C2 repeat expansion.
C9ORF72 36x pure G4C2 hexanucleotide repeat mouse model
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Supplementary figure 2: GFP expression in EDL muscle, heart, lung, liver and kidney of 
TRE-36xG4C2-GFP/hnRNP-rtTA double transgenic mice. No GFP staining was observed in the 
hippocampus dentate gyrus or in the spinal cord of DT mice. Single transgenic littermates, con-
sisting of either TRE-only or rtTA-only, are all negative for GFP staining. Scale bars are 20 µm.
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Supplementary figure 3: No sense nor antisense RNA foci were found in TRE-
36xG4C2-GFP/Camk2-alpha-rtTA and TRE-36xG4C2-GFP/hnRNP-rtTA double trans-
genic mice and control single transgenic littermates. Only frontal cortex samples of 
C9FTD cases present with some nuclear sense and antisense foci. Scale bars are 10 µm.
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Supplementary figure 4: Poly-GA expression in EDL muscle, lung, liver and kidney of TRE-
36xG4C2-GFP/hnRNP-rtTA double transgenic mice. No poly-GA staining was observed in the 
hippocampus dentate gyrus or in the spinal cord of DT mice. Single transgenic littermates, consi-
sting of either TRE-only or rtTA-only, are all negative for poly-GA staining. Scale bars are 20 µm.
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Supplementary figure 5 (left side): Expression of 36x G4C2 human repeats does not cause 
abundant p62, pTDP-43 and cleaved-caspase 3 pathology. TRE-36xG4C2-GFP/Camk2-alpha-
rtTA double transgenic mice show some sparse perinuclear aggregates of p62 in the hippocampus 
dentate gyrus (arrow). TRE-36xG4C2-GFP/hnRNP-rtTA double transgenic mice do not present with 
any p62, pTDP-43 or cleaved-caspase-3 pathology in EDL muscle. Single transgenic littermates, 
consisting of either TRE-only or rtTA-only, are negative for all pathology. All scale bars are 20 µm.
Supplementary figure 6: TRE-36xG4C2-GFP/Camk2-alpha-rtTA double transgenic mice do not 
show astrogliosis or microgliosis. Astrogliosis was assessed with GFAP labeling and microgli-
osis was tested with Iba1 staining. No differences in amount or morphology of GFAP-positive and 
Iba1-positive cells were seen in the hippocampus dentate gyrus of TRE-36xG4C2-GFP/Camk2-al-
pha-rtTA double transgenic mice and single transgenic control littermates. Scale bars are 20 μm.
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Supplementary figure 7: GFP and sense DPRs are cleared from the kidney after 2 weeks of dox 
withdrawal. A) GFP staining on kidney of TRE-36xG4C2-GFP/hnRNP-rtTA double transgenic mice 
shows clearance of GFP staining when mice received 2 weeks of dox water followed by 2 weeks of 
normal drinking water compared to DT littermates that received 4 weeks of dox. B) Poly-GA staining 
of kidney shows clearance of poly-GA after two weeks of dox withdrawal. C) Poly-GP staining and D) 
Poly-GR staining are also cleared from kidneys after 2 weeks of dox withdrawal. Single transgenic lit-
termates received 2 or 4 weeks of dox and are all negative for GFP and DPRs. All scale bars are 50 µm.
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Abstract
Human homologue of yeast UV excision repair protein Rad23b (HR23B) in-
clusions are found in a number of neurodegenerative diseases, including 
frontotemporal dementia (FTD), Huntington’s disease (HD), spinocerebellar 
ataxia type 3 and 7 (SCA3/7), fragile X associated tremor/ataxia syndrome 
(FXTAS) and Parkinson’s disease (PD). Here, we describe HR23B pathol-
ogy in C9ORF72 linked FTD and amyotrophic lateral sclerosis (ALS) cas-
es. HR23B presented in neuropils, intranuclear inclusions and cytoplas-
mic and perinuclear inclusions and was predominantly found in cortices 
(frontal, temporal and motor), spinal cord and hippocampal dentate gyrus. 
HR23B co-localized with poly-GA-, pTDP-43- and p62-positive inclusions 
in frontal cortex and in hippocampal dentate gyrus, the latter showing 
higher co-localization percentages. HR23B binding partners XPC, 20S and 
ataxin-3, which are involved in nucleotide excision repair (NER) and the 
ubiquitin-proteasome system (UPS), did not show an aberrant distribution. 
However, C9ORF72 fibroblasts were more sensitive for UV-C damage than 
healthy control fibroblasts, even though all factors involved in NER local-
ized normally to DNA damage and the efficiency of DNA repair was not 
reduced. HR23Bs other binding partner NGly1/PNGase, involved in ER-as-
sociated degradation (ERAD) of misfolded proteins, was not expressed in 
the majority of neurons in C9FTD/ALS brain sections compared to non-de-
mented controls. Our results suggest a difference in HR23B aggregation 
and co-localization pattern with DPRs, pTDP-43 and p62 between different 
brain areas from C9FTD/ALS cases. We hypothesize that HR23B may play 
a role in C9ORF72 pathogenesis, possibly by aberrant ERAD functioning.
Keywords
C9ORF72; ALS; FTD; HR23B; ERAD; NGly1; DPRs; poly-GA 
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Introduction
The hexanucleotide (G4C2) repeat expansion in the chromosome 9 open read-
ing frame 72 (C9ORF72) gene is the most common genetic cause of FTD and 
ALS[22, 23]. FTD is characterized by the degeneration of the frontal and tem-
poral parts of the brain, leading to abnormalities in behavior, language and per-
sonality[1]. ALS affects motor neurons in the brain and spinal cord, leading to 
loss of motor function, muscle weakness, breathing problems and eventually pa-
ralysis[7]. Clinical, pathological and genetic factors connect FTD and ALS, and 
in families often patients present with symptoms of both disorders[14]. The dis-
covery of the C9ORF72 hexanucleotide repeat expansion confirmed the genetic 
overlap between FTD and ALS, collectively referred to as C9FTD/ALS. Patholog-
ically, both diseases present with inclusions of autophagy protein p62/sequesto-
some 1 (p62) and inclusions of phosphorylated 43kDa TAR DNA-binding protein 
(pTDP-43), of which the latter is predominantly found in areas that are known to 
display substantial neurodegeneration[51, 85]. 
 The possible pathological mechanisms by which the C9ORF72 repeat 
expansion can lead to FTD and ALS are: 1) hypermethylation of the repeat ex-
pansion and the CpG promoter region of the C9ORF72 gene leading to haploin-
sufficiency [53, 101], 2) retention of repeat containing intron 1 in mRNAs causing 
RNA foci to appear in both nucleus and cytoplasm that sequester RNA-binding 
proteins[61, 152] or 3) the production of dipeptide repeats (DPR) by unconven-
tional repeat-associated-non-AUG (RAN) translation of the repeat[57, 66, 67]. 
These DPRs are produced from both sense and antisense transcripts resulting 
in 5 possibly toxic peptides (poly-GA, -GP, -GR, -PR and -PA) and are found as 
inclusions in post-mortem brain material of C9ORF72 carriers [69, 70].
 How these three mechanisms – alone or in combination – cause neu-
rodegeneration is currently under investigation. Several studies have indicated 
that especially the DPRs are toxic in both cell culture and in vivo models, with 
the arginine-containing poly-GR and -PR DPRs being the most detrimental[77, 
168, 171]. And poly-GR has been associated with neurodegeneration in human 
post-mortem brain sections[72, 73]. DPRs seem to cause various types of stress 
to the cell, including ER-stress, mitochondrial stress and nucleolar stress[77]. 
They can disturb the formation of membrane-less organelles, including RNA 
granules, nucleoli, spliceosomes and the nuclear pore complex (NPC) and fa-
cilitate the formation of stress granules[176]. Furthermore, nucleocytoplasmic 
transport and autophagy defects have been reported[75, 187, 188]. In addition to 
the list of disturbed pathways found in model systems of C9FTD/ALS, there have 
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also been a substantial number of proteins found to interact, bind or aggregate 
with repeat-containing RNA or DPRs[62, 240]. Currently, the primary affected 
pathways involved in the pathogeneses of C9FTD/ALS are under debate[77, 98, 
241]. Constituents of inclusions in human C9FTD/ALS brain material might pro-
vide a tool to identify key players in neurodegeneration. 
 Here, we tested a set of proteins implicated in aberrant pathways in 
C9ORF72 disease models for their presence in pathology or abnormal localiza-
tion in post-mortem human C9FTD/ALS brain sections. We selected Ran-GAP 
for its implication in nucleocytoplasmic transport defects[155], ADARB2 for its 
role in RNA binding and editing[107] and HR23B for its dual function in both DNA 
repair and the UPS[242]. FMRP and Pur-alpha were selected for their binding to 
C9ORF72 mRNA, their localization in stress granules and their rescue effect in 
multiple C9ORF72 models[149]. Surprisingly, we found only HR23B protein to 
be a constituent of inclusions observed in C9FTD/ALS cases. In this report, we 
describe HR23B distribution and its co-localization with known C9ORF72 patho-
logical hallmarks (DPRs, p62 and pTDP-43). Furthermore, we analyze HR23B 
function in DNA damage repair, the ubiquitin-proteasome system and ER-associ-
ated degradation. Disturbances of these pathways may contribute to the disease 
onset and/or progression of C9FTD/ALS.
Methods
Five C9ORF72 FTD, two GRN FTD, two MAPT FTD, three sporadic ALS and 
three non-demented control human brain sections were provided by the Dutch 
Brain Bank. C9ORF72 ALS  brain material of two patients was collected post-mor-
tem at the department of Neuropathology of Amsterdam UMC, University of Am-
sterdam, according to local legal and ethical regulations. Patients or relatives 
gave informed consent for autopsy and use of brain tissue for research purposes. 
Information about our patient cohort can be found in table 1. Human fibroblasts 
lines were provided by the cell repository of the department of clinical genet-
ics. All participants gave written informed consent for all obtained materials. The 
study was approved by the Medical and Ethical Review Committee of the Eras-
mus Medical Center. All procedures performed in studies involving human par-
ticipants were in accordance with the ethical standards of the institutional and/or 
national research committee and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards.
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Immunohistochemistry on human brain sections
Human brain sections (6 µm) were deparaffinized in xylene and rehydrated 
(100%-96%-90%-80%-70%-50% EtOH serie). Antigen retrieval was done in 
0.01 M sodium citrate, pH6.0 using pressure cooker treatment. Endogenous 
peroxidase activity was blocked with 0.6% H2O2 and 1,25% sodium azide in 
0.1M PBS. Immunostaining was performed overnight at 4°C in PSB block buffer 
(0.1M PBS/0.5%protifar/0.15%glycine). Antibodies used in this study are listed 
Table 1: Patient characteristics
Patient Clinical 
diagnosis
Family 
history
Genetic 
diagnosis
Age of 
onset
Disease 
duration
Male /  
Female
Brain 
weight
1 bvFTD FTD C9ORF72 51,8 8,7 Male 960 gr
2 bvFTD FTD C9ORF72 55,8 9,1 Male 1184 gr
3 bvFTD FTD and 
ALS
C9ORF72 66,4 8,1 Female 1060 gr
4 bvFTD ALS and 
dementia
C9ORF72 63,2 6,8 Female 958 gr
5 bvFTD FTD and 
ALS
C9ORF72 55,2 9,5 Male 1075 gr
6 FTD N/A Progranulin 
(Gln200X)
60,6 5,5 Female 894 gr
7 FTD FTD Progranu-
lin (Ser82 
ValfsX174)
47,4 4,3 Female un-
known
8 FTD FTD MAPT 
(G272V)
42,6 8,4 Male 962 gr
9 FTD FTD MAPT 
(P301L)
51,1 9,7 Male 887 gr
10 ALS N/A unknown 70 1 Male 1428 gr
11 ALS N/A unknown 65 2,2 Female 1125 gr
12 ALS N/A unknown 75 1,1 Male 1255 gr
13 ALS N/A C9ORF72 60 4,4 Female 1390 gr
14 ALS N/A C9ORF72 66 3,5 Male 1275 gr
15 ALS N/A C9ORF72 71 2,4 Female 1080 gr
16 Non- 
demented
N/A unknown N/A N/A Female 1080 gr
17 Non- 
demented
N/A unknown N/A N/A Male 1215 gr
18 Non- 
demented
N/A unknown N/A N/A Female 1139 gr
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in supplementary table 3, including concentration and brand/catalogue number. 
Antigen-antibody complexes were visualized by incubation with DAB substrate 
(DAKO) after incubation with Brightvision poly-HRP-linker (Immunologic) or 
anti-mouse/rabbit HRP (DAKO). Slides were counterstained with Mayer’s hae-
matoxylin and mounted with Entellan (Merck Millipore International). The slides 
were then left to dry in the fume hood for an hour and thereafter put in an 37°C 
incubater overnight. Pictures were taken by using an Olympus BX40 microscope 
(Olympus).
Immunofluorescence staining on human brain sections
Human brain sections were treated as described above. After incubation with the 
primary antibody, sections were washed with PBS block buffer (1xPBS/0.5%pro-
tifar/0.15%glycine) and incubated with secondary anti-mouse/rabbit Cy2/3 linked 
antibodies (Jackson). To remove background staining, a 10 min incubation with 
Sudan Black (Sigma, 0.1 gr in 100ml 70% ethanol, filtered) was done. To visu-
alize nuclei, slides were incubated for 10 min with Hoechst 33342(Invitrogen). 
Slides were mounted with ProLongGold (Invitrogen) and kept at 4°C until imaging 
at a Zeiss LSM700 Confocal microscope.
Assessment of neurodegeneration and protein pathology
For the neuropathological assessment we used brain sections from 5 C9ORF72 
FTD cases (see table 1). Five different brain regions (frontal cortex, temporal cor-
tex, motor cortex, hippocampus and cerebellum) per patient were semi-quantified 
on neurodegeneration and pathological score of p62, pTDP-43 and HR23B (sup-
plementary table 1). Counting was not performed in a blinded fashion. Neurode-
generation was assessed on haematoxylin and eosin (HE) sections and graded 
as absent (0), mild (1), moderate (2) or severe (3) based on the presence of neu-
ronal loss. The neurodegenerative score from the pathological report was also 
taken into account. Pathological scores were rated as (0) if completely absent, 
rare (1) if only a few could be found one brain section, occasional (2) if they not 
present in every microscopic field, moderate (3) if at least a few examples were 
present in most microscopic fields, and numerous (4) when many were present 
in every microscopic field[69]. We reported the overall number of immunoreac-
tive inclusions (total score) as well as the number of neuronal cytoplasmic inclu-
sions (NCI), neuronal intranuclear inclusions (NII) and dystrophic neurites (DN) 
(supplementary table 1). Total scores were assessed independent from NCI, NII 
and DN scores and represent an impression of the global load of pathology and 
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the number of inclusions using the same grading system as described above. 
Quantification of co-localization of HR23B with DPRs, p62 and pTDP-43 was not 
performed in a blinded fashion.
Colony forming assays
Human fibroblast lines from 4 C9ORF72 carriers (13E634, 13E659, 17E0225, 
17E0278) and 4 controls (81E253, 86E1375, 06E0717 and 99E0774) were 
obtained from the cell repository of the department of clinical genetics and the 
XP25RO fibroblast line was provided by the department of molecular genet-
ics. Fibroblasts were cultured in DMEM medium (Gibco) with 10% fetal calf se-
rum, 1% penicillin/streptavidin and 1% non-essential amino acids. To determine 
UV-sensitivity, human fibroblasts were seeded in triplicate in 10 cm plates (Grein-
er Bio-one) in a density of 2000 cells/plate. After 24 hours, cells were treated with 
increasing doses of UV-C (254 nm UV-C lamp, Philips). After 5-7 days, colonies 
were fixed with 0.1 % w/v Coomassie Blue (Bio-Rad) in a 50% Methanol, 10% 
Acetic Acid solution. Colonies were counted with the integrated colony count-
er GelCount (Oxford Optronix). Counting was performed automatically with the 
same settings for each fibroblast cell line, but not in a blinded fashion.
Immunofluorescence on human fibroblasts
To determine DNA damage recruitment of NER proteins, human fibroblasts were 
seeded on coverslips and after 1 week in culture irradiated with 60 J/m2 (254 
nm UVC lamp, Philips) through an 8 µm microporous filter (Millipore) to induce 
sub-nuclear local DNA damage. Cells were fixed after 30 min with 2% parafor-
maldehyde and permeabilized with 0.1 % Triton X-100 for 20 min. Next, cells 
were incubated with fresh 0.07 M NaOH in PBS for 5 min to denature DNA and 
enable CPD staining. Cells were then washed with PBS containing 0.15% glycine 
and 0.5% BSA and incubated with primary antibodies (see supplementary table 
3) overnight at 4°C. The next day, cells were washed with 0.1% Triton X-100 and 
incubated with Alexa Fluor conjugated secondary antibodies (488, 555 and 633; 
Invitrogen) for 1 hour at RT. Coverslips were mounted using ProLongGold with 
DAPI (Invitrogen) and imaged using a Zeiss LSM700 microscope. 
Unscheduled DNA Synthesis (UDS)
To measure NER capacity, human fibroblasts were grown on coverslips for 1 
week in culture and irradiated with 16 J/m2 UV-C. After irradiation, cells were 
incubated for 1 h in UDS medium (F10, 1% PS, 10% dialyzed serum) with 2% 
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HEPES and 1% 5-ethynyl-2’-deoxyuridine (EdU, Invitrogen). After 1 hour, medi-
um was changed to normal DMEM medium (10% FCS, 1% NEAA, 1% PS) for 
10 min. Next, cells were fixed in 4% paraformaldehyde and permeabilized with 
0.1% Triton X-100. Blocking was done using 1.5% BSA in PBS for 30 min. EdU 
incorporation was visualized by incubating cells for 1 h at room temperature with 
Click-it reaction cocktail containing Atto 594 Azide (60 µM, Atto Tec.), Tris-HCl (50 
mM, pH 7.6), CuSO4*5H2O (4 mM, Sigma) and ascorbic acid (10 mM, Sigma). 
After the Click-it reaction, cells were washed with 0.1% Triton X-100, incubated 
with Hoechst 33342 (Invitrogen) for 10 min and mounted with ProLongGold (In-
vitrogen). Images were acquired using a Zeiss LSM700 microscope. UDS levels 
were quantified by measuring the total nuclear fluorescence intensities (in at least 
50 cells per experiment) with FIJI image analysis software. Intensity levels were 
averaged and normalized to the fluorescence levels in unirradiated cells. Quanti-
fication of intensity levels was done automatically with FIJI but was not performed 
in a blinded fashion.
Results
Characterizing Ran-GAP, ADARB2, HR23B, FMRP and Pur-alpha in a cohort 
of C9FTD patients and non-demented controls
We started with assessing the localization of ras-related nuclear protein GTPase 
activating protein (Ran-GAP) in C9FTD patient brain sections. We studied five 
FTLD-TDP cases with the C9ORF72 repeat expansion and three non-demented 
cases (for information about our cohort, see table 1). We predominantly found 
a diffuse nuclear staining or nuclear envelop staining of Ran-GAP. Most nuclei 
were round-shaped but occasionally we observed misfolded nuclei or the in-
vagination of the nuclear membrane (supplementary figure 1). The number of 
oddly-shaped nuclei did not clearly differ between C9FTD cases and non-de-
mented controls. Next, we investigated Adenosine Deaminase, RNA Specific 
B2 (ADARB2) localization. ADARB2 immunostaining showed both nuclear and 
cytoplasmic localization in both C9FTD and non-demented controls. We could 
detect some intranuclear inclusions in the hippocampus dentate gyrus of C9FTD 
patients (supplementary figure 2A). However, IF double staining of ADARB2 with 
p62 showed similar results between hippocampal nuclei of C9FTD patients and 
non-demented cases (supplementary figure 2B).
 Next, we stained for HR23B and found different types of inclusions in cor-
tical areas, hippocampus and cerebellum of C9FTD cases (figure 1 and supple-
mentary figure 5). Most cytoplasmic inclusions showed a round and perinuclear 
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appearance (figure 1A & 1C), while some inclusions had a negative central core 
surrounded by a positive halo labeling (figure 1E). Neuropils were mostly found in 
layer 2 of cortical areas (figure 1A). Intranuclear inclusions were also observed, 
including cat-eye inclusions (figure 1B). Overall, layer 2/3 and layer 5/6 of frontal 
and temporal cortices showed the highest HR23B pathological burden in C9FTD 
cases, followed by motor cortex, hippocampus and cerebellum (figure 1G and 
supplementary table 1). Hippocampus dentate gyrus (DG) harbored some peri-
nuclear inclusions and hippocampus cornu ammonis (CA) showed some cells 
with strong nuclear staining (supplementary figure 5). Cerebellum showed low 
HR23B staining with some nuclear and perinuclear inclusions in the granular 
layer and nearly absent in the molecular layer (supplementary figure 5). Non-de-
mented controls showed normal nuclear localization of HR23B (supplementary 
figure 5).
 Furthermore, we assessed fragile X mental retardation protein (FMRP) 
localization in C9FTD cases. Punctuated FMRP staining in the cytoplasm indica-
tive of the formation of stress granules was absent in our C9FTD cases (supple-
Figure 1: Type and spreading of HR23B pathology found in C9FTD cases. Different types of 
HR23B pathology in C9FTD cases: A) neuropils and puncta in frontal cortex layer 2. B) intranuclear 
(cat eye) inclusion in hippocampus dentate gyrus. C) perinuclear inclusion in hippocampus dentate 
gyrus. D) round intranuclear inclusion in hippocampus dentate gyrus. E) round or oval inclusion with 
a hole in frontal cortex F) dystrophic neuron in cerebellum molecular layer. G) Spreading of HR23B 
compared to known p62 and pTDP-43 pathology. Depicted are semi-quantitive measures of neuro-
degeneration and pathological score in C9FTD. Neuronal loss score was based on hematoxylin and 
eosin (HE) staining and pathological report and scored as absent (0), mild (1), moderate (2) or severe 
(3). Pathological scores were based on the degree of pathology as absent (0), rare (1), occasional 
(2), moderate (3), or numerous (4). See also supplementary table 2 for details of pathological quanti-
fications. All scale bars are 20µm.
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mentary figure 3). FMRP was evenly distributed in the cytoplasm in both C9FTD 
cases and controls. Very occasionally, we could detect inclusions in the hippo-
campus dentate gyrus in both C9FTD cases and controls (supplementary figure 
3). Finally, we set out to test Pur-alpha staining, which showed to be located in 
stress granules in both C9FTD cases and controls (supplementary figure 4). We 
did not find Pur-alpha intranuclear inclusions in the cerebellum or other brain 
areas of C9FTD cases nor controls (supplementary figure 4). 
HR23B pathology is also present in C9ALS and GRN FTD post-mortem 
brain tissue
In order to validate the observed HR23B pathology, we used a second inde-
pendent HR23B antibody (for details see methods) that revealed similar results 
(supplementary figure 6). Furthermore, we expanded our cohort with three ALS 
cases with the C9ORF72 repeat expansion, three sporadic ALS cases with un-
known genetic cause, two FTD with GRN mutation and two FTD-MAPT cases. In 
non-demented controls, we observed immunoreactivity for HR23B in nuclei (sup-
plementary figure 5 and 6). C9ALS cases showed very strong HR23B staining 
in nuclei and some cytoplasmic inclusions in motor cortex (figure 2A) and spinal 
cord sections (figure 2B). Sporadic ALS cases also showed very strong nucle-
ar HR23B staining but no pathology in motor cortex (figure 2C) nor spinal cord 
(figure 2D). GRN FTD cases showed the same extend of HR23B pathology as 
C9FTD in frontal cortex, consisting of some intranuclear inclusions, cytoplasmic 
inclusions and neuropils (figure 2E). HR23B pathology was absent in MAPT FTD 
cases (figure 2F). 
HR23B co-localizes with poly-GA, pTDP-43 and p62 in C9FTD cases
To evaluate HR23B’s aggregation process in C9FTD, we performed double la-
beling with known pathological hallmarks, including DPRs, pTDP-43 and p62 in 
five C9FTD frontal cortices (figure 3). HR23B was mostly found to be co-local-
ized with p62 (figure 3), as 66% of all HR23B inclusions were also positive for 
p62 (supplementary table 2). Next is pTDP-43 with 22.6% of HR23B inclusions 
being positive for pTDP-43 (figure 3 and supplementary table 2). From all DPRs, 
HR23B showed partial co-localization with poly-GA (figure 3), for 6.6% (supple-
mentary table 2). The other DPRs only co-stained with 0-3% of all HR23B inclu-
sions. We did not evaluate poly-PA because we found too few inclusions. 
 Interestingly, hippocampus dentate gyrus showed a much higher co-lo-
calization between DPRs and HR23B than frontal cortex (figure 4 and supplemen-
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tary table 2). We found 60.6% of HR23B inclusions being positive for poly-GA in 
the dentate gyrus, which is nearly a 10-fold increase compared to the frontal cor-
tex (figure 4 and supplementary table 2). Poly-GP increased from 0.8% in frontal 
cortex to 4.7% in hippocampus and poly-GR also showed a 10-fold increase from 
1% in frontal cortex to 10.5% in hippocampus (figure 4 and supplementary table 
2). Only poly-PR stayed fairly undetectable with a slight increase from 0.65% 
in frontal cortex to almost 1% in hippocampus. HR23B co-localization with p62 
in dentate gyrus was also higher in hippocampus than in frontal cortex (87.4% 
vs 66%) (figure 4 and supplementary table 2). We performed a 2-way ANOVA 
to compare co-localization percentages of HR23B with pathological hallmarks 
between different brain areas (p<0.0001). Post Bonferroni test indicated that per-
centages of poly-GA and p62 were significantly different between hippocampus 
DG and frontal cortex (figure 4 and supplementary table 2). For the other DPRs 
and pTDP-43, differences were not significant (figure 4 and supplementary table 
2). These data suggest a difference in aggregation formation and co-localization 
patterns between different brain areas or cell types.
A
E
B C
FD
C9ALS C9ALS sALS
sALS GRN FTD MAPT FTD
Figure 2: HR23B pathology is also present in C9ALS and GRN FTD cases. A) HR23B staining in 
C9ALS motor cortex shows strong staining in the nucleus and a cytoplasmic inclusion. B) C9ALS spi-
nal cord section with cytoplasmic HR23B pathology. C) Sporadic ALS with very strong nuclear HR23B 
staining in motor cortex D) and in spinal cord. E) GRN FTD case with an intranuclear inclusion and 
neurites positive for HR23B in frontal cortex. F) HR23B pathology is absent in frontal cortex of MAPT 
FTD. All scale bars are 20µm.
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HR23B GA DAPI Merge
HR23B GP DAPI Merge
HR23B GR DAPI Merge
HR23B PR DAPI Merge
HR23B p62 DAPI Merge
HR23B pTDP-43 DAPI Merge
Figure 3: HR23B co-localizes with p62, TDP-43 and poly-GA in C9FTD cases. Immunofluores-
cent staining for HR23B (shown in red) in combination with DPRs (poly-GA, -GP, -GR and -PR) or p62 
or pTDP-43 (shown in green). Poly-PA was not evaluated because too few inclusions were found. All 
pictures are from frontal cortex of C9FTD cases. All scale bars are 10µm.
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Nucleotide excision repair is not affected in C9ORF72 patient fibroblasts
To assess any changes in the normal cellular function of HR23B, we first focused 
on its role in DNA damage repair. HR23B interacts with and stabilizes Xeroderma 
pigmentosum, complementation group C (XPC) protein [243], which is involved 
in the recognition of bulky DNA adducts in global genome nucleotide excision re-
pair (GG-NER). Staining with XPC antibody did not reveal any gross differences 
between C9FTD and non-demented control post-mortem brain sections (figure 
5). To assess nucleotide excision repair capacity in living cells, we performed 
UV-sensitivity assays with four C9ORF72 patient fibroblast lines and compared 
these to four healthy control fibroblast lines. Intriguingly, C9ORF72 fibroblasts 
were more sensitive to UV-C damage than healthy control fibroblasts (supple-
mentary figure 7A), but not as sensitive as a fibroblast line that is fully deficient in 
NER (XP25RO, homozygous for 619C>T causing an ARG207X change in exon 
5 of the XPA gene). 
 The GG-NER pathway is initiated by recognition of DNA damage by the 
HR23B/XPC/CETN2 complex, which is then followed by multiple downstream 
steps to verify and excise the damage[244]. We therefore assessed whether fac-
tors involved in each of the steps of the NER pathway were recruited normally to 
DNA damage in C9ORF72 fibroblasts. To do so, we evoked local DNA damage 
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Figure 4: HR23B co-localization percentages with poly-GA and p62 differ between frontal cor-
tex and hippocampus DG. Semi-quantification of co-localization of HR23B with pathological hall-
marks such as DPRs, p62 and pTDP-43 based on raw data in table S2. Two-way ANOVA is significant 
(p<0.0001) for pathology, brain area and interaction. Bonferroni test indicates that only poly-GA and 
p62 are significantly different between frontal cortex and hippocampus DG (both p<0.001).
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by UV-C irradiation through a microporous filter in our fibroblast lines and per-
formed immunofluorescence to visualize DNA damage (by cyclobutane pyrimi-
dine dimers (CPD) antibody) and DNA damage recruitment of NER factors XPC, 
XPB, XPA, XPF and XPG. All tested NER proteins clearly co-localized with DNA 
damage in C9ORF72 patient fibroblasts, indicating that recognition and process-
ing of CPDs is still functional in these cells (supplementary figure 7B). To finally 
verify that NER is fully operational, we measured incorporation of the thymidine 
analogue 5-ethynyl-2-deoxiuridine (EdU) after UV-C irradiation to quantify the 
efficiency of DNA repair in our fibroblast lines. The NER-deficient XP25RO cell 
line, which we used as negative control, did not show any EdU incorporation. 
In contrast, we still observed efficient EdU incorporation in our four C9ORF72 
patients cell lines to similar levels as in four healthy control lines (supplementary 
figure 7C), indicating that NER is not deficient in C9ORF72 patient fibroblasts.
NGly1, ERAD factor and HR23B binding partner, is less abundant in C9FTD 
brain sections
Besides its role in DNA damage repair, HR23B is also known for its function in 
the ubiquitin-proteasome system. Various HR23B binding partners have been 
identified which are involved in the unfolded protein response (UPR), transcrip-
tional regulation, cell cycle control and ER-associated degradation (ERAD)[242]. 
To assess if HR23B aggregation also evokes changes in the localization of the 
proteasome, we stained our sections for proteasome subunit 20S. However, we 
did not observe any obvious changes in 20S normal localization (figure 5). An-
other binding partner of HR23B is ataxin-3, a deubiquitinase enzyme in which 
a poly-glutamine expansion is linked to SCA3[245]. HR23B-positive inclusions 
have been found in post-mortem brain material of SCA3 patients[246] however 
we could not detect ataxin-3 pathology in C9FTD cases (figure 5). Besides the 
proteasome, we wondered if we could find any changes in ERAD. HR23B did not 
sequester NGly1, one of its known binding partners involved in ERAD, into pro-
tein inclusions. Strikingly, however, we did observe clearance of NGly1 staining in 
C9FTD frontal cortex (figure 5). Although some neurons showed the same strong 
peri-nuclear staining as almost all non-demented control cells, in the majority of 
patient neurons no NGly1 staining was observed, indicating reduced expression 
of NGly1 in C9FTD brains. This may suggest a partial loss of function of ERAD in 
a subset of neurons in the brain of C9FTD patients.
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Figure 5: HR23B does not sequester its bindings partners into inclusions. XPC, 20S and atax-
in-3 staining does not reveal any differences between C9FTD patients and non-demented controls. 
For NGly1, we observed less nuclei with perinuclear staining in C9ORF72 FTD brains than in non-de-
mented controls. All pictures are from frontal cortex. All scale bars are 20µm.
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Discussion
In the present study, we characterize HR23B pathology distribution and its co-lo-
calization pattern with pathological hallmarks. To our knowledge, we are the 
first to show that HR23B co-localizes with pTDP-43 pathology in brain tissue of 
C9FTD patients. We could also demonstrate HR23B pathology in C9ALS and 
sporadic ALS. HR23B pathology has been described before in HD, SCA3, SCA7, 
FXTAS and PD[246]. HR23B pathology was also present in both C9ORF72 and 
GRN FTD cases, but not in MAPT FTD cases, in contrast to a previous report of 
HR23B pathology described for FTDP-17 (FTD with parkinsonism with Pick bod-
ies consisting of tau protein) [246]. Also Alzheimer’s disease (AD) brain material 
did not show HR23B pathology[246]. Why AD and some FTLD-tau patients are 
an exception and do not present with HR23B pathology is unclear and requires 
further investigation. It should be noted that our study cohort was rather small 
(see table 1), which might explain why we could not confirm HR23B patholo-
gy in MAPT FTD cases. Next to HR23B, HR23A inclusions have been reported 
in FXTAS and in C9FTD post-mortem brain tissue[213, 246]. In general, HR23 
pathology seems to be widespread among neurodegenerative diseases, which 
underscores its relevance in a common disease pathogenesis of these disorders. 
 In our semi-quantitative co-localization studies, we found HR23B to be 
co-localized predominantly with p62, followed by pTDP-43 and poly-GA. HR23B 
inclusions were nearly always negative for the other DPRs. Overexpression of 
poly-GA in mouse models is enough to sequester HR23B[213, 229] and in a 
co-immunoprecipitation experiment of lysates from cells expressing GFP-tagged 
poly-GP, -GR and -GA, only poly-GA was found to bind HR23B[213]. This could 
also be a stochastic event, given the fact that poly-GA inclusions are the most 
abundant DPR in C9FTD/ALS brains [69]. It could also be caused by the ag-
gregation-prone nature of the poly-GA peptide itself [247], causing HR23B to 
bind easier or faster to poly-GA peptides than other DPRs. Binding of HR23B to 
DPRs also differs between brain areas; in the frontal cortex, only 6.6% of HR23B 
inclusions were poly-GA positive, while this increased to 60.6% in the hippo-
campus dentate gyrus. The same is true for poly-GP and -GR; co-localization 
with HR23B increased 5- to 10-fold between frontal cortex and hippocampus, 
although it remained low (1-10%). Subtypes of neurons may differ in their vul-
nerability for DPRs or there might be differences in the expression level and 
availability of HR23B and/or its binding partners between frontal cortex and hip-
pocampus dentate gyrus. Levels of HR23B can influence aggregation of poly-GA 
and toxicity of mutant TDP-43 and mutant SOD1[213, 248]. Overexpression of 
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HR23B protected for the formation of poly-GA inclusions in mouse primary neu-
ronal cultures[213]. In contrast, loss of HR23B seems to protect against motor 
neuron disease by enhancing mutant protein clearance[248]. Levels of HR23B 
seem to have opposite effects on aggregation, clearance and solubility of several 
proteins, which could result in differences in aggregation and co-localization pat-
terns observed between different brain areas. 
 HR23B can directly bind the proteasome and ataxin-3, a deubiquitinase 
enzyme that binds ubiquitinated proteins and can also bind to the proteasome[245, 
249]. Even though HR23B and proteasome subunits are sequestered into intra-
nuclear inclusions of ataxin-3 in SCA3 patients brain tissue[246, 250], ataxin-3 
and 20S do not show an aberrant localization in C9FTD patients post-mortem 
brain tissue. HR23B can also bind PNGase, a deglycosylation hydrolase involved 
in ERAD of misfolded glycoproteins. The affinity of PNGase for the proteasome is 
HR23B-dependent, which makes HR23B essential for the shuttling of misfolded 
proteins to the proteasome[251]. If HR23B is sequestrated into inclusions and be-
comes unavailable for PNGase, this might cause loss of initiation of ERAD. This 
is in line with our observation that a substantial number of neurons of C9FTD/
ALS patients show less abundant NGly1 staining. Many FTD-causing mutations 
are associated with protein degradation pathways[252]. In addition, mutations in 
NGLY1, the gene encoding PNGase, are linked to motor impairment, intellectual 
disability, and neuropathy in humans[253].
 HR23B is well known for its role in global genome nucleotide excision 
repair (GG-NER) and genetic polymorphisms in RAD23B are modifiers of laryn-
geal cancer risk in human [254]. The DNA damage response can be induced by 
the C9ORF72 repeat expansion[190] and elevated levels of R-loops (DNA-RNA 
hybrids), double strand breaks and ATM-mediated DNA repair signaling defects 
have been described before in rat neurons, human cells and C9ALS spinal cord 
tissue[145, 190]. Furthermore, ALS and C9ORF72 repeat carriers have an in-
creased risk for melanoma[255, 256], suggesting they may have an reduced re-
sponse to DNA damage. XPC, the binding partner of HR23B in NER, was found 
in inclusions in a poly-GA mouse model of C9FTD/ALS[213]. Nonetheless, we 
could not find XPC pathology in our human brain sections nor deficits in the 
NER pathway in C9ORF72 patient fibroblasts, even though C9ORF72 patient 
fibroblasts seem to be more sensitive for UV-C damage than healthy control fi-
broblasts. Why we do not find a clear impairment of NER in our study is unknown. 
Species-specific factors, overexpression of poly-GA in the mouse model or dif-
ference between fibroblasts and neurons might explain a part of the absence 
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of an effect. In addition, it could be possible that HR23A takes over the DNA 
repair function of HR23B when the latter is sequestered or dysfunctional. This 
has been demonstrated in mHr23b knockout (KO) mice that show no impairment 
in NER[242]. Still, mHr23b KO mice display impaired embryonic development, 
retarded growth and facial dysmorphologies that are not observed in mouse 
models deficient in other NER genes[242], which suggests a second function of 
HR23B. Although HR23A and HR23B have similar functions in DNA repair, they 
form distinct interactions with various cellular factors, including proteasomes, 
multi-ubiquitinated proteins and stress-related factors[257].
 Here, we set out to validate the aggregation of several proteins that have 
been described to mis-localize or bind RNA foci in C9FTD/ALS. Strikingly, we 
could not reproduce earlier published pathology for Ran-GAP, ADARB2, Pur-al-
pha and FMRP. The differences observed between our study and previous pub-
lications can be explained by multiple factors. First of all, we used post-mortem 
brain material that only presents the end-stage of the disease, so changes in 
localization of proteins in early stages of the disease can be missed. Also, the 
number of cells presenting with stress granules varies a lot between subjects 
and might be attributed to autolytic processes during human brain preservation, 
which can make it hard to detect subtle differences. Secondly, this study focused 
on FTD rather than ALS. This could especially be important for ADARB2, as one 
of the targets of ADAR proteins is the Q/R site of the GluR2 AMPA receptor [156]. 
Changes in ADARB2 localization could therefore mostly affect ALS cases and 
may be missed in our FTD cohort. Thirdly, pathology observed in cell culture 
and in vivo models could be due to overexpression of C9ORF72 RNA or DPRs 
in these models. Changes in patient neurons with endogenous expression can 
be more subtle but still act disturbing over time. Most model systems used so 
far do not include haploinsufficiency, which can be a modifying factor for cellular 
toxicity as well[126]. Finally, effects might be missed due to our small cohort. 
For example, differences in oddly-shaped nuclei in the Ran-GAP staining might 
only become evident when quantifying large number of cells. However, Saberi et 
al. also were unable to confirm Ran-GAP pathology[72], which strengthens our 
findings and illustrates the need for validation studies in biomedical research. 
Even though we did not observe any pathology of Ran-GAP, ADARB2, FMRP 
and Pur-alpha, their levels could still have a modifying effect on disease pro-
gression of FTD, as has been shown in iPSC-derived neurons and Drosophila 
models[107, 153, 155, 258]. 
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Conclusion
In this study, we confirm HR23B aggregation and its implication in C9FTD/ALS. 
HR23B has an important function in both the DNA damage response and the 
degradation of proteins via the UPS, UPR and ERAD. Our results in human 
postmortem brain tissue suggests that especially the degradation of proteins via 
ERAD may be involved in the pathogenesis of ALS and FTD. The exact role and 
timing of HR23B in disease onset and progression needs further investigation, 
including its interaction with and possible degradation of proteins implicated in 
neurodegenerative disorders.
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Supplementary figure 1: Ran-GAP staining in C9FTD cases and non-demented controls. Ran-
GAP is predominantly localized to the nucleus and nuclear membrane. Unevenly shaped nuclear 
membranes occur in both C9ORF72 FTD cases (n=5) and non-demented controls (n=3). All scale 
bars are 20µm.
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Supplementary figure 2: ADARB2 staining in C9FTD cases and non-demented controls. A) 
Staining of ADARB2 in C9ORF72 FTD cases (n=5) and non-demented control (n=3) post-mortem 
brain sections shows some intranuclear inclusions in hippocampus CA and DG. All scale bars are 
20µm B) Immunofluorescence staining of ADARB2 (red) and p62 (green) in hippocampal dentate 
gyrus reveals ADARB2 punctuated staining and some intranuclear inclusions in both C9ORF72 FTD 
cases (n=5) and non-demented controls (n=3). Scale bars in fluorescent pictures are 10µm.
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Supplementary figure 3: FMRP staining in C9FTD cases and non-demented controls. FMRP 
staining does not reveal any differences between C9ORF72 FTD cases (n=5) and non-demented 
control (n=3) post-mortem brain sections. Occasional inclusions are found in the hippocampus den-
tate gyrus in both C9FTD cases and controls. All scale bars are 20µm.
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Supplementary figure 4: Pur-alpha staining in C9FTD cases and non-demented controls. 
Pur-alpha staining reveals abundant stress granules in both C9ORF72 FTD cases (n=5) and non-de-
mented controls (n=3) post-mortem brain sections. All scale bars are 20µm.
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Supplementary figure 5: HR23B pathology in different brain areas of C9FTD cases. Staining of 
HR23B in several brain areas of C9FTD cases and non-demented controls. Pathology burden was 
highest in cortices (frontal, temporal and motor) and was mostly cytoplasmic (inclusions and neuro-
pils) and intranuclear (cateye). Hippocampus dentate gyrus (DG) harbors perinuclear inclusions, and 
hippocampus cornu ammonis (CA) had some cells with strong nuclear staining. Pathology was low 
in cerebellum granular layer with only some nuclear and perinuclear inclusions and almost absent in 
cerebellum molecular layer. Our C9FTD cases did not show HR23B pathology in spinal cord neurons. 
All scale bars are 20µm
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Supplementary figure 6: Validation of HR23B pathology by a second independent antibody. 
HR23B staining using Abcam antibody in C9ORF72 FTD cases (n=5) and non-demented control 
(n=3) post-mortem brain sections. Staining pattern is consistent with HR23B GeneTex antibody (see 
figure 1 and 2). All scale bars are 20µm
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Supplementary figure 7: Nucleotide excision repair is not affected in C9ORF72 human fibro-
blasts. A) Dose-response curve for 4 healthy control human fibroblast lines and 4 C9ORF72 human 
fibroblast lines and the NER deficient XP25RO human fibroblast line treated with increasing dose 
of UV-C light (0-12 J/m2). B) Immunofluorescence staining showing the recruitment of NER factors 
XPC, XPB, XPA, XPF and XPG to local DNA damage (visualized by CPD antibody), induced by 60 
J/m2 UV-C irradiation through a microporous filter. C) Human fibroblasts lines were treated with 16 
J/m2 UV-C light and incubated with EdU for 1 h to measure unscheduled DNA synthesis (UDS) as 
measure of DNA repair. The NER-deficient XPC25RO cell line is shown as negative control.
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Supplementary table 1: Neuropathological scores of C9ORF72 FTD patients. Neuronal loss 
score was based on hematoxylin and eosin (HE) staining and pathological report and scored as 
absent (0), mild (1), moderate (2) or severe (3). Pathological scores were based on the degree of pa-
thology as absent (0), rare (1), occasional (2), moderate (3), or numerous (4). Brain areas: F= frontal 
cortex, T= temporal cortex, M = motor cortex, H = hippocampus dentate gyrus, C = cerebellum. NCI 
= neuronal cytoplasmic inclusion, NII = neuronal intranuclear inclusion, DNs = dystrophic neurites.
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HR23B +
Gene & 
diagnosis
ID Brain 
area
Poly- 
GA
Poly- 
GP*1
Poly- 
GR
Poly- 
PR
Poly- 
PA *2
pTDP-
43
p62
C9ORF72 
FTD
1 F 11/153 
= 7%
0/103 
= 0%
1/109  
= 1%
0/150 = 
0%
N/A 19/121 = 
16 %
72/105 = 
68%
H 77/90 
= 85%
3/91  
= 3,3%
20/191 
= 10%
2/285 = 
0,7%
N/A 32/104 = 
31%
118/150 = 
78%
2 F 7/62  
= 11%
3/102 
= 3%
3/102  
= 3%
1/80 = 
1,25%
N/A 42/101 = 
42 %
72/107 = 
67%
H 62/135 
= 46%
3/173 
=1,7%
9/212  
= 4,3%
3/469 = 
0,6%
N/A 39/111 = 
35%
140/156 = 
90%
3 F 11/180 
= 6%
0/107 
= 0%
1/237  
= 0,4%
0/120 = 
0%
N/A 35/140 = 
25%
79/106 = 
75%
H 52/97 
= 54%
5/115 
= 4,3%
13/99  
= 13%
1/176 = 
0,5%
N/A 31/106 = 
30%
65/74 = 
88%
4 F 6/103 
= 6%
1/105 
= 1%
0/115  
= 0%
2/100 = 
2%
N/A 26/117 = 
22%
63/116 = 
54%
H 42/72 
= 58%
5/102 
= 4,9%
16/105 
= 15%
4/154 = 
2,6%
N/A 39/115 = 
34 %
92/102 = 
90%
5 F 5/175 
= 3%
0/100 
= 0%
1/131  
= 0,8%
0/160 = 
0%
N/A 9/105 =  
9%
92/136 = 
68%
H 54/90 
= 60%
10/107 
= 9,3%
10/105 
= 9,5%
0/68 = 
0%
N/A 22/100 = 
22%
61/66 = 
92%
GRN  
FTD
6 F 0% 0% 0% 0% N/A 59/178 = 
33%
118/157 = 
75%
H 0% 0% 0% 0% N/A 5/33 = 
15%
5/5 =  
100%
7 F 0% 0% 0% 0% N/A 61/125 = 
49%
100/154 = 
65%
H 0% 0% 0% 0% N/A 1/13 =  
8%
3/3 =  
100%
Non-de-
mented 
cases *3
16 F 0% 0% 0% 0% N/A 0% ½ = 50%
H 0% 0% 0% 0% N/A 0% 0%
17 F 0% 0% 0% 0% N/A 0% 1/3 = 33%
H 0% 0% 0% 0% N/A 0% 1/1=100%
18 F 0% 0% 0% 0% N/A 0% 2/2 = 
100%
H 0% 0% 0% 0% N/A 0% 1/1=100%
Supplementary table 2: Co-localization of HR23B with DPRs/pTDP-43/p62 differs between 
brain areas. Legend see next page
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Supplementary table 2 (continued): The percentage is the amount of HR23B inclusions also pos-
itive for other pathological hallmarks (not the other way around). For example 11/153 for poly-GA in 
C9FTD patient 1 means that out of 153 HR23B inclusions, 11 were also positive for poly- GA, which 
is 7%. F = frontal cortex. H = hippocampus dentate gyrus. *1 = All co-localizations are fibrils of po-
ly-GP and HR23B in frontal cortex. Perinuclear inclusions of poly-GP did not stain positive for HR23B. 
*2 = In total 2 poly-PA inclusions have been found in frontal cortex of 5 C9FTD patients, too less to 
quantify. We therefore state N/A = non-applicable in this table. *3 = Non-demented cases had some 
p62 and some HR23B inclusions per person per section, which sometimes overlapped. No pTDP-43 
inclusions were found so no co-localization of pTDP-43 with HR23B in non-demented cases.
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Supplementary table 3: Antibodies
Ab name Host Company Cat.nr Dilution
Rad23B mouse GeneTex GTX16485 1:50
Rad23B rabbit Abcam ab86781 1:250
XPC rabbit Bethyl A301-122A 1:100
20S rabbit ENZO life sciences BML-PW8155-0025 1:100
NGly rabbit Novus NBP1-83793 1:100
Ataxin-3 mouse Millipore MAP5360 1:1000
ADARB2 rabbit Atlas Antibodies HPA031333 1:100
Pur-alpha rabbit LS Bio LS-B6784 1:200
FMRP mouse N/A N/A 1:100
Ran-GAP rabbit Abcam Ab4784 1:1000
Poly-GR mouse LifeTein Services N/A 1:4000
Poly-PR mouse LifeTein Services N/A 1:500
Poly-GP rabbit Bio Connect Life Sciences 24494-1-AP 1:250
Poly-GA mouse Millipore, clone 5E9 MABN889 1:500
Poly-PA mouse Gift from Petrucelli n.a. 1:2500
pTDP-43 mouse Cosmo bio CAC-TIP-PTD-M01 1:1000
p62 mouse BD Biosciences 610833 1:100
XPA rabbit Santa Cruz sc-853 1:50
XPB rabbit Santa Cruz sc-293 1:1000
XPC rabbit Bethyl A301-121A 1:1000
XPF mouse Santa Cruz sc-136153 1:1000
XPG rabbit Bethyl A301-484A 1:100
CPD mouse CosmoBio TDM-2 1:1000
poly-HRP anti Ms/
Rb IgG
goat Immunologic DPV055HRP undiluted
anti-mouse HRP goat DAKO P0260 1:100
anti-rabbit HRP  goat DAKO P0217 1:100
anti-mouse Cy2 goat Jackson 715-255-150 1:100
anti-rabbit Cy3 goat Jackson 711-165-152 1:100
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Abstract
The C9ORF72 hexanucleotide G4C2 repeat expansion explains the majority 
of genetic frontotemporal dementia (FTD) and amyotrophic lateral sclerosis 
(ALS) cases. The expanded G4C2 repeat is translated into dipeptide repeat 
proteins (DPRs) that can form cellular aggregates in the central nervous 
system (CNS) of C9FTD/ALS patients. Especially arginine-containing DPRs 
are very toxic in cell culture and animal models. Poly-glycine-arginine (po-
ly-GR) has been associated with neurodegeneration in human post-mortem 
brain. To date, rapid progression has been made in the development of 
therapies for C9FTD/ALS in the preclinical phase. However, biomarkers that 
assess efficacy of treatment response in human clinical studies are much 
needed. Here we show that poly-GR can be specifically detected in brain 
sections and protein homogenates from frontal cortex of C9FTD/ALS cases 
using a new monoclonal antibody against poly-GR. The average amount of 
poly-GR measured in frontal cortex of seven C9FTD patients was 22.7 ng/
ml. Next, we investigated if poly-GR is present in cerebrospinal fluid (CSF) 
and could be used as a potential fluid biomarker in C9FTD/ALS. Unfortu-
nately, we were unable to detect poly-GR levels in CSF of both pre- and 
symptomatic C9ORF72 repeat carriers using an Enzyme-Linked Immuno 
Sorbent Assay (ELISA). This indicates that poly-GR may not be present 
in CSF or the levels are below our detection limit of 200pg/ml. In addition, 
poly-GR levels in peripheral blood mononuclear cells (PBMCs) of both pre- 
and symptomatic C9ORF72 repeat carriers were also below the detection 
level of our assay. More sensitive methods, like single molecule array (SI-
MOA), might be able to detect poly-GR in CSF and PBMCs in the near future 
using this new antibody. 
Keywords
C9ORF72, biomarker, poly-GR, FTD, ALS, ELISA, CSF
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Introduction
FTD is a neurological disease that is caused by degeneration of neurons in the 
frontal and temporal lobes of the brain, leading to changes in language, behavior 
and personality[1, 4]. ALS is a motor neuron disorder in which the upper motor 
neurons in the motor cortex and the lower motor neurons in the anterior horn of 
the spinal cord are affected[8, 9]. The hexanucleotide G4C2 repeat expansion in 
the C9ORF72 gene has been identified in 2011 as the most common genetic 
cause for both ALS and FTD[22, 23]. Individuals carrying this mutation can devel-
op symptoms related to both disorders[13, 33, 227] and are collectively referred 
to as C9FTD/ALS patients. The C9ORF72 repeat expansion can cause neuro-
degeneration via three potential mechanisms: 1) partial loss of function of the 
normal C9ORF72 protein, 2) gain of function of RNA foci that could sequester 
RNA binding proteins and 3) gain of function of possible toxic DPRs[77]. DPRs 
are produced from the expanded G4C2 repeat expansion via repeat-associat-
ed-non-AUG (RAN) translation. This occurs in both sense and antisense direc-
tion resulting in six different dipeptides; poly-glycine-alanine (GA), -glycine-pro-
line (GP), -glycine-arginine (GR), poly–proline-alanine (PA), -proline-arginine 
(PR) and –proline-glycine (PG)[52, 57, 67]. Note that poly-GP and PG are similar 
products from the sense and antisense strand but can differ in their N- and C-ter-
minus. DPRs accumulate during life in the CNS of C9FTD/ALS patients, with the 
sense products being most prominently found[51, 59, 69]. However, only poly-GR 
has been associated with neurodegeneration[72, 73]. Furthermore, the arginine 
containing DPRs, poly-GR and poly-PR, seem to be the most toxic in multiple in 
vitro and in vivo models of C9ORF72[168, 172-174, 176, 199, 220]. 
 Currently, antisense oligonucleotide (AON) therapy has provided prom-
ising results in preclinical studies for the treatment of C9FTD/ALS[136, 259]. For 
the successful implementation into clinical trials, biomarkers that measure target 
engagement, disease onset and progression are highly needed. Neurofilament 
light chain is a marker for axonal injury that correlates with prognosis and dis-
ease severity in genetic FTD, but is not suited for pharmacodynamic studies[260, 
261]. DPRs might be used as fluid biomarkers because of their high specificity 
for C9FTD/ALS. Assessment of DPR levels in for example brain samples from 
C9ORF72 mouse models has proven to be useful in target engagement studies 
that estimate the efficiency of drugs or compounds that directly target the repeat 
or RAN translation and ameliorate C9ORF72 repeat toxicity[78, 136, 197, 236]. 
Quantification of DPR levels could be used for the same reason in clinical trials. 
In 2014, Su et al. showed for the first time that poly-GP could be detected in CSF 
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of C9ALS patients[78]. Quantification of poly-GP in CSF in 3 cohorts containing 
C9ALS, C9FTD and C9FTD/ALS patients revealed stable levels over time that 
enables its potential use as pharmacodynamic marker in clinical trials[197, 262, 
263]. However, poly-GP levels did not correlate with age of onset or survival, 
cognitive or behavioral impairment nor gray matter deficits in any of these co-
horts[197, 262, 263]. Also in cellular and in vivo models of C9ORF72, poly-GP 
has been proven as non-toxic, in contrast to other DPRs like poly-GR (reviewed 
in [77, 264]). From all DPRs, poly-GR most often co-localizes with pTDP-43 and 
it is the only DPR that has been correlated with neurodegeneration in C9FTD/
ALS cases[72, 73]. We therefore assessed if poly-GR could be used as fluid bio-
marker in C9FTD/ALS cases. Here, we characterize a new monoclonal antibody 
against poly-GR and developed an ELISA that specifically detects poly-GR in the 
frontal cortex of C9FTD patients. Next, we tested for presence of poly-GR in CSF 
and PBMCs in a cohort of C9ORF72 carriers (pre-symptomatic and symptomatic 
FTD and ALS) and healthy controls. 
Methods
C9FTD/ALS and non-demented control human brain sections were provided by 
the Dutch Brain Bank. CSF samples were obtained from 6 patients with C9FTD, 3 
patients with C9ALS and 16 healthy first-degree family members. The unaffected 
family members consisted of 11 pre-symptomatic C9ORF72 repeat carriers and 5 
healthy control non-carriers. PBMC samples consisted of 3 C9FTD, 9 pre-symp-
tomatic C9ORF72 repeat carriers and 8 non-C9ORF72 healthy controls.  The 
presence of a C9ORF72 repeat expansion >30 was ascertained at the local 
clinical genetics diagnostics laboratory. C9ALS CSF samples were provided by 
the population based ALS study in the Netherlands (PAN)[265]. CSF of C9FTD, 
pre-symptomatic C9ORF72 carriers and healthy control samples were provid-
ed by the Frontotemporal Dementia Risk Cohort (FTD-RisC) study, in which 
C9FTD patients and healthy at-risk first-degree relatives are longitudinally fol-
lowed. Participants are followed yearly or two-yearly by a semi-structured health 
questionnaire, neurological and neuropsychological examination, blood sample 
collection, MRI imaging and CSF sampling. This study was approved by the local 
ethics committee (MEC-2009-409) and all participants (or a legal representative) 
provided written informed consent. Patient information regarding age-of-onset 
and disease duration can be found in supplementary table 1.
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COS7 and primary hippocampal mouse neuronal culture
COS7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gib-
co) supplemented with 10% fetal calf serum (FCS), 1% Penicillin/Streptomycin 
(P/S) and 1% non-essential amino acids (NEAA; Lonza) at 37°C in a 5% CO2 
humidified incubator. Primary hippocampal neurons of C57Bl/6J mice were pre-
pared and cultured as described in de Vrij et al. (2008)[266]. In short, a pregnant 
female mouse from the C57Bl/6J background was sacrificed when embryos were 
at day E17. Neurons were pooled from all embryos per litter, plated 100.000 
cells dropwise in a 6-wells plate and cultured with Neurobasal medium (Gibco) 
supplemented with 1% P/S, 1% glutamax (Gibco) and 2% B27 (Gibco). Mice 
were housed at the Erasmus MC animal facility (Rotterdam, the Netherlands), 
under standard housing and husbandry conditions, approved by the local animal 
welfare committee. Project license: AVD1010020172224, protocol number 17-
2224-04.
Transfection and immunocytochemistry
COS7 cells were plated at 150.000 cells/well in a 6-wells plate and transfected 
with 3 µl GeneJuice (Novagen) for 1µg DNA. Neurons were cultured for 14 days 
and transfected with 7µl Lipofectamin 2000 (Invitrogen) per 1 µg DNA. Two days 
after transfection, the cells were fixed with 4% paraformaldehyde (PFA) in 0.1M 
PBS and permeabilized with 0.5% Triton X-100 in 0.1M PBS. Immunostaining 
was performed overnight at 4°C in PBS block buffer (0.1M PBS/ 0.5% protifar/ 
0.15% glycine) with the monoclonal poly-GR antibody diluted 1:4000. The next 
day, cells were washed with block buffer and incubated with secondary antibody 
anti-mouse Cy3 (Jackson) 1:200 in block buffer at room temperature for 1 hour. 
After washing with 0.1M PBS, cells were shortly incubated with Hoechst 33342 
(Invitrogen) and mounted with ProLong Gold (Invitrogen). 
Immunohistochemistry on paraffin brain sections
Human brain sections (6µm) were deparaffinized with xylene and rehydrated 
(100%-96%-90%-80%-70%-50% EtOH serie). Antigen retrieval was done in 
0.01M sodium citrate, pH6.0 using pressure cooker treatment. Endogenous per-
oxidase activity was blocked with 0,6% H2O2 and 1,25% sodiumazide in 0.1M 
PBS. Immunostaining was performed overnight at 4°C in PBS block buffer (0.1M 
PBS/ 0.5% protifar/ 0.15% glycine) with the poly-GR antibody diluted 1:4000. 
Antigen-antibody complexes were visualized by incubation with DAB substrate 
(DAKO) after incubation with Brightvision poly-HRP-linker (Immunologic). Slides 
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were counterstained with Mayer’s haematoxylin and mounted with Entellan (Mer-
ck Millipore International). Pictures were taken using an Olympus BX40 micro-
scope (Olympus).
Protein isolation from frozen frontal cortex and PBMCs
Prior to lysing, frontal cortex samples were thawed on ice and supplied with RIPA 
buffer containing 0.05% protease inhibitors (Roche) and 0.3% 1M DTT (Invi-
trogen). Samples were mechanically lysed, followed by 30 min incubation on 
ice. After 30 min incubation, mechanical lysing was repeated and samples were 
centrifuged for 20 min at 4°C, followed by 3x 1 min sonication. After sonication, 
samples were centrifuged for 20 min at 4°C and the supernatant was used for 
ELISA. Whole protein content was determined using BCA assay (Thermo Fisher 
Scientific). The pellet was incubated at 95°C for 2.5 hours in 150µl 20% SDS with 
every 30 min 5 sec vortexing at max intensity. After incubation, samples were 
added up to 500µl with 2% SDS and tested on ELISA.
 PBMCs were isolated from peripheral blood ACD tubes following stan-
dard operating procedures. For lysing, samples were thawed on ice and supplied 
with ice cold Co-IP buffer (50mM Tris-HCl, pH 7.4; 300mM NaCl, 5mM EDTA, 1% 
Triton-X 100, 2% SDS) containing 0.01% protease and phosphatase inhibitors 
(Roche) and 0.3% 1M DTT (Invitrogen). Samples were lysed by agitation for 30 
min at 4°C. After 30 min agitation, samples were centrifuged for 20 min at 4°C, 
followed by 3x 1 min sonication. After sonication, samples were centrifuged for 20 
min at 4°C. Whole protein content of the supernatant was determined using BCA 
assay (Thermo Fisher Scientific).
Enzyme-Linked Immuno Sorbent Assay (ELISA)
MaxiSorp 96 well F-bottom plates (Thermo Fisher) were coated for 2h with 5.0 
µg/ml monoclonal GR antibody followed by overnight blocking with 1% BSA in 
PBS-Tween (0.05% Tween-20, Sigma Aldrich) at 4°C. After washing, 300µg total 
protein lysate was added per sample. As positive control, a 15x GR synthetic 
peptide (LifeTein) was used. This peptide was serial diluted to create a standard 
curve (in duplo).  All samples were measured both undiluted and diluted 2x and 
4x with 0.1M PBS. Samples and GR peptide were incubated on the plate for 1h 
at room temperature. After washing, all wells were incubated for 1h with bioti-
nylated monoclonal anti-GR antibody at a final concentration of 0.25 µg/ml in 
PBS-Tween/1% BSA. After washing again, samples were incubated for 20 min 
with Poly-HRP conjugate (Thermo Scientific) diluted 1:15.000 in PBS-Tween/1% 
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BSA. Following extensive washing, samples were incubated with substrate reac-
tion mix (R&D Sciences) for 15 min and stopped using 2N H2SO4. Read-out was 
carried out using a plate reader (Varioskan) at 450nm and 570nm. 1-way ANO-
VA with Barlett’s test for equal variances showed a significant difference in the 
variance per group, so we performed a Kruskal-Wallis test that does not assume 
equal variances and post Dunn’s multiple comparison test to compare groups.
Results
In this study we use a newly generated mouse monoclonal antibody against a 
synthetic 15xGR peptide (LifeTein). To validate this antibody we first co-transfect-
ed COS7 and wildtype primary mouse hippocampal neurons with GFP and a con-
struct encoding 100xGR (ATG-mediated, kind gift of Isaacs lab) and performed 
immunocytochemistry (ICC). Only cells positive for GFP (transfection ratio GFP 
3:1 GR) were stained with our anti-GR antibody clone 1G3 (supplementary fig-
ure 1). We selected and purified this clone for further use (for information about 
the production process of this antibody and selection of clone 1G3, see supple-
mentary figure 2). As a second validation, we performed immunohistochemistry 
Figure 1: Poly-GR pathology is selectively detected in C9FTD and C9ALS cases. A) Frontal cor-
tex of C9FTD and B) motor cortex of C9ALS shows poly-GR staining in brown. Poly-GR can be found 
as neuronal cytoplasmic inclusions or shows a complete staining of a neuron and its neurites. C) Po-
ly-GR inclusions are occasionally found in the spinal cord of C9ALS. D) Non-demented control frontal 
cortex, E) GRN FTD frontal cortex and F) MAPT FTD frontal cortex are negative for poly-GR staining.
A
E
B C
FD
C9ALSC9FTD
GRN FTD MAPT FTDnon-demented
C9ALS
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(IHC) labeling of post-mortem brain sections of C9FTD and C9ALS patients and 
non-demented controls. This revealed specific staining of poly-GR in perinuclear 
inclusions in frontal and temporal cortex, hippocampus and cerebellum of C9FTD 
patients but not of non-demented controls (figure 1 and supplementary figure 
3). C9ALS patients showed poly-GR neuronal cytoplasmic inclusions (NCIs) in 
motor cortex and occasionally in spinal cord (figure 1B-C). Poly-GR staining was 
mostly perinuclear in neurons, but sometimes also diffusely stained the cyto-
plasm (figure 1A-B). We also observed some neuropils in the temporal cortex of 
C9FTD cases (supplementary figure 3). Neuronal intranuclear inclusions (NIIs) 
were occasionally observed. We further tested the specificity of our antibody by 
including some post-mortem brain sections of GRN FTD and MAPT FTD cases, 
that did not reveal any positive poly-GR staining in the frontal cortex (figure 1E-F).
Figure 2: ELISA analysis shows poly-GR in human frontal cortex of C9FTD cases but not in 
CSF and PBMC samples. A) Our ELISA shows a positive selective signal for a synthetic 15xGR pep-
tide over a synthetic 15xPR peptide. B) Dose-response curves for the synthetic 15xGR peptide in the 
low (0-3130pg) and high (1-12.500pg) range. The limit of detection in the low rage is 200pg. C) ELISA 
on frontal cortex samples of C9FTD/ALS patients (n=7), FTD cases with other genetic mutations in 
GRN (n=2), VCP (n=2) and MAPT (n=1) and in non-demented controls (n=5). Poly-GR was signifi-
cantly higher in C9FTD patients with an average of 22.7 ng/ml. Kruskal-Wallis test with post Dunn’s 
multiple comparison test p = 0.0017 D) ELISA on CSF samples from C9FTD (n=6), C9ALS (n=3), 
C9ORF72-carrier pre-symptomatic (n=11) and non-C9ORF72 healthy control (n=5). No difference 
could be detected between OD values of the different CSF samples. E) ELISA on PBMCs of C9FTD 
(n=3), pre-symptomatic C9ORF72 repeat carriers (n=9) and non-C9ORF72 healthy controls (n=8). 
No difference could be detected between OD values of all PBMC samples.
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 After using our poly-GR antibody for immunohistochemistry in human 
C9FTD and C9ALS cases, we developed an ELISA using a synthetic 15xGR 
peptide (LifeTein) (figure 2). Our ELISA shows high specificity for GR, as it did 
not show any signal for a 15xPR synthetic peptide (LifeTein) (figure 2A). Next, 
we diluted the 15xGR peptide to make a dose-response curve in the high and 
low range, which revealed a sensitivity of 200 pg/ml (figure 2B). To further val-
idate our ELISA we isolated proteins from the frontal cortex of seven C9FTD/
ALS cases, five FTD cases due to other genetic causes (GRN, VCP or MAPT) 
and five non-demented controls (figure 2C). Poly-GR was significantly higher in 
frontal cortex samples of C9FTD/ALS cases (Kruskal-Wallis test with post Dunn’s 
multiple comparison test p = 0.0017), again illustrating the specificity of our as-
say. The calculated amount of poly-GR was on average 22.7 ng/ml in frontal 
cortices of C9FTD/ALS patients. Additional protein isolation using 20% SDS and 
95°C incubation (see methods) to extract more poly-GR from the insoluble frac-
tion only yielded 1.28 ng/ml extra poly-GR (data not shown). Next, we tested for 
the presence of the poly-GR peptide in CSF from a cohort of pre-symptomatic 
C9ORF72 expanded repeat carriers, symptomatic C9ORF72 expanded repeat 
FTD and ALS cases and related healthy controls. Unfortunately, we could not 
detect poly-GR in the CSF of any of the C9ORF72 expanded repeat carriers nor 
controls (figure 2D). Finally, we tested protein lysates from PBMCs isolated from 
peripheral blood of expanded repeat carriers (pre-symptomatic and symptomatic) 
but could not detect poly-GR, in none of the C9ORF72 repeat carriers nor con-
trols (figure 2E).
Discussion
In this study we show that poly-GR can be specifically detected in brain sec-
tions and protein isolates from frontal cortex of C9FTD/ALS cases using a new 
monoclonal antibody against poly-GR. We could not detect poly-GR in CSF from 
C9ORF72 repeat carriers, which suggests that poly-GR levels might be below our 
detection limit of 200 pg/ml or poly-GR is simply absent from CSF. More sensitive 
techniques such as SIMOA might be able to detect lower poly-GR levels. It could 
also be that poly-GR is mainly present as insoluble inclusions which complicates 
assessment by ELISA. Our antibody is able to recognize both the cytoplasmic 
form of poly-GR in transfected cells and poly-GR inclusions in post-mortem brain 
tissue. Stringent protein isolation protocols of C9FTD frontal cortex samples did 
not yield a higher ELISA signal, indicating that almost all poly-GR was already de-
tected in our standard ELISA procedure. Still, some insoluble poly-GR molecules 
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might be missed in CSF samples in our ELISA set-up.
 Previous assessment of poly-GP levels in CSF by Gendron et al. re-
vealed an average of 0.5ng/ml for asymptomatic C9ORF72 repeat carriers and 
0.8ng/ml for symptomatic C9ALS/FTD patients[197]. Our ELISA should be sen-
sitive enough to detect poly-GR levels in the same range. However, poly-GR 
pathology is less abundant than poly-GP in C9ORF72 human post-mortem brain 
sections[69] and might therefore also be lower in CSF than poly-GP. In addition, it 
could be possible that only poly-GP is present in CSF because of its high solubil-
ity compared to the other DPRs that are more polar and aggregation prone[264]. 
Since DPRs were detected in ependymal and sub-ependymal cells of the ventri-
cle wall[70], it is conceivable that DPRs might be secreted in CSF by these cells. 
Notably, DPRs are almost always observed as neuronal cytoplasmic inclusions 
throughout the CNS[51] and thus might be released in the extracellular space 
after neuronal death as well. DPRs are rare in spinal cord and lower motor neu-
rons of C9ALS cases[71], making a release of DPRs in CSF from axonal injury 
unlikely to contribute to DPR levels in CSF. In addition, DPRs can also be trans-
mitted from cell-to-cell in vitro[267] and arginine-containing DPRs can penetrate 
the membrane[268]. Interestingly, antibody therapy inhibits cell-to-cell transmis-
sion, seeding and aggregation of poly-GA[269], indicating an important role for 
detection of extracellular DPRs for drug discovery and treatment. 
 C9ORF72 is highly expressed in myeloid cells, particularly CD14+ 
cells[97] and poly-GP levels in PBMCs were previously reported[197]. We were 
unable to detect poly-GR in PBMCs of C9ORF72 repeat carriers, maybe because 
the levels are too low to detect with our ELISA. In contrast, Poly-GP might have 
higher levels in PBMCs because it is produced from both sense and antisense 
C9ORF72 transcripts. Therefore, Poly-GP does show great promise as a phar-
macodynamic biomarker for assessing new therapeutic approaches that target 
C9ORF72 repeat RNA, RAN translation or DPRs directly[197]. A combination 
with neurofilament light chain levels, that reflect neurodegeneration, will probably 
best predict disease progression and survival of C9FTD/ALS patients[260, 262]. 
As the field is now moving towards the development of therapies for C9FTD/ALS 
from the preclinical to the clinical phase, such fluid biomarkers are essential for 
successful assessment of clinical trials[270, 271].
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A
GR GFP DAPI Merge
B
GR GFP DAPI Merge
Supplementary figure 1: GR antibody specifically stains transfected cells. A) COS7 cells were 
transfected with a CMV-GFP plasmid and a 100xGR plasmid (both ATG-mediated, pcDNA3.1+ vec-
tor) in ratio GFP 3:1 GR. Two days after transfection, cells were fixed and stained for poly-GR and 
revealed co-localization between GFP expressing cells and poly-GR staining. B) The same procedure 
was performed using primary hippocampal neurons from wildtype C57BL/6J mice. Untransfected 
cells never showed positive poly-GR staining.
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direct ELISA:
Supplementary figure 2: Information about poly-GR mouse monoclonal antibody production 
process provided by IGBMC.
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Supplementary figure 3: Poly-GR pathology in several brain areas of C9FTD cases. Poly-GR 
neuropathology was most often observed as neuronal cytoplasmic inclusions (NCIs) in layer 2 and 5 
of the frontal and temporal cortex. In addition, temporal cortex harbored some neuropils. Hippocam-
pus dentate gyrus and cornu ammonis and cerebellum granular and molecular layers also show the 
presence of NCIs. Non-demented controls did not show any positive poly-GR staining using our new 
mouse monoclonal antibody.
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Supplementary table 1: Patient characteristics
Patient 
ID
Clinical  
diagnosis
Genetic  
diagnosis
Age of 
onset
Disease 
duration 
in years *
Male /  
Female
Used for
1 bvFTD C9ORF72 51,8 8,7 Male IHC
2 bvFTD C9ORF72 55,8 9,1 Male IHC
3 bvFTD C9ORF72 66,4 8,1 Female IHC
4 bvFTD C9ORF72 63,2 6,8 Female IHC
5 bvFTD C9ORF72 55,2 9,5 Male IHC
6 FTD GRN (Gln200X) 60,6 5,5 Female IHC
7 FTD GRN (Ser82 
ValfsX174)
47,4 4,3 Female IHC
8 FTD MAPT (G272V) 42,6 8,4 Male IHC
9 FTD MAPT (P301L) 51,1 9,7 Male IHC
10 ALS unknown 70 1 Male IHC
11 ALS unknown 65 2,2 Female IHC
12 ALS unknown 75 1,1 Male IHC
13 ALS C9ORF72 60 4,4 Female IHC
14 ALS C9ORF72 66 3,5 Male IHC
15 ALS C9ORF72 71 2,4 Female IHC
16 FTD C9ORF72 48 10 Male Protein isola-
tion of frontal 
cortex (PFC)
17 FTD/ALS C9ORF72 60 8 Female proteins PFC
18 FTD C9ORF72 61 7 Female proteins PFC
19 FTD C9ORF72 71 7 Male proteins PFC
20 FTD C9ORF72 69 6 Male proteins PFC
21 FTD/ALS C9ORF72 39 3 Female proteins PFC
22 FTD/ALS C9ORF72 61 2,8 Female proteins PFC
23 FTD GRN (Gln24X) 54 5 Male proteins PFC
24 FTD GRN (Gly387fs) 57 3 Male proteins PFC
25 FTD VCP (p.R159S) 56 5 Female proteins PFC
26 FTD VCP (p.T262S) 60 7 Female proteins PFC
27 FTD MAPT (P301L) 58 8 Female proteins PFC
28 Non-demented N/A N/A N/A Male proteins PFC
29 Non-demented N/A N/A N/A Female proteins PFC
30 Non-demented N/A N/A N/A Male proteins PFC
31 Non-demented N/A N/A N/A Female proteins PFC
32 Non-demented N/A N/A N/A Female proteins PFC
33 bvFTD C9ORF72 38 8,3 Female CSF& PBMCs
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34 bvFTD C9ORF72 51 3,2 Male CSF& PBMCs
35 AD-like FTD C9ORF72 71 4 Male CSF
36 bvFTD C9ORF72 79 2 Male CSF
37 ALS C9ORF72 57 0,3 Female CSF
38 bvFTD C9ORF72 52 7,2 Male CSF
39 bvFTD C9ORF72 61 11,3 Male CSF
40 ALS C9ORF72 53 4 Male CSF
41 ALS C9ORF72 56 2 Male CSF
42 presymptomatic C9ORF72 N/A N/A Female CSF& PBMCs
43 presymptomatic C9ORF72 N/A N/A Female CSF
44 presymptomatic C9ORF72 N/A N/A Female CSF
45 presymptomatic C9ORF72 N/A N/A Female CSF
46 presymptomatic C9ORF72 N/A N/A Female CSF& PBMCs
47 presymptomatic C9ORF72 N/A N/A Female CSF& PBMCs
48 presymptomatic C9ORF72 N/A N/A Female CSF& PBMCs
49 presymptomatic C9ORF72 N/A N/A Male CSF
50 presymptomatic C9ORF72 N/A N/A Male CSF& PBMCs
51 presymptomatic C9ORF72 N/A N/A Male CSF& PBMCs
52 presymptomatic C9ORF72 N/A N/A Male CSF& PBMCs
53 presymptomatic C9ORF72 N/A N/A Female PBMCs
54 presymptomatic C9ORF72 N/A N/A Female PBMCs
55 Healthy control N/A N/A N/A Male CSF
56 Healthy control N/A N/A N/A Male CSF& PBMCs
57 Healthy control N/A N/A N/A Female CSF& PBMCs
58 Healthy control N/A N/A N/A Male CSF
59 Healthy control N/A N/A N/A Male CSF& PBMCs
60 Healthy control N/A N/A N/A Female PBMCs
61 Healthy control N/A N/A N/A Male PBMCs
62 Healthy control N/A N/A N/A Female PBMCs
63 Healthy control N/A N/A N/A Male PBMCs
64 Healthy control N/A N/A N/A Female PBMCs
* Disease duration has been estimated from the onset of first symptoms (retrospectively determined, 
not date of diagnosis) until death or until CSF sample collection.
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Abstract
In this thesis, we have shown that both poly-GR and –PR clearly evoke 
cellular toxicity in our zebrafish model. In our inducible transgenic mouse 
model, overexpression of 36x pure G4C2 repeats produces sense DPRs and 
elicits a motor phenotype. Our data therefore support a gain-of-function 
mechanism as major cause of the neurodegeneration observed in C9FTD/
ALS cases. However, we do not assess the effect of loss-of-function, which 
could be a disease modifying factor. Also, expression of all DPRs, RNA foci 
and haploinsufficiency together might differently affect molecular targets 
and cellular functioning. In this discussion, we will evaluate our own data 
and recent literature to identify key pathological and molecular events that 
drive neurodegeneration in C9FTD/ALS patients. In the last part, we will ad-
dress the development of reliable biomarkers that can help to find the best 
time to start treatment and can provide information on treatment response, 
which is essential for the right implementation of new therapies.
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1. What is the toxic culprit?
1.1 RNA vs DPR toxicity
In our zebrafish study, we observed a combined effect of RNA and DPR cellular 
toxicity. We used ATG-mediated constructs encoding poly-GR and –PR without 
G4C2 sequence (using alternative codons) to investigate protein-only toxicity. Mu-
tating the ATG start site generated constructs to investigate RNA-only toxicity. 
Injections with these RNA-only constructs evoked cellular toxicity in zebrafish 
embryos. However, this does not provide any information about RNA toxicity of 
the pure G4C2 repeat structure. We can therefore only use our model to obtain 
information about relative toxicity of protein-only constructs, which was clearly 
higher than the sole effect of RNA-only injections.
 Several studies have made a direct comparison between G4C2 RNA and 
DPR toxicity. In Drosophila, overexpression of 36x and 100+ expanded G4C2 re-
peats in eyes or neurons caused profound neurodegeneration[168]. This effect 
disappeared when repeats were interrupted with stop-codons (RNA-only con-
struct)[168], indicating that DPRs were responsible for the observed toxicity. In-
deed, overexpression of ATG-mediated DPR constructs were far more toxic than 
the RNA-only construct[168]. However, the introduction of stop-codons could 
affect secondary structures of the G4C2 repeat and thereby alter its biological ef-
fect. To circumvent this problem, two other Drosophila studies investigated pure 
G4C2 repeats. Overexpression of 160x pure G4C2 repeats in an intronic context 
caused formation of RNA foci in both glia and neurons, but did not cause neuro-
degeneration[212]. Also long (100-1000x) sense and antisense repeat constructs 
either inside an intron of GFP or part of a poly-adenylated transcript generated 
many nuclear and cytoplasmic RNA foci, but neither construct led to cellular tox-
icity[272]. These three drosophila models indicate that DPRs are more toxic than 
the expression of G4C2 repeats in an (intronic) RNA context.
 Other studies interpret their results as caused by RNA toxicity only, be-
cause DPRs were undetectable. Swinnen et al. injected zebrafish embryos with 
pure 70x G4C2 repeat RNA, which led to cellular toxicity[154]. In Drosophila, 
overexpressing 30x G4C2 interrupted repeats caused toxicity in eyes and motor 
neurons[153, 155]. Also in primary rat cortical and motor neuron cultures, overex-
pression of expanded G4C2 repeats caused reduced survival[171]. As DPRs were 
not detectable in these studies, the toxic effect could be attributed to an RNA-only 
gain-of-function mechanism[153-155, 171]. However, in our experience very low 
poly-GR and –PR levels already can have an effect on cell death in zebrafish, 
while DPR levels are too low to detect with dot blot or Western blot and could only 
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be detected with ELISA. We should therefore be cautious with interpreting these 
studies as RNA-only models. Combined with the studies discussed above, DPRs 
seem to have a more profound effect on cellular toxicity than G4C2 RNA toxicity 
alone. However, we have to keep in mind that these are all overexpression stud-
ies, which makes it hard to translate these models to the human situation.
1.2 Functional effects of RNA foci
The G4C2 repeat RNA can capture several RNA-binding proteins, such as hn-
RNP-A3, hnRNP-H, eIF2α, FUS, SC35, ALYREF, Ran-GAP and Pur-alpha (see 
also table 1 of the general introduction). But this does not always seem to have 
functional consequences, as only a small percentage of a certain protein is se-
questered or other proteins can compensate for its loss. In Drosophila, RNA foci 
were able to sequester Glorund, the Drosophila ortholog of hnRNP-H, but this 
did not lead to cellular toxicity[272]. Also, the number of neurons in which RNA 
foci co-localized with hnRNP-H in cerebellum of C9ALS cases was extremely 
low (less than 3%)[149]. Other sequestered proteins like eIF2α, FUS and SC35 
also rarely (<5%) co-localized with G4C2 RNA foci in cerebellum of C9FTD/ALS 
patients[149, 152]. This suggests that the formation of RNA foci does not affect 
the overall distribution of these sequestered proteins and that sufficient free pro-
teins remains available to fulfill their normal cellular function. Alternatively, other 
proteins may take over their function; when ALYREF was depleted from HeLa 
cells, this only caused a partial block of nuclear export, suggesting the existence 
of other proteins with redundant function[148]. Binding of some proteins to RNA 
foci might even be protective, as has been suggested for hnRNP-A3[273]. Knock-
down of hnRNP-A3 causes more RNA foci and DPR formation in primary rat 
hippocampal neurons and fibroblasts from C9ALS patients[273]. These studies 
illustrate that the sequestration of proteins by RNA foci does not necessary result 
in their reduced normal functioning.
 In contrast, several rescue experiments indicate that RNA foci do have 
an effect on the availability and function of the sequestered proteins. Overex-
pression of Pur-alpha in Drosophila rescued the phenotype observed in eye de-
velopment[153]. Overexpression of Ran-GAP also rescued 30xG4C2 repeat in-
duced-toxicity in Drosophila eyes and motor neurons[155]. Furthermore, Conlon 
et al. showed that splicing targets of hnRNP-H were changed in cerebellum tis-
sue of seven C9ALS cases compared to non-demented controls[274]. Sequenc-
ing of RNA isolated from brain tissue of C9ALS patients revealed global changes 
in alternative splicing, particularly skipping of exons that are predicted targets of 
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hnRNP-H[158]. These results illustrate that the G4C2 repeat is able to sequester 
these proteins, causing the loss of their normal cellular function and thereby have 
an impact on for example splicing. In general, the effect of sequestration by RNA 
foci might be different for each protein. Reduction of Ran-GAP and Pur-alpha 
levels clearly impacts cellular viability. On the other hand, RNA foci might not se-
quester enough eIF2α, FUS and SC35 proteins to affect their normal functioning.
1.3 Correlation of RNA foci and DPRs with clinical features
Two studies investigated the relationship between RNA foci and clinical features. 
The first study showed that more sense RNA foci in the frontal cortex correlated 
with an earlier age of onset[56]. The second, a larger study, showed that more 
antisense RNA foci in the middle frontal gyrus were correlated with a later age 
at onset[58]. Thus, these two studies reported contradictory findings for sense 
versus antisense foci and to date we cannot conclude that numbers of RNA foci 
show an association with any feature of C9ORF72 carriers[58]. For DPRs, the 
correlation with neurodegeneration has often been assessed but never found 
when all DPRs or only poly-GA was taken into account (reviewed in [51]). When 
focusing on poly-GR alone, an association was found in two recent studies[72, 
73]. Poly-GR was significantly more abundant in clinically-related areas com-
pared to unrelated areas of C9ALS cases[72] and correlated with neurodegener-
ation in a cohort of 40 C9FTD, C9ALS and C9FTD/ALS cases[73]. Together, this 
highlights a role for poly-GR in the pathophysiology of C9FTD/ALS, and less for 
RNA foci and other DPRs.
1.4 Contribution of loss-of-function
Loss-of-function is not sufficient to cause FTD and/or ALS symptoms in knock-
out mouse models of C9ORF72 (reviewed in [228]). But haploinsufficiency can 
influence gain-of-function mechanisms. This was nicely shown in C9FTD/ALS 
iPSC-derived motor neurons, which are susceptible to glutamate toxicity[126]. 
Overexpression of poly-GR or –PR in C9FTD/ALS or C9ORF72 crispr-cas9 
knock-out (C9KO) iPSC-derived neurons resulted in enhanced cellular toxici-
ty[126]. C9FTD/ALS or C9KO iPSC-derived motor neurons contain less lyso-
somes and more glutamate receptors at spines. They also show a slower degra-
dation of poly-PR[126]. All these effects could be rescued by overexpression of 
both the short and long isoform of the C9ORF72 protein or by enhancing endo-
some and lysosome function with small molecules[126].
 The in vivo synergistic effect of both loss- and gain-of-function mech-
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anisms in the pathogenesis of C9FTD/ALS was confirmed by Qiang Zhu et 
al.[275]. Previously published BAC mice expressing 450x G4C2 repeats (C9BAC) 
were crossed with previously published C9KO mice[136]. These combination 
C9KO/C9BAC mice showed enhanced cognitive deficits, hippocampal neuron 
loss and glial activation. C9BAC repeat mice also showed an elevation of LC3B 
levels indicative for enhanced autophagy, which was reduced by depletion of the 
C9orf72 protein, suggesting that loss of C9orf72 protein reduces autophagy in 
the C9BAC mouse. Interestingly, combination C9KO/C9BAC mice showed accel-
erated accumulation of poly-GA and higher soluble levels of poly-GP in the cortex 
using ELISA. Strikingly, injections of AAV-66xG4C2 repeats in ventricles of hetero-
zygous C9KO mice caused premature death. Normally, both the AAV-66x G4C2 
repeat mouse model and the heterozygous C9KO mouse model have a normal 
life span, but the combination of the two apparently causes a higher toxic effect 
than their sole effect. These results provide direct support that reduced C9orf72 
protein enhances the repeat-dependent gain-of-function mechanisms in C9FTD/
ALS.
 C9ORF72 haploinsufficiency could also influence the aggregation or ac-
cumulation of other proteins than DPRs. Neurons with reduced levels of the short 
isoform of C9ORF72 protein (C9-S) more often contained cytoplasmic pTDP-43 
inclusions[276]. C9-S shuttles between the nucleus and the cytoplasm and loss of 
C9-S might induce pTDP-43 mis-localization[276]. A combination between alfa-
1 KO (homologue of C9ORF72) in C. elegans and dominant active TDP-43A315T 
mutant worms also led to an additive effect on aberrant motor dysfunction[128]. 
Finally, C9orf72 protein knock-down using shRNA increased the aggregation and 
cellular toxicity of Ataxin 2 Q30x in primary mouse cortical neurons[118]. Alto-
gether, this provides evidence that C9ORF72 loss-of-function is a disease modi-
fying factor.
2. Pathological hallmarks in C9FTD/ALS
RNA foci and neuronal cytoplasmic inclusions of DPRs are known to be the first 
pathological hallmarks that arise in C9FTD/ALS patients’ brain, even before the 
onset of symptoms, as shown in C9ORF72 repeat carriers that died due to other 
causes[59]. But accumulation of DPRs might not be necessary for their toxicity, 
and could even alter their cellular target(s). Sequestered proteins or their inter-
action with RNA foci and/or DPRs might be the target of new drugs in the future. 
Validation of newly identified protein pathology in post-mortem brain tissue is 
therefore essential to gain information about the pathogenesis of C9FTD/ALS.
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2.1 Is the aggregation of DPRs necessary for their toxicity?
In chapter 2 of this thesis, we overexpressed ATG-mediated poly-GR or –PR in 
zebrafish embryo’s and show their immediate effect on cell death. Detection of 
DPRs by immunohistochemistry and ELISA indicated that poly-GR seems to be 
present in both a diffuse form and as puncta in the nucleus, while poly-PR was 
mostly present as nuclear puncta. This indicates that the observed cellular tox-
icity is predominantly caused by soluble and aggregated poly-GR and nuclear 
accumulation of poly-PR. However, more research is needed to confirm these 
observations. In our mouse model, we mainly observed soluble forms of sense 
DPRs; poly-GA, -GP and –GR. Poly-GA was present in a diffuse form in the nu-
cleus and cytoplasm, while poly-GP and –GR were mainly diffusely localized in 
the nucleus. It is unclear if one single DPR or the simultaneous expression of all 
soluble sense DPRs is responsible for the muscular toxicity observed in this mod-
el. Mouse models investigating the sole expression of poly-GA, -GR or -PR may 
provide more information about this phenomenon and are discussed below[199, 
200, 213].
 In a mouse model for poly-GA, Zhang and colleagues nicely demon-
strated that aggregation of poly-GA was essential for its cellular toxicity[213]. 
They generated mice expressing GFP-tagged 50x poly-GAmutated in which the GA 
sequence was interrupted by proline residues that disrupted fibril formation. Po-
ly-GAmutated remained soluble both in HEK293T cells and mouse cortical tissue 
and did not cause caspase-3 activation nor any cell loss or behavioral changes 
in mice. In contrast, mice expressing ‘normal’ GFP-tagged 50x poly-GA did show 
inclusions that were ubiquitin-positive, exhibited neurodegeneration in several 
brain areas and developed motor deficits, hyperactivity, anxiety and cognitive 
deficits[213]. 
 In contrast to poly-GA, expression of soluble poly-GR or poly-PR was 
enough to evoke a phenotype in two AAV-mediated mouse models[199, 200]. 
GFP-tagged poly-GR100 was mostly cytoplasmic and diffusely localized in neu-
rons in the cortex and led to cortical thinning, hippocampal and cerebellar Pur-
kinje cell loss. After 6 months, mice showed (loco)motor impairment in open field 
and rotarod tests in combination with decreased cued freezing in a fear-condi-
tioning test[199]. Overexpressed GFP-tagged poly-PR50 showed a diffuse nucle-
ar distribution and led to 60% mortality of mice at 4 weeks of age[200]. Surviving 
mice showed a reduction in the number of PR-positive cells, displayed cortical 
thinning and reduced hippocampal volume at 3 months of age, combined with 
worse performance on the rotarod and cued freezing in fear-conditioning[200]. 
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This suggests that aggregation of poly-GR and -PR is not necessary to evoke 
toxic effects. 
 Poly-GR might even have different effects depending on its conforma-
tional state. In AAV-66x G4C2 and AAV-149x G4C2 mice, cytoplasmic inclusions of 
poly-GR were observed. These mouse models exhibit both RNA foci and all other 
DPRs, suggesting that these or other factors are needed to evoke aggregation 
of poly-GR[195, 199]. In the AAV-66x and 149x G4C2 mouse models, cytoplasmic 
inclusions of poly-GR co-localized with pTDP-43 and TIA1, a constituent of stress 
granules[195]. This phenomenon was not observed in the – soluble – poly-GR 
only mouse model[199], implying that the aggregation of poly-GR is needed to 
sequester pTDP-43 and to influence stress granule dynamics. This indicates that 
poly-GR has different cellular targets depending on its conformational state but 
can be toxic in both soluble and aggregated form.
 Interestingly, poly-GA can sequester both poly-GR and –PR in inclusions 
and partially reduce their cellular toxicity[74, 196]. In AAV-66x and AAV-149x 
G4C2 repeat mouse models for C9ORF72, poly-GR co-aggregated with poly-GA 
in cells expressing poly-GA, but remained diffuse in cells devoid of poly-GA ex-
pression[199] Co-overexpression of poly-GA and –GR altered the localization of 
poly-GR from diffuse to inclusions in the cytoplasm of Drosophila salivary gland 
cells[74]. Furthermore, poly-GA overexpression partially suppressed the poly-GR 
induced cell loss in the wings of Drosophila[74]. The same holds true for the com-
bination of poly-GA and -PR. Co-overexpression of poly-GA abolished cellular 
toxicity of low concentrations of poly-PR and changed its localization from diffuse 
nuclear to cytoplasmic inclusions in NSC34 cells[196]. This suggests that soluble 
poly-GR and –PR are more toxic than their aggregated form, but this effect has 
only been observed for low concentrations. Together, these data suggest that the 
combined overexpression of all DPRs produces different cellular outcomes and 
structural conformations compared with the effects of overexpression of single 
DPRs. 
2.2 Validation of sequestered proteins in human post-mortem brain tissue
Identification of new protein pathology in post-mortem brain material could pro-
vide clues about the pathophysiology of C9FTD/ALS. In chapter 4 of this thesis, 
we show that HR23B is mis-localized in the CNS of C9FTD/ALS cases. HR23B 
is a multifunctional protein that plays a role in DNA repair and in the degradation 
of proteins via endoplasmic reticulum-associated degradation (ERAD) and via 
the proteasome[242]. We showed that HR23B mostly co-localized with poly-GA 
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and less with other DPRs. Other proteins that show mis-localization in C9FTD/
ALS patient post-mortem brain material are Drosha[277], KPNA2/4[278], hn-
RNP-A3[150] and Unc119[175]. Drosha is a endonuclease and is involved in 
miRNA biogenesis[277]. Almost all Drosha neuronal cytoplasmic inclusions were 
also positive for poly-GA[277]. KPNA2 and KPNA4 are involved in the classical 
nuclear import pathway[278]. They show nuclear clearing and cytoplasmic inclu-
sions in C9FTD cases and sometimes co-localize with DPRs and pTDP-43[278]. 
HnRNP-A3 is involved in both pre-mRNA splicing and export of mRNA into the 
cytoplasm. Reduction of hnRNP-A3 from hippocampal nuclei in brain tissue of 
34 C9FTD/ALS patients correlated with increased poly-GA aggregation[273]. 
Unc119 is a trafficking factor for myristoylated proteins and Unc119 knockout C. 
elegans caused paralysis and disturbed axonal development[279]. All together, 
these studies indicate that the aggregation or nuclear clearing of these specific 
proteins might impact normal nucleocytoplasmic transport (NCT) and RNA pro-
cessing, as many of the described proteins function in these cellular processes. 
Interestingly, most of these proteins co-localize with poly-GA and might provide 
information on how poly-GA affects normal cellular functioning. For example, 
overexpression of Unc119 and HR23B rescued poly-GA toxicity in primary mu-
rine neuronal cultures[175, 213].
 Mis-localization of some proteins identified in cell and animal models 
could not be confirmed in post-mortem brain tissue of C9FTD/ALS patients. Ran-
GAP was found to be sequestered in a poly-GA mouse model[213] and signifi-
cantly more cells showed nuclear invagination of Ran-GAP in an AAV-149xG4C2 
mouse model[195]. However, we (chapter 4) and others[51, 72] were unable to 
confirm Ran-GAP neuropathology in C9FTD/ALS patients. A possible explana-
tion for this discrepancy may be that post-mortem brain material only represent 
the end-stage of FTD/ALS and early changes might be missed. Also, differenc-
es in oddly-shaped nuclei in the Ran-GAP staining might only become evident 
if large number of cells are quantified. We were also unable to confirm FMRP, 
Pur-alpha and ADARB2 pathology in post-mortem brain sections of C9FTD pa-
tients (chapter 4). This illustrates the importance of validation of results obtained 
from cell and mouse models to human post-mortem brain material.
 Finally, Poly-GR has been shown to co-localize with several ribosomal 
proteins (S6, S25, L19, L21, L36A), RNA binding protein STAU2 and translation 
initiation factor eIF3n in the frontal cortex of C9FTD/ALS cases[199, 280]. These 
last findings indicate that poly-GR aggregation might evoke reduced translation 
by the sequestration of ribosomes and translation initiation factors.
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2.3 Co-localization patterns between pathological hallmarks of C9FTD/ALS
Co-localization patterns between pathological hallmarks can also provide essen-
tial information about the order and impact of (neuro)pathological processes. In-
terestingly, the presence of antisense foci in motor neurons was associated with 
nuclear loss of TDP-43, as 77% of all antisense RNA foci positive cells showed 
loss of nuclear TDP-43[60]. Especially antisense foci that surround the nucleolus 
have been associated with cytoplasmic TDP-43 pathology in the anterior horn 
of the spinal cord of C9ALS cases[164]. Antisense RNA foci that sequester NCT 
factors or antisense DPR products like poly-PR can affect NCT[155, 177, 178, 
187] which could cause nuclear clearing of TDP-43, but to date no empirical 
data is available to support the last part of this hypothesis. No correlation exists 
between the presence of RNA foci and the amount of DPRs or p62 inclusions in 
a cell[56, 61].
 Saberi et al. showed that poly-GR is the only DPR that showed co-lo-
calization with pTDP-43[72]. From all poly-GR dendritic inclusions in the motor 
cortex, 80% was pTDP-43 positive, while none of the other DPR-positive dendrit-
ic inclusions were pTDP-43 positive[72]. Twenty percent of perinuclear poly-GR 
inclusions in the motor cortex co-localized with pTDP-43, compared to 1-10% of 
the other DPRs[72]. Occasionally, poly-PA inclusions in the spinal cord were also 
positive for pTDP-43[71]. And sometimes, pTDP-43 has been detected around 
perinuclear poly-GA inclusions[66]. In SH-SY5Y cells, poly-GA proceeded TDP-
43 aggregation[281]. But co-localization studies between poly-GA and pTDP-43 
in human post-mortem brain sections of C9FTD/ALS patients are missing. So far, 
the most prominent DPR that co-localizes with pTDP-43 is poly-GR. Importantly, 
only pTDP-43 and poly-GR are associated with neurodegeneration[72, 73], while 
RNA foci, the other DPRs and ubiquitin/p62 are not[51].
 Co-localization patterns can differ between brain regions, which we show 
for HR23B and poly-GA in chapter 4. In the frontal cortex, only 7% of HR23B in-
clusions were poly-GA positive, while this increased to 60% in the hippocampal 
dentate gyrus. The same phenomenon has been reported for Mlf2, a chaper-
one-associated protein. Co-localization of Mlf2 with poly-GA increased from 1% 
in frontal cortex to 3% in the hippocampus dentate gyrus[229]. Also hnRNP-A3 
inclusions were more often observed in hippocampal dentate gyrus than in cere-
bellum[282]. An explanation for this phenomenon could be that subtypes of neu-
rons may influence aggregation patterns by differences in expression levels and 
availability of HR23B, Mlf2, hnRNP-A3 and/or their binding partners. Interesting-
ly, overexpression of HR23B protected for the formation of poly-GA inclusions in 
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mouse primary neuronal cultures[213]. Also, reduced nuclear hnRNPA3 in the 
hippocampus of 34 C9FTD/ALS patients correlated with increased poly-GA ag-
gregation[273]. Further in depth studies about expression levels and aggregation 
patterns are warranted to gain knowledge on the different vulnerability of specific 
subtypes of neurons. This could provide crucial information why the C9ORF72 
repeat mutation causes abundant neurodegeneration in certain brain areas while 
other brain areas are relatively spared.
2.4 The role of pTDP-43 aggregation in neurodegeneration
In chapter 2 and 3 (zebrafish and mouse models) we show that overexpression 
of G4C2 repeat RNA and/or DPRs is sufficient to evoke cellular toxicity and a be-
havioral phenotype without aggregation or mis-localization of pTDP-43 from the 
nucleus to the cytoplasm. This raises the question whether pTDP-43 pathology 
is essential to cause neurodegeneration or if it is simply a “by-product” of neu-
ropathological processes. The presence of pTDP-43 neuropathology is thought 
to be a late event[59, 77]. Many mouse models already show behavior pheno-
types and some mild neurodegeneration before the onset of pTDP-43 neuropa-
thology[136, 194, 199, 213, 229]. Also in humans several examples have been 
reported of affected C9FTD/ALS individuals with DPR pathology but moderate 
or lack of TDP-43 neuropathology[27, 59, 66, 234, 235]. Together, this implies 
that pTDP-43 aggregation is not essential to evoke initial neurodegeneration. 
However, changes in subcellular localization or solubility of TDP-43 could already 
arise earlier and add to cellular distress before the onset of pathology. This is also 
confirmed by mouse models for TARDBP, in which cytoplasmic aggregation of 
pTDP-43 is not essential for its cellular toxicity[283]. TDP-43 functionality is very 
important for many cellular processes and for cellular survival[96] and any chang-
es in its availability might shift the balance to cellular dysfunction[284]. Together, 
this argues for an important role for pTDP-43 in C9FTD/ALS pathogenesis with-
out the need for cytoplasmic aggregation per se.
3. Aberrant downstream molecular pathways in C9FTD/ALS pathogenesis
The C9ORF72 research field has produced a multitude of abrogated molecular 
pathways (also see general introduction). RNA foci, poly-GR, -GA and -PR are 
able to bind many different proteins inside the cell and probably affect many path-
ways simultaneously. It may therefore be important to identify pathways that are 
primary affected or that are dysregulated via multiple directions.
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3.1 Central role of the integrated stress response
In this thesis, we have shown that poly-PR mediated cell death could be prevent-
ed by ISRIB, indicating that activation of the integrated stress response (ISR) un-
derlies poly-PR mediated toxicity (chapter 2). Endoplasmic reticulum (ER) stress 
is one of the factors that can activate the ISR (see figure 1 about the ISR [207]). 
Downstream effects of ISR activation are translation inhibition and increase in 
ATF4 and CHOP levels, which are known to induce apoptosis[207]. The forma-
tion of stress granules and NCT defects can be indirect downstream effects[183, 
188]. Interestingly, in C9ALS iPSC-derived motor neurons, poly-PR cellular tox-
icity can be modified by the ER membrane protein complex and ER-resident 
proteins such as TMX2 and CANX[210], which strengthens the involvement of 
ER-stress and the ISR in PR-mediated cellular toxicity. Recent reports indicate 
that both poly-GR and –PR interact with many ribosomal proteins and inhibit 
Figure 1: schematic representation of the integrated stress response. Image reused with per-
mission from Pakos-Zebrucka et al. [207]. Copyright @ EMBO reports.
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translation when expressed in healthy iPSC-derived neurons, in Drosophila and 
in a poly-GR mouse model[199, 220, 280]. Cytoplasmic poly-GR co-localized 
with ribosomal subunits and translation initiation factor eIF3n in poly-GR100 mice 
and C9FTD/ALS patients brain[199]. Poly-GR and –PR could therefore inhibit 
translation in multiple ways; directly by binding ribosomal proteins and translation 
initiation factors or indirectly by ISR pathway activation.
 Next to poly-PR, we found that poly-GR mainly mediates its cellular tox-
icity in zebrafish embryo’s via oxidative stress of mitochondria (chapter 2). Oth-
er papers indicate that poly-GR mainly affects the ER and translation[174, 199, 
220]. These findings might seem contradictory, but many connections exist be-
tween ER and mitochondrial stress. For example, the membrane of the ER and 
mitochondria are interconnected, thus dysregulation of one cell organelle can 
lead to disruptions of the other cell organelle[225]. Oxidative stress can worsen 
ER stress by reducing the efficiency of the protein folding pathways and thereby 
increasing the amount of misfolded proteins[208]. The accumulation of misfolded 
proteins in the ER causes ER stress and consequently activation of the ISR and 
the unfolded protein response (UPR)[207]. A nice example of combined ER and 
mitochondrial dysfunction has been found in C9FTD/ALS iPSC-derived motor 
neurons; decreased cell survival correlated with dysfunction in Ca2+ homeostasis, 
increased ER stress, and reduced mitochondrial membrane potential[201]. This 
indicates that poly-GR might exert its toxic effect via both mitochondrial and ER 
stress.
 Finally, poly-GR cytoplasmic inclusions co-localized with various stress 
markers in a mouse model expressing AAV-149x G4C2[195]. As formation of 
stress granules is a downstream effect of activation of the ISR, poly-GR may 
cause translational inhibition and chronic stress granule formation via activation 
of this pathway. Thus, both poly-GR and –PR might activate the ISR via multiple 
ways, which suggests an important role of this pathway in the pathogenesis of 
C9FTD/ALS.
3.2 Overlap between RNA and DPR gain-of-function mechanisms
Synergy and overlap between RNA and DPR gain-of-function mechanisms has 
been observed and can help to identify important affected molecular pathways. 
For example, the overexpression of poly-PR in combination with expanded G4C2 
repeat RNA in primary rat cortical neurons synergized cellular toxicity, suggesting 
a convergence of mechanisms[171]. Also, injections of a pure 70x G4C2 repeat 
construct, producing RNA and DPRs, was more toxic than RNA-only injections in 
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zebrafish, indicating a synergistic effect on cellular toxicity[154]. Both expanded 
G4C2 repeat RNA and poly-GR and –PR can bind many RNA-binding proteins, 
nucleolar proteins, hnRNPs and spliceosome components and thereby disrupt 
normal splicing[169, 174]. Furthermore, translation initiation factors such as hn-
RNP-A1 and Pur-alpha co-localized with RNA foci[61, 151] and poly-GR co-lo-
calized with hnRNP-A1 in post-mortem brain sections of C9ALS patients[174]. 
These results indicate that both expanded G4C2 repeat RNA and poly-GR and 
–PR can synergize their cellular toxicity, and probably convergence on aberrant 
splicing and translation, as many interacting proteins function in these pathways.
 NCT defects could also be mediated by expanded G4C2 repeat RNA and 
DPRs simultaneously. Both G4C2 repeat RNA and DPRs seem to affect Ran-
GAP, an important nucleocytoplasmic transport factor. G4C2 repeat RNA binds 
Ran-GAP[107] and RNA foci co-localized with Ran-GAP in C9ALS iPSC-derived 
neurons[155]. Furthermore, Ran-GAP was sequestered by poly-GA in a AAV-50x 
poly-GA mouse model[213]. Splicing of Ran-GAP was found to be altered in cul-
tured human astrocyte cells that were exposed to a synthetic PR20 peptide[169] 
and NCT factors are modifiers of poly-PR toxicity in Drosophila[178]. Next to 
Ran-GAP, other NCT factors such as importins, NUPs and the laminin B receptor 
could bind to poly-GR and –PR[176, 186, 187]. Poly-PR can also directly bind to 
the nuclear pore and reduce trafficking through the pore[187].
 In animal models for C9ORF72 gain-of-function, profound NCT de-
fects have been found. Overexpression of pure G4C2 repeats (thus investigat-
ing both RNA and DPR toxicity) in Drosophila models caused NCT defects[155, 
177]. And in an AAV-149x pure G4C2 mouse model, aberrant invaginations of the 
nuclear membrane of neurons has been reported using immunostaining with 
Ran-GAP[195]. Together, this implies that both RNA and DPR gain-of-function 
mechanisms can evoke NCT defects and highlight NCT as central pathological 
mechanism in C9ORF72 pathogenesis.
3.3 Hypothetical model of C9ORF72 pathogenesis
Here we propose a hypothetical model of the underlying pathogenesis of 
C9ORF72-linked neurodegeneration (see figure 2) in which we include insights 
from our own studies combined with literature.
 The starting point in C9ORF72 pathogenesis is the expression of RNA 
containing an expanded G4C2 repeat, causing the formation of RNA foci and pro-
duction of DPRs. Expression of G4C2 RNA-only is not always sufficient to cause 
cellular toxicity but can synergize with DPR toxicity (as discussed above) and 
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might be disease modifying[154, 171, 195]. RNA toxicity probably disturbs the 
normal function of splicing factors, NCT transport factors and translation initiation 
factors, as these factors can be bound by RNA molecules containing an expand-
ed G4C2 repeat[61, 149, 152, 155]. Reduced expression of C9ORF72 protein in 
neurons disturbed normal autophagy and may cause additional accumulation of 
DPRs[126, 275], classifying loss-of-function as disease modifier.
 Soluble arginine-containing DPRs, poly-GR and poly-PR, probably 
cause the first and immediate effect on cellular processes. They are able to bind 
heterochromatin, mitochondrial proteins, ribosomal proteins, nucleolar proteins, 
RNA-binding proteins and proteins containing low-complexity domains (LCDs)
[169, 174, 176, 181, 186, 200]. LCD proteins can form membrane-less organ-
elles such as nucleoli, the nuclear pore and stress granules. Poly-GR and -PR 
have been shown to alter phase transition and the dynamics and assembly of 
these organelles, leading to heterochromatin changes, nucleolar stress and ER 
stress[176, 181, 200]. In our zebrafish model, we showed that poly-GR increased 
ROS levels and poly-PR exerted its toxicity via the ISR. Probably, this caus-
es a feedback loop in the pathological process. Activation of the ISR has been 
shown to increase RAN translation and DPR formation[82, 83, 226, 285]. More 
DPRs are produced in the cell and start to further disturb the processes described 
above. 
 Poly-GA has been shown to sequester proteasome subunits[75, 175] 
and HR23B into cytoplasmic inclusions[213, 229], which could lead to reduced 
functionality of the UPS, UPR and ERAD, the latter shown in our chapter 4. Dis-
turbance of these processes may cause the next feedback loop in the patho-
logical process: insufficient clearing of DPRs leads to even faster accumulation 
of DPRs and other protein inclusions in the cell. Poly-GA inclusions sequester 
poly-GR and -PR, which subsequently start to sequester ribosomal proteins and 
stress granule factors[74, 195, 196, 199]. 
 The aggregation of poly-GR and -PR completes their 3-fold effect on 
translation: first, they disrupt splicing and nucleolar functioning, which causes 
reduced ribosomal RNA maturation and reduces the pool of ribosomes[169, 174]. 
Secondly, they activate the ISR and impair the disassembly of stress granules, 
which inhibits normal translation (this thesis and [210, 226]). Thirdly, they bind 
and sequester ribosomal proteins[199, 220]. These combined actions make the 
block on translation complete. Together with the effects of poly-GA on the UPS, 
UPR and ERAD[75, 175, 213], normal cellular functioning is probably at serious 
risk. 
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Figure 2: Overview of impact and important steps in the pathogenesis of C9FTD/ALS. Indicated 
for loss-of-function, RNA gain-of-function and poly-GA, -GR and –PR DPR gain-of-function mecha-
nisms. NCT = nucleocytoplasmic transport, ISR = integrated stress response.
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 Furthermore NCT defects arise, due to direct binding of poly-PR to the 
nuclear pore[187], binding of NUPs and importins by poly-GR and -PR[176, 187] 
and sequestration of NCT factors by poly-GA[213]. Overexpression of poly-PR in 
a recent mouse model also evoked nuclear lamina invaginations[200]. Prolonged 
ISR activation and stress granule formation can also cause NCT defects[188]. Al-
together, this could lead to the final step in C9ORF72 pathogenesis process: NCT 
defects can evoke the mis-localization of pTDP-43 from the nucleus to the cyto-
plasm. In addition, poly-GR might be able to sequester pTPD-43 in inclusions, as 
co-localization has been demonstrated in an AAV-149xG4C2 mouse model[195] 
and in human post-mortem brain tissue from C9ALS patients[72]. Cytoplasmic 
aggregation of pTDP-43 is a known late event[51, 59, 77] and nuclear clearing of 
pTDP-43 has a major impact on normal cellular functioning[283, 286]. This might 
be the last straw that breaks the camel’s back.
4. Therapies
4.1 Determining treatment windows
In chapter 3 of this thesis, we started to investigate potential treatment windows 
of C9FTD/ALS in our transgenic mouse model. Since this is an inducible mouse 
model, we can turn expression of 36xG4C2 repeat RNA on and off, at different 
time intervals. We showed that two weeks of expression followed by two weeks of 
wash-out (expression turned off) is not sufficient to prevent mice from developing 
muscle degeneration. RNA or DPR cellular toxicity that is initiated in the first two 
weeks apparently lasts long enough to evoke a phenotype at 4 weeks of age. 
Indeed, we found poly-GA and –GP still present in muscles after 2 weeks of wash 
out, indicating that DPRs are long-lasting. Recently, Westergard et al showed 
that the half-lives of most DPRs is estimated to be >200 hours[226]. These data 
suggest that long treatment is essential to reduce DPR levels.
 In order to further estimate the correct time for targeted treatment, in-
formation about DPR levels and neurodegeneration in C9FTD/ALS patients is 
highly needed, especially at the pre-clinical stage. Most treatments that are cur-
rently being developed (and discussed below) focus on G4C2 RNA and DPR ex-
pression and are not targeting downstream effects. These therapies will therefore 
be most useful in preventing pre-symptomatic C9ORF72 repeat carriers from 
developing FTD and ALS symptoms. It is unknown if future therapies will also 
be able to stop disease progression in the symptomatic phase. The develop-
ment of reliable biomarkers assessing pre-clinical changes in behavior, (motor-) 
neurodegeneration or rise of DPR levels will therefore be essential. In chapter 
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5 of this thesis, we show that poly-GR levels in CSF and PBMCs of C9FTD/
ALS cases and pre-symptomatic carriers is extremely low, if not absent. So far, 
only poly-GP could be detected in CSF and PBMCs of C9FTD/ALS cases and 
pre-symptomatic carriers[197]. Poly-GP levels remain constant over time but do 
not correlate with disease progression or diagnosis[197]. Poly-GP levels in CSF 
can be used for determining pharmacodynamics of treatments that target the 
expression of DPRs[197]. Interestingly, neurofilament light levels in CSF did as-
sociate with gray matter atrophy, disease severity and shorter survival of C9FTD/
ALS patients[262]. A combination of these two fluid biomarkers could be used 
in clinical trials. Tracing DPR accumulation in the brains of C9FTD/ALS patients 
using tracers and PET scanning might also be an interesting approach if liquid 
biomarkers are unable to provide information about increasing DPR levels. This 
technology has been used for Alzheimer’s Disease; Pittsburgh compound B sen-
sitively detects amyloid-B deposits in vivo[287]. Other imaging techniques as-
sessing gray matter atrophy and hypometabolism are validated biomarkers that 
show (pre-clinical) changes at a group level, but longitudinal research is needed 
before they can be used at the individual level[271]. Thus, more research is need-
ed to develop sensitive and specific biomarkers that detect pre-clinical changes 
in C9FTD/ALS patients and to correctly implement potential therapies.
4.2 AON therapy
Antisense oligonucleotides (AONs) are small oligonucleotides that can bind RNA 
and recruit RNase-H to degrade the target mRNA. AONs can also block (RAN) 
translation without degradation of the target RNA. AON therapy is currently devel-
oped for ALS, Duchenne muscular dystrophy, spinal muscular atrophy, myotonic 
dystrophy, Alzheimer’s disease and Huntington’s disease[259]. In C9BAC mice 
expressing 450x G4C2 repeats, a single injection of an AON that specifically tar-
gets the G4C2 repeat RNA reduced the amount of RNA foci, DPRs and ameliorat-
ed behavioral deficits[136]. This AON was intraventricular injected at 9 months of 
age, a time point that C9BAC mice already show abundant RNA foci and DPRs 
in cortex and hippocampus but before the onset of behavioral symptoms[136]. 
This indicates that early AON treatment can prevent the development of behav-
ioral deficits, despite the presence of RNA foci and DPRs. Furthermore, deficits 
in nuclear import and Ran-GAP mis-localization were rescued by AON treatment 
of Drosophila expressing 30x G4C2 RNA and iPSC-derived neurons of C9ALS 
patients[155]. Of note, AONs should be specifically targeted at the transcripts 
containing an G4C2 repeat without affecting normal C9ORF72 protein levels, as 
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reduction in those levels may cause immunologic problems[77, 136]. To date, 
clinical trials using AON therapy targeting the C9ORF72 repeat expansion are 
ongoing, also in the Netherlands (https://www.umcutrecht.nl/nl/Nieuws/Start-ex-
perimentele-behandeling-tegen-ziekte-ALS?feed=news). 
4.3 Small molecules targeting repeat RNA and/or RAN translation
Several compounds have been developed that specifically bind the expanded 
G4C2 repeat and block RAN translation. In iPSC-derived neurons from C9FTD/
ALS patients, compound 1a interferes with the hairpin structure of the expand-
ed G4C2 repeat and significantly reduced RNA foci and expression of DPR pro-
teins[78]. Other compounds can specifically bind the G-quadruplex structure in 
mRNA containing an expanded G4C2 repeat followed by degradation[236, 237]. 
The compound TMPyP4 can bind the G-quadruplex formed by 8xG4C2 repeat 
RNA, and this blocks the interaction of either hnRNPA1 or ASF/SF2 with this 
normal sized G4C2 repeat[237]. Administration of another compound, DB1273, 
to C9ALS iPSC-derived neurons and Drosophila expressing 36x G4C2 repeat 
RNA, reduced RNA foci, poly-GP and –GR levels and increased the life-span of 
the flies[236]. These results seem promising, but it remains unclear whether the 
compounds actually prevent degradation of RNA foci or just impair the binding of 
probes that visualize RNA foci and block their detection.
 New studies on RAN translation indicate that a number of stressors, 
including neuronal excitation, can activate RAN translation[226]. All identified 
stressors convene at the ISR pathway[82, 83, 226]. Activation of the ISR blocks 
canonical translation while enhancing RAN translation[82, 83, 226]. Compounds 
that inhibit phosphorylation of eIF2α, the core initiator of the ISR, are shown to 
suppress RAN translation[82, 83, 226]. These studies were performed in HeLa 
cells [83], HEK293T cells[82], NSC34 cells, primary rat cortical neurons and iP-
SC-derived motor neurons from C9ALS patients[226, 285]. As DPRs induce ac-
tivation of the ISR (this thesis and [210, 285]), this creates a feed-forward loop in 
which enhanced RAN translation produces more DPRs that further activate the 
ISR. Inhibition of the ISR might therefore be a double hit therapy; inhibiting both 
the downstream effects of DPRs while at the same time the prevention of forma-
tion of more DPRs. 
4.4 Therapies blocking spreading of DPRs
Interestingly, in C9ALS patients DPR pathology has been described as a distinct 
clustered pattern[55] and it has been shown that DPRs are able to spread via 
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cell-to-cell transmission in vitro[267]. This can occur via the take-up of exosomes 
from culture media of cells expressing DPRs, or via direct cell-to-cell contact be-
tween neurons[267]. Especially arginine-rich DPRs can penetrate the membrane 
of HEK293T and NSC34 cells[268]. Also extracellular (GFP-tagged) poly-GA in-
clusions can be taken up by HEK239T cells and primary neurons and act as 
seeds to enhance cellular aggregation of (Flag-tagged) poly-GA[247, 269]. Expo-
sure to recombinant poly-GA or cerebellar extracts of C9FTD patients increased 
G4C2 repeat RNA levels and seeded aggregation of all DPRs in HEK293T cells 
expressing 80xG4C2[269]. Treatment with anti-poly-GA antibodies inhibited the 
seeding effect of C9FTD brain extracts and reduced poly-GA aggregation[269]. 
These results highlight the possibility of antibody therapy to reduce spreading 
and seeding of DPRs in C9FTD/ALS.
Conclusion
In conclusion, research described in this thesis shows that ubiquitous overex-
pression of 36xG4C2 repeat RNA results in production of sense DPRs and evokes 
a locomotor phenotype in an inducible transgenic mouse model. Furthermore, 
overexpression of poly-GR and –PR in zebrafish embryo’s is sufficient to cause 
cellular toxicity and cell death. Our data therefore supports a gain-of-function 
hypothesis as the underlying molecular mechanism for C9FTD/ALS. C9ORF72 
protein haploinsufficiency has been categorized as disease modifier in recent 
publications. Synergy between loss- and gain-of-function mechanism can easily 
be studied by crossing our mouse or zebrafish model with C9KO mouse or ze-
brafish. The functional consequences of RNA molecules containing expanded 
G4C2 repeats and RNA foci, that bind and sequester several RNA-binding pro-
teins, is unclear and needs further investigation. Important downstream pathways 
underlying cellular toxicity probably converge at the ISR and NCT defects. Re-
duced function and saturation of the UPR, UPS, ERAD and autophagy systems 
probably adds to the accumulation of toxic proteins in the cell. Furthermore, acti-
vation of the ISR stimulates RAN translation, causing a possible feedback loop. 
Potential therapeutic interventions for C9FTD/ALS include AONs or small com-
pounds that degrade or block translation of mRNA containing an expanded G4C2 
repeat. Pre-clinically, AON therapy shows promising results and is currently being 
assessed in clinical trials. However, for the correct implementation of efficient 
therapeutic interventions, more information is needed about the best treatment 
window. First insights from mouse models suggests that early and long treatment 
is essential to prevent RNA and DPR cellular toxicity and the development of be-
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havioral symptoms. Finally, the development of reliable biomarkers assessing the 
precise time to start treatment and treatment response is essential for the suc-
cessful implementation of new therapies. We hope that in the future, C9ORF72 
repeat expansion carriers can be (pre-clinically) treated to prevent the onset of 
disease or halt disease progression of FTD and ALS.
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List of abbreviations
5-AZA  5-aza-2-deoxycytidine
A-I  Adenosine to inosine
AChRs  Acetylcholine receptors
AD  Alzheimer’s Disease
ADARB2 Adenosine Deaminase, RNA Specific B2
ALS  Amyotrophic Lateral Sclerosis
AON  Antisense oligonucleotide
BAC  Bacterial artificial chromosome
bvFTD  Behavioral variant FTD
C9-L  C9ORF72 long protein isoform A
C9-S  C9ORF72 short protein isoform B
C9ALS  C9ORF72-linked ALS
C9BAC  C9ORF72 bacterial artificial chromosome
C9FTD  C9ORF72-linked FTD
C9FTD/ALS C9ORF72-linked FTD and/or ALS
C9KO  C9ORF72 knock-out
C9ORF72  Chromosome 9 open reading frame 72
CA  Cornu ammonis 
CamK2  Ca2+/calmodulin-dependent protein kinase II
ChAT   Choline acetyltransferase
CHCHD10 Coiled-coil-helix-coiled-coil-helix domain containing 10 
CHMP2B  Multivesicular body protein 2B gene
CNS  Central nervous system
CPD  Cyclobutane pyrimidine dimers
CpG  Cytosine-phosphate-guanine
CSF  Cerebrospinal fluid
DENN  Differentially expressed in normal and neoplastic cells
DG  Dentate gyrus
DM1/2  Myotonic Dystrophy type 1 or 2
DNs  Dystrophic neurites 
Dox  Doxycycline
DPRs  Dipeptide repeats
DT  Double transgenic
EDL  Extensor digitorum longus
EdU  5-ethynyl-2-deoxiuridine
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ERAD  Endoplasmic reticulum associated degradation
FISH  Fluorescent in situ hybridization
FMRP  Fragile X mental retardation protein
FTD  Frontotemporal Dementia
FUS  Fused in sarcoma
FXTAS  Fragile X-associated tremor/ataxia syndrome
GEFs  Rab-GDP/GTP exchange factors
GG-NER Global genome nucleotide excision repair
GRN  Progranulin
HD  Huntington’s disease 
HE  Haematoxyline-eosine
HNRNP Heterogeneous nuclear ribonucleoprotein
HR23B  Human homologue of yeast UV excision repair protein Rad23b
ICC  Immunocytochemistry
ICV  Intracerebroventricular
IHC  Immunohistochemistry
iPSCs  Induced pluripotent stem cells
LCDs   low-complexity domains
LMN   Lower Motor Neuron
lvPPA  Logopenic variant PPA
MAPT  Microtubule-associated protein tau
MBNL1  Muscleblind-like 1
METC  Medical Ethical Test Committee
MND  Motor Neuron Disease
Morphants  Morpholino-injected zebrafish
NCI  Neuronal cytoplasmic inclusions
NCT  Nucleocytoplasmic transport
NER  Nucleotide excision repair
nfvPPA  Nonfluent variant PPA
NII  Neuronal intranuclear inclusions
NMJ  Neuromuscular junction
NPC  Nuclear pore complex
o/n  Overnight
OPTN   Optineurin
P0  Postnatal day 0
P62  Autophagy protein p62/sequestosome 1
PBMCs  Peripheral blood mononuclear cells
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PBP  Progressive Bulbar Palsy
PBS  Phosphate-buffered saline
PD  Parkinson’s Disease
PFA  Paraformaldehyde
PFC  Prefrontal cortex
PiD  Pick’s Disease
PLS  Primary Lateral Sclerosis
PMA  Progressive Muscular Atrophy
Poly-GA Poly-glycine-alanine 
Poly-GP Poly-glycine-proline 
Poly-GR Poly-glycine-arginine
Poly-PA  Poly-proline-alanine 
Poly-PG Poly-proline-glycine
Poly-PR Poly-proline-arginine 
PPA  Primary Progressive Aphasia
pTDP-43 Phosphorylated 43kDa TAR DNA-binding protein
RAN  Repeat-associated non-AUG translation
Ran-GAP Ras-related nuclear protein GTPase activating protein
RBPs  RNA-binding proteins
rtTA  Reverse tetracycline-controlled trans-activator
SCA8/31/37 Spinocerebellar Ataxia type 8 , 31 or 37
SEM  Standard error of the mean
SIMOA  Single molecule array
snRNP   Small nuclear ribonucleoprotein
SOD1  Superoxide dismutase 1
SQSTM1 Sequestosome-1
ST  Single trangenic
svPPA  Sematic variant PPA
TA  Tibialis anterior muscle
TARDBP Trans-activation response element DNA-binding protein 43 
  encoding gene
TBK1  TANK-binding kinase 1 
TMEM106B  Transmembrane protein 106B
TRE  Tetracycline response element
UBQLN2 Ubiquilin 2
UDS  Unscheduled DNA Synthesis
UMN  Upper Motor Neuron
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UPR  Unfolded-protein response
UPS  Ubiquitin-proteasome system
VCP  Valosin-containing protein
XPC  Xeroderma pigmentosum complementation group C
zC9ORF72 Zebrafish orthologue of C9ORF72
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Summary
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two 
neurological disorders that are part of a disease continuum. FTD is characterized 
by the degeneration of frontal and temporal lobes of the brain. Patients develop 
behavioral and personality changes, often including less empathy and foresight. 
Language speaking, writing and comprehension can sometimes also be affected. 
The prevalence of FTD is about 15 in 100.000 people and it is the most common 
type of dementia after Alzheimer’s disease under the age of 65. FTD is often di-
agnosed between 50 and 60 years of age and disease duration can be 20 years.
 ALS is a motor neuron disorder in which the nerve cells that innervate 
the muscles are affected. This causes muscle weakening starting in extremities 
and spreading over the body eventually leading to walking, eating, speaking and 
breathing problems. ALS is the most common motor neuron disease with a prev-
alence of 5 in 100.000 people. ALS is often diagnosed between 40 and 60 years 
of age and disease duration is only a few (1-5) years.
 Patients diagnosed with FTD can sometimes develop ALS symptoms 
and about half of all ALS patients develop cognitive problems. Several genes 
have been identified that can cause both FTD and ALS, including the chromo-
some 9 open reading frame 72 (C9ORF72) gene. A hexanucleotide (G4C2) re-
peat expansion in this gene is the most common genetic cause of FTD and ALS. 
Healthy individuals often carry 2-8 repeats while repeat lengths of 30-4400 are 
linked to FTD and ALS. Patients harboring the mutation in this gene can develop 
symptoms of both FTD and ALS and are collectively referred to as C9FTD/ALS 
patients.
 The pathological mechanism of the repeat expansion is not completely 
understood but could work in three different ways. First of all, the repeat expan-
sion can methylate the C9ORF72 gene causing (partial) loss-of-function of the 
normal C9ORF72 protein. Knock-out mouse models of C9orf72 display immune 
system problems but no FTD or ALS symptoms, suggesting that reduced levels 
of C9ORF72 protein are not sufficient to cause neurodegeneration. 
 Secondly, RNA molecules containing the G4C2 repeat can form RNA foci 
and bind several RNA-binding proteins in the cell. These proteins can be seques-
tered by G4C2 repeat RNA and might become unable to fulfill their normal function 
in the cell. 
 Thirdly, the G4C2 repeat is translated into dipeptides via a newly identified 
mechanism called repeat-associated non-AUG (RAN) translation. RAN transla-
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tion happens in both sense and antisense direction and produces the following 
dipeptide repeat (DPR) proteins: poly-glycine-alanine (GA), poly-glycine-proline 
(GP), poly-glycine-arginine (GR), poly-proline-alanine (PA) and poly-proline-argi-
nine (PR). These DPRs can form protein aggregates and are found in post-mor-
tem brain sections of C9FTD/ALS patients. 
 Both loss-of-function, RNA gain-of-function and DPR protein gain-of-
function could contribute to the neurodegeneration observed in C9FTD/ALS. The 
aim of this thesis is to study the molecular mechanisms underlying the pathogen-
esis of C9FTD/ALS in order to gain more information for the development of new 
drugs and to facilitate clinical research. 
 First of all, we overexpress poly-GR and poly-PR individually in zebrafish 
embryo’s to investigate their cellular toxicity and mode of action (chapter 2). Both 
arginine-containing poly-GR and poly-PR DPRs evoke abundant apoptosis in the 
brain and abnormal motor neuron morphology in the tail of embryos at 1-4 days 
post fertilization (dpf). Both poly-GR and -PR can bind to several molecules and 
proteins in the cell, which could disrupt basic cellular processes and eventually 
causes cell death. In order to separate primary from secondary effects, we use 
a pharmacological approach. To our surprise, we identify both Trolox (reactive 
oxygen species inhibitor) and ISRIB (integrated stress response inhibitor) to give 
a full rescue of poly-GR and –PR induced cell death, respectively. This highlights 
the role of mitochondrial and oxidative stress and the activation of the integrated 
stress response pathway in the pathogenesis of C9FTD/ALS.
 Besides studying poly-GR and -PR DPRs in a zebrafish model, we inves-
tigated the combination of RNA and DPR toxicity in a mouse model for C9FTD/
ALS. This inducible transgenic mouse model contains 36x pure G4C2 repeats 
with 100bp upstream and downstream human flanking regions (chapter 3). Brain 
specific expression causes the formation of sporadic sense DPRs aggregates 
after six months of induction, but no apparent neurodegeneration. Ubiquitous ex-
pression evokes abundant sense DPRs in multiple organs, leading to weight loss, 
neuromuscular junction disruption, myopathy and a locomotor phenotype within 
the time frame of four weeks. The inducible system in the mouse model allows 
us to study time-windows for treatment. In a pilot study, we show that expression 
of two weeks followed by two weeks wash-out (expression turned off) was not 
enough to reduce muscle dystrophy. Sense DPRs were reduced but not com-
pletely cleared from muscle tissues. This indicates that toxic entities produced in 
the first two weeks of expression continue to excise their effects in the following 
2 weeks.
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 In chapter 4, we shift our focus to human post-mortem brain material of 
C9FTD/ALS cases to further characterize human homologue of yeast UV exci-
sion repair protein Rad23b (HR23B) neuropathology. HR23B presented in neu-
ropils, intranuclear inclusions and cytoplasmic and perinuclear inclusions and 
was predominantly found in cortices (frontal, temporal and motor), spinal cord 
and hippocampal dentate gyrus. HR23B preferentially co-localized with poly-GA-, 
pTDP-43- and p62-positive inclusions in frontal cortex and in hippocampal den-
tate gyrus, the latter showing higher co-localization percentages. HR23B binding 
partners XPC, 20S and ataxin-3, which are involved in nucleotide excision repair 
(NER) and the ubiquitin-proteasome system (UPS), did not show an aberrant 
distribution. Another binding partner of HR23B is NGly1/PNGase, involved in 
ER-associated degradation (ERAD) of misfolded proteins. NGly1/PNGase was 
not expressed in the majority of neurons in C9FTD/ALS brain sections compared 
to non-demented controls. Our results suggest a difference in HR23B aggrega-
tion and co-localization pattern with DPRs, pTDP-43 and p62 between different 
brain areas from C9FTD/ALS cases. Also, we hypothesize that HR23B may play 
a role in C9ORF72 pathogenesis, possibly by aberrant ERAD functioning.
 To date, rapid progression has been made in the development of thera-
peutic interventions for C9FTD/ALS in the preclinical phase. However, biomark-
ers that assess efficacy of treatment response in human clinical studies are much 
needed. We therefore investigated if poly-GR can be used as a reliable fluid 
biomarker for C9FTD/ALS. We show that poly-GR can be specifically detected 
in brain sections and protein isolates from frontal cortex of C9FTD/ALS cases 
using a new monoclonal antibody against poly-GR. Unfortunately, we are unable 
to detect poly-GR in cerebrospinal fluid (CSF) and peripheral blood mononuclear 
cells (PBMCs) of C9FTD/ALS patients and pre-symptomatic C9 mutation carri-
ers. Levels of poly-GR could be below our detection limit of 200pg in our ELISA 
set-up or simply be absent from CSF. More sensitive techniques might be able to 
detect poly-GR or other dipeptides that could be used as biomarkers.
 The final chapter (6) gives a general discussion of our results in the con-
text of the research field. We discuss the contribution of each of the pathological 
mechanism (loss- and gain-of-function) and their downstream effects on normal 
cellular functioning. C9ORF72 protein loss-of-function has been categorized as 
disease modifier in recent publications. At the same time, the effect of RNA con-
taining the G4C2 repeat and RNA foci is variable and needs further investigation. 
Especially arginine-containing DPRs seem to be very toxic in multiple models of 
C9FTD/ALS, which is supported by our data. Important molecular mechanisms 
Appendix
&
189
underlying DPR toxicity seem to converge at the integrated stress response, in-
hibition of translation and nucleocytoplasmic transport defects. DPRs might also 
affect multiple protein degradation systems. 
 Together, the research in this thesis indicates an important role of DPRs 
and supports a gain-of-function in the pathogenesis of C9ORF72. Future re-
search is needed to further disentangle pathological mechanisms in C9FTD/ALS. 
So far, antisense oligonucleotide therapy that targets repeat-containing RNA and 
reduces DPRs has been successful in a mouse model for C9FTD/ALS and is 
currently being set-up in clinical trials. To enable correct implementation of this 
therapy, biomarkers are needed to provide information about disease progres-
sion and treatment response. Many new drugs are under development and we 
hope that C9FTD/ALS patients can be successfully treated in the near future.
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Samenvatting
Frontotemporale dementie (FTD) en amyotrofische laterale sclerosis (ALS) zijn 
twee neurologische ziektes die soms samen voorkomen. FTD wordt veroorzaakt 
door het verlies van hersencellen in de frontale en de temporale kwab van het 
brein. FTD patiënten ontwikkelen gedrags- en persoonlijkheidsveranderingen, zo 
laten ze minder empathie zien en hebben ze minder inzicht in de consequenties 
van eigen handelen. Ook hebben ze moeite met spreken, schrijven en begrijpen 
van taal. FTD komt gemiddeld bij 15 op de 100.000 personen voor. Onder de 
leeftijd van 65 jaar is FTD de meest voorkomende vorm van dementie na de 
ziekte van Alzheimer. FTD word vaak gediagnosticeerd bij personen tussen 50 
en 60 jaar en het ziekteproces kan 20 jaar duren.
 ALS is een neuromusculaire ziekte waarbij de zenuwcellen die de spi-
eren aansturen afsterven. Dit veroorzaakt spierzwakte, welke vaak begint in de 
ledematen en zich daarna verspreidt over het lichaam. Uiteindelijk krijgen ALS 
patiënten problemen met lopen, eten, praten en ademen. ALS is de meest voor-
komende vorm van neuromusculaire ziekte en komt voor bij 5 op de 100.0000 
personen. ALS wordt vaak gediagnosticeerd bij personen tussen de 40 en 60 jaar 
en de ziekte voltrekt zich erg snel, meestal tussen de 1 en 5 jaar.
 Sommige patiënten met FTD krijgen later in het ziekteproces symptom-
en van ALS. Andersom krijgt ongeveer de helft van de ALS patiënten te maken 
met cognitieve achteruitgang. Er zijn meerdere genen bekend die FTD en ALS 
veroorzaken, zoals het chromosoom 9 open reading frame 72 (C9ORF72) gen. 
Gezonde personen hebben in dit C9ORF72 gen 2 a 8 keer de lettervolgorde GG-
GGCC. Bij patiënten met FTD en/of ALS worden wel 30 tot 4000 keer deze letters 
herhaald (GGGGCCGGGGCC etc.). Dit is de meest voorkomende genetische 
oorzaak van FTD en ALS. Personen met deze genetische mutatie kunnen zowel 
symptomen krijgen van FTD als ALS en hebben een erg divers ziekteverloop. 
Deze patiënten worden in het kort C9FTD/ALS patiënten genoemd. 
 Hoe de verlengde GGGGCC herhaling in het C9ORF72 gen kan leiden 
tot de hersenceldood die we in ALS en FTD zien is onbekend. Er zijn drie ver-
schillende theorieën hierover. Volgens de eerste theorie kan de verlengde GGG-
GCC herhaling het C9ORF72 gen uitschakelen met als gevolg (gedeeltelijk) ver-
lies van het C9ORF72 eiwit. Echter bij muis modellen waarin het C9orf72 gen is 
uitgeschakeld komen wel vaak immunologische problemen voor, maar geen FTD 
of ALS. Hieruit kunnen we opmaken dat verminderde C9ORF72 eiwit niveaus op 
zichzelf waarschijnlijk niet genoeg zijn voor het veroorzaken van hersenceldood. 
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 Volgens de tweede theorie kan de verlengde GGGGCC herhaling ook 
problemen veroorzaken op RNA niveau (RNA dient als communicatie tussen 
DNA en eiwit). RNA dat de verlengde GGGGCC herhaling bevat kan ophopen 
waardoor zogenoemde RNA foci worden gevormd. Ook kan de GGGGCC herh-
aling in het RNA binden aan allerlei eiwitten die daardoor hun normale rol in de 
cel niet meer kunnen uitoefenen. 
 Als derde wordt de verlengde GGGGCC herhaling in het RNA vertaald 
in korte eiwitten genaamd dipeptiden (DPRs). Dit gebeurt via een nieuw ontdekt 
mechanisme: repeat-geassocieerde non-AUG (RAN) vertaling. RAN vertaling 
gebeurt zowel in sense als antisense richting (van links naar rechts in het RNA 
en andersom) en produceert de volgende dipeptiden: poly-glycine-alanine (GA), 
poly-glycine-proline (GP), poly-glycine-arginine (GR), poly-proline-alanine (PA) 
en poly-proline-arginine (PR). Deze dipeptiden zijn teruggevonden als eiwitoph-
opingen in het brein van overleden patiënten met C9FTD/ALS. Het is echter nog 
onduidelijk of deze dipeptiden en de ophopingen hiervan schadelijk zijn voor de 
hersencellen. Zowel verlies van het C9ORF72 eiwit (theorie 1), RNA giftigheid 
(theorie 2) en dipeptide giftigheid (theorie 3) kunnen leiden tot de hersenceldood 
welke optreedt bij C9FTD/ALS patiënten. 
 Het doel van het onderzoek in deze thesis is te na te gaan hoe de 
hersenceldood ontstaat om zo nieuwe aangrijppunten te ontdekken voor medicijn 
ontwikkeling en om verder klinisch onderzoek te faciliteren.
 In het eerste deel van het onderzoek (hoofdstuk 2) hebben we ons gericht 
op het poly-GR en poly-PR dipeptide (onderdeel van theorie 3). Deze dipeptiden 
hebben we los van elkaar geïnjecteerd in zebravis embryo’s om zo het effect van 
deze dipeptiden te onderzoeken. Beide dipeptiden veroorzaakten grote hoeveel-
heden celdood in het brein van de zebravis embryo’s. In de staart van 1-4 dagen 
oude zebravis embryo’s zagen we ook een abnormale structuur van de motor 
neuronen. Zowel poly-GR als –PR binden verschillende moleculen en eiwitten 
in de cel en verstoren daarmee verschillende cellulaire processen. Onduideli-
jk is welke van deze verstoorde cellulaire processen de hoofdoorzaak van de 
celdood is. Om hier meer informatie over te verkrijgen hebben we de embryo’s 
behandeld met diverse bekende medicijnen die verschillende processen herstel-
len. Twee medicijnen, Trolox (zuurstofradicalen remmer) en ISRIB (integratieve 
stress reactie remmer), brachten de hoeveelheid celdood terug naar het niveau 
van controle zebravis embryo’s. Dit geeft aan dat stress door zuurstofradicalen 
en de activatie van de integratieve stress reactie een belangrijke rol spelen in de 
hersenceldood die optreedt bij C9FTD/ALS patiënten.
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 Verder hebben we ook de combinatie van RNA en dipeptide giftigheid 
(theorie 2 en 3) onderzocht in een muismodel (hoofdstuk 3). Dit muismodel bevat 
36 keer de verlengde GGGGCC herhaling met 100 letters menselijk DNA aan 
beide kanten van de GGGGCC herhaling. Deze 36 keer verlengde GGGGCC 
herhaling kan aan en uit worden gezet door het zogenaamde Tet-on systeem. 
Dit Tet-on systeem stelt ons in staat de locatie (waar in het lichaam van de muis) 
en de tijdsduur (wanneer in het leven van de muis) van de 36 keer GGGGCC 
herhaling te bepalen. Activatie in alleen het brein van de muis veroorzaakte na 
6 maanden sporadische eiwit ophopingen van sense dipeptiden, maar veroor-
zaakte geen duidelijke hersenceldood. Activatie in het hele lichaam van de muis 
veroorzaakte aanwezigheid van sense dipeptiden in meerdere organen. Binnen 
4 weken na activatie zagen we bij deze muizen gewichtsverlies, verstoring van 
de aanhechting van de zenuw op de spier, spierschade en problemen met lopen. 
Om te kijken of het ziekteproces geremd kon worden hebben we een experiment 
gedaan waarin we de 36 keer GGGGCC herhaling eerst 2 weken aan hebben 
gezet en daarna 2 weken uit hebben gezet. Gevolg: sense dipeptiden waren ver-
minderd maar nog steeds aanwezig in de spieren. Ook was er nog steeds schade 
aan de spieren en schade aan de aanhechting van de zenuw aan de spier. Dit 
geeft aan dat de giftige producten die in de eerste twee weken zijn aangemaakt 
lang aanwezig blijven en dat hun effect in de twee weken daarna nog aantoon-
baar is.
 We leren niet alleen veel over het ziekteproces door het gebruik van 
diermodellen maar ook door het bestuderen van brein materiaal van overleden 
C9FTD/ALS patiënten. In hoofdstuk 4 brengen we afwijkingen in kaart van het 
eiwit HR23B in brein materiaal van overleden C9FTD/ALS patiënten. HR23B kan 
gaan ophopen en deze eiwit ophopingen bevinden zich vooral in de frontale, tem-
porale en motor kwab van het brein van C9FTD/ALS patiënten. HR23B ophopin-
gen bevatten ook vaak andere ziektekenmerken van C9FTD/ALS patiënten zoals 
het ophopen van de eiwitten p62, pTDP-43 en poly-GA. Overlap tussen HR23B 
en deze andere kenmerken kwam voor in de frontale kwab maar vaker nog in de 
hippocampus. Waarom dit patroon verschilt tussen hersengebieden is onbekend 
maar kan wellicht informatie verschaffen over verschillen in ziektemechanismen 
tussen hersengebieden. 
 Het HR23B eiwit heeft twee positieve functies: hij repareert DNA schade 
(via nucleotide excisie herstel; NER) en breekt eiwitten af (via het ubiquitine-pro-
teasoom systeem; UPS). HR23B kan aan verschillende andere eiwitten binden 
zoals XPC, 20S en ataxin-3 (bindingspartners). Uit ons onderzoek blijkt dat deze 
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eiwitten XPC, 20S en ataxin-3 op hun normale locatie in de cel blijven en niet 
ophopen zoals HR23B zelf. Een vierde bindingspartner van HR23B is NGly1/
PNGase, welke ervoor zorgt dat verkeerd gevouwen eiwitten worden afgebroken 
(via ER-geassocieerde afbraak; ERAD). In hersencellen van C9FTD/ALS pa-
tiënten kwam minder vaak NGly1/PNGase voor dan in hersencellen van controle 
personen. Dit zou kunnen betekenen dat het ophopen van het HR23B eiwit kan 
leiden tot verminderde functie van het ERAD proces in het brein van C9FTD/ALS 
patiënten.
 Op dit moment worden er nieuwe therapieën ontwikkeld voor C9FTD/
ALS patiënten. De doelgerichtheid en efficiëntie van deze nieuwe behandelin-
gen zijn niet altijd goed te meten. Hiervoor hebben we nieuwe biomarkers (in-
dicatoren over het ziekteproces) nodig. We hebben onderzocht of het poly-GR 
dipeptide te gebruiken is als biomarker voor C9ALS/FTD patiënten (hoofdstuk 
5). We hebben de aanwezigheid van het poly-GR dipeptide aangetoond en de 
hoeveelheid gemeten in de frontale kwab van het brein van overleden C9FTD/
ALS patiënten. In hersenvocht en bloedcellen van levende C9FTD/ALS patiënten 
kunnen wij op dit moment het poly-GR dipeptide niet detecteren. Het is mogelijk 
dat het poly-GR dipeptide hierin niet aanwezig is, of dat onze (ELISA) techniek 
om het poly-GR dipeptide op te sporen niet gevoelig genoeg is. We hopen dat 
gevoeligere technieken in de toekomst poly-GR wel kunnen detecteren, zodat 
dit extra informatie kan verschaffen over het verloop van het ziekteproces en de 
effectiviteit van behandelingen voor C9FTD/ALS patiënten.
 Samengevat bevat het onderzoek in deze thesis nieuwe informatie over 
pathologische mechanismen die C9FTD/ALS kunnen veroorzaken. Onze resul-
taten ondersteunen vooral de giftigheid van de dipeptiden (theorie 3). Meer on-
derzoek is nodig om de gezamenlijke effecten van verlies van het C9ORF72 eiwit 
(theorie 1) en RNA en dipeptide giftigheid (theorie 2 en 3) te bepalen. Meerdere 
nieuwe therapieën zijn momenteel in ontwikkeling en we hopen dat in de toe-
komst patiënten met FTD en/of ALS succesvol behandeld kunnen worden.
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Jaaaaaaaaaaa! Het gaat eindelijk gebeuren! Ik ga nu echt promoveren! Dat had 
natuurlijk nooit gekund zonder de hulp van een aantal mensen die ik hierbij graag 
wil bedanken.
 Als eerste mijn promotoren en co-promotor. Beste Rob, bedankt voor 
het vertrouwen dat je in mij hebt gehad. Toen ik halverwege mijn PhD op het 
punt stond om op te geven heb je van alles geregeld zodat ik toch kon en wilde 
blijven. Daaruit sprak veel vertrouwen en dat heb ik erg gewaardeerd. Het leukste 
moment van de afgelopen jaren was wat mij betreft het conferentie diner in het 
aquarium in Vancouver. Tijdens het diner heb ik de bewaker overgehaald om ons 
naar de beluga’s te laten kijken. Je laat je eigenlijk nooit gek maken door mijn 
ideeën of ongeduld, maar die keer stond je toch wel perplex dat ik dat voor elkaar 
had gekregen. Ook aan de leuke etentjes bij jullie huisje op de Veluwe heb ik 
goede herinneringen. Beste John, bedankt voor je advies bij alle humane studies 
en het beschikbaar stellen van de biobank. Ik kan me meerdere leuke etentjes op 
congressen en een kerstborrel bij je thuis herinneren. Aan het einde van elk jaar 
kreeg ik ook een mooi flesje wijn, bedankt! Renate, het was niet altijd makkelijk 
om met je samen te werken, maar ik heb er veel van geleerd. Bedankt voor de 
vele leuke discussies over o.a. RAN translatie, het begeleiden van studenten en 
meer vrouwen in de wetenschap!
  Ik wil ook graag de rest van de commissie bedanken. Peter Heu-
tink, mijn allereerste stage liep ik op jouw lab. Je hebt me geadviseerd om func-
tioneel werk te gaan doen en dat is me zeer goed bevallen! Bedankt ook dat ik 
halverwege mijn PhD bij je terecht kon voor advies. Rick Wansink, bedankt voor 
de leuke RNA meetings en discussies die we hebben gevoerd over repeats en 
AONs. Max Kros, bedankt voor je tips voor mijn wetenschappelijke carrière, ik 
hoop dat mij ook een mooi avontuur in het buitenland te wachten staat! Robert 
Hofstra, bedankt voor je interesse in mijn onderzoek en je steun tijdens mijn PhD.
 De meeste hulp de afgelopen jaren kreeg ik van mijn twee paranimfen. 
Rob en Esmay, zonder jullie harde werk had dit boekje er niet zo mooi uitgezien. 
Rob bedankt voor je tomeloze inzet en enthousiasme. Je was altijd nog gemo-
tiveerder dan ikzelf als we iets nieuws wilden proberen en je kunt eindeloos door-
gaan met perfectioneren. Esmay, bedankt voor al je hulp met de muizenstudie. 
De cover is mede voor en van jou, de mooiste kleuring van de afgelopen jaren :). 
Ook buiten het lab zijn jullie mijn vrienden geworden. Het is altijd lachen met jullie 
en ik zal onze vakantie naar Bergamo nooit vergeten!
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 Naast mijn twee paranimfen wil ik natuurlijk ook de rest van de FXS-
FTD-FXTAS groep bedanken. Ronald, ik heb super veel van je geleerd in de 
eerste paar jaar van mijn PhD. Bedankt dat je me overal bij hebt betrokken, ook 
bij alle sociale activiteiten. Ik zal je grappen en grollen op het lab nooit vergeten, 
evenals de inmiddels legendarische quote: “Ik kan niet veel, maar DNA isoleren 
dát kan ik”. Lieve Shimriet en Helen, het duurde niet lang voordat ik ook buiten 
het lab met jullie begon af te spreken. Na meerdere avonden gevuld met etentjes 
kan ik jullie niet meer wegdenken uit mijn vriendengroep. Shimriet, het was mooi 
om jouw paranimf te mogen zijn. Twee dagen na mijn eigen bruiloft, het was met 
recht een echte feestweek! Helen, laten we snel weer eens samen een dagje 
sauna doen! Lies-Anne en Shami, ook jullie zijn onmisbaar. Lies-Anne, je bent 
werkelijk het geheugen van het lab en ik kon altijd bij je terecht met al mijn vra-
gen over kleuringen en antilichamen. Shami je was mijn eerste student en bent 
sindsdien op het lab gebleven als analist. Je doet het super goed en ik ben nog 
steeds trots op je! Je legt snel contact met mensen en bent mijn informatiebron 
over alles van de neurologie afdeling. Saif, ook met jou was het meteen gezellig 
op het lab, tijdens de MGC workshops en op WIDM avondjes. Ik hoop dat je va-
naf nu in rustiger vaarwater komt en je kan genieten van je laatste paar jaar op 
het lab, net zoals ik heb gedaan.
 De afgelopen jaren heb ik maar liefst 10 studenten gehad. Mijn eerste 
twee studenten waren Shami en Santoesha, die nu allebei op de afdeling werken 
als analist. Shami, ik ga je lach missen. Santoesha, naast je werk heb je ook altijd 
veel inzet getoond voor je familie. Ik hoop dat je nu meer tijd hebt voor jezelf en 
volop kan genieten van de komende periode. Daarna Charlene en Chantal, ook 
al kon Rob jullie niet uit elkaar halen, voor mij zijn jullie allebei bijzonder. Charlene 
bedankt voor alle kleuringen die je hebt gedaan. Op donderdag had je altijd al alle 
taken af voor de hele week. Chantal, bedankt voor de vele FISH op vis experi-
menten. Niels en Feiko, het was erg gezellig met jullie op het lab tijdens de Junior 
Med School. De vortex en magnetische roerbonen waren jullie favoriet, net zoals 
het maken van cappuccino van PBS+. Mijn masterstudenten Wim en Daphne, 
het zebravis hoofdstuk is voor het grootste gedeelte gebaseerd op jullie werk. 
Bedankt voor jullie hulp en ik ben ook super trots dat jullie nu allebei als PhD op 
de afdeling zijn begonnen. Martina, thank you for your happiness and joy in the 
lab. We had some cultural miscommunications at the beginning of your internship 
but in the end we celebrated your graduation together in Bergamo. You are a very 
social person and I wish you all the best with your new job! Als laatste Samantha, 
bedankt voor al je hulp met de celkweek. Je bent een stoere en super lieve meid.
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mensen van de afdeling Klinische Genetica. Als eerste mijn kamergenoten Atze, 
Rajendra, Danny, Roy, Judith, Stefan en Gerben, het was vaak erg gezellig en we 
konden naast werkaangelegenheden ook praten over voetbal, vakanties, politiek 
en nog veel meer. Nynke, Laura K, Katherine, Laura V, Martyna, Demy, Ana, Eva 
en Elena, bedankt voor de leuke uitjes zoals schaatsen, girls-nights en escape 
rooms. Ik kan nog steeds in een deuk liggen als ik het filmpje van Roy terugkijk! 
Alle PhD studenten bedankt voor de gezellige MGC workshops. Atze, Silvia en 
Madeleine, ik vond het super leuk om een MGC workshop met jullie te organ-
iseren! Michelle, Bianca, Rachel en Marianne, bedankt voor alle leuke lunches 
en etentjes. Koffie om 3 uur zit nog steeds in mijn systeem. Tjakko en Herma, 
bedankt voor jullie (gevraagde en ongevraagde) adviezen en de leuke weten-
schappelijke discussies. Alle andere collega’s van de afdeling bedankt voor de 
leuke tijd op het lab, tijdens de borrels en laser-game activiteiten: Erik, Kyra, Na-
tasha, Wojtek, Stijn, Tom, Guido, Esmee, Adriana, Quishi, Soheil, Erwin, William, 
Nathalie, Isa, Maria, Wim M, Monica, Douglas, Pablo, Rodrigo, Mike, Alessandro, 
Fabio, Pim, Joon, Merel, Anita, Vincenzo, Chantal, Jonathan, Mark, Leontien, 
Yuying and Almira. Beste Jeannette, Bep, Rachel, Marike en Marjoleine bedankt 
voor al jullie administratieve hulp; voor het Simonsfonds, het verzenden van vele 
pakketjes en het regelen van allerlei contracten voor mij en mijn studenten. Voor 
iedereen: ik heb me altijd welkom gevoeld op de afdeling, bedankt voor de leuke 
tijd!
 Daarnaast heb ik ook veel contact gehad met mensen buiten onze ei-
gen afdeling, als eerste natuurlijk de Neurologie afdeling. Lieke, Emma, Harro, 
Leonie, Janne, Jessica, Tsz, Jeroen, Laura, Diana, Rebecca, Sophie, Elise en 
Lize. Bedankt voor de gezelligheid tijdens de FTD meetings in Vancouver en 
München. Het was fijn dat ik altijd bij jullie kon komen buurten als ik weer eens 
coupes nodig had. Lieke en Emma bedankt voor jullie hulp bij het uitzoeken van 
alle patiënten gegevens van NHB nummers en CSF samples. En Harro super 
bedankt voor je hulp bij het scoren van de HR23B pathologie! 
 Ook wil ik graag meerdere mensen bedanken voor de goede samenw-
erking. Als eerste Hannes Lans. Toen ik opeens voor je neus stond omdat ik een 
artikel van je had gelezen en met je wilde samenwerken werd ik met open armen 
ontvangen. Bedankt voor je enthousiasme, ik heb veel van je geleerd over DNA 
repair. Wim Vermeulen en Arjen Theil, jullie ook bedankt voor het warme welkom 
en de hulp op het lab. Laurens Bosman, bedankt voor je hulp bij het opzetten 
van de gedragsstudies voor ons muismodel. Jeroen Pasterkamp, Jan Veltink en 
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Eleonora Aronica, bedankt voor het delen van de C9ORF72 ALS coupes en CSF. 
Charlotte Teunissen, Anne Koelewijn en Inge Verberk, bedankt dat jullie meteen 
open stonden voor het idee om de SIMOA techniek te gebruiken voor de po-
ly-GR biomarker studie. Het was leuk om een dagje samen te werken op jullie 
lab op het VUmc. Ik heb ondertussen jullie vriezer vol gestopt met samples en 
ben erg benieuwd naar de resultaten. Ik wil ook graag alle dierverzorgers bedan-
ken voor hun goede zorgen voor de muizen en de vissen. Alex Maas bedankt 
voor het beantwoorden van allerlei vragen over het muizenwerk en de hulp bij 
bestellingen en injecties. Gert-Jan, Gert en Alex van het OIC, bedankt voor de 
hulp met de microscopen. Zonder jullie uitleg had ik nooit zulke mooie plaatjes 
kunnen schieten.
 Lieve vrienden, jullie ook bedankt voor de steun en interesse die jullie 
altijd hebben getoond in mijn werk. Arwen, met jou kan ik altijd over alle leuke en 
lastige dingen van een PhD praten. Ik vond het super leuk om je paranimf te zijn 
en wens je alle succes met je post-doc in Cambridge. Ayla, jouw PhD ging ook 
niet vanzelf. We kunnen daar goed over praten en ik heb het idee dat we elkaar 
daardoor nog beter begrijpen. Ik heb genoten van onze weekendjes weg. Petra, 
Emma, Marit en Renske, bedankt voor alle leuke etentjes, borrels, weekendjes 
Groningen en sauna-uitjes waarbij ik helemaal mezelf kon zijn. Voor alle andere 
vrienden, bedankt voor jullie interesse en gezelligheid afgelopen jaren. Het leven 
draait om zo veel meer dan werk en door jullie kon en kan ik daar nog meer van 
genieten.
 Lieve Joke en Dis, bedankt voor jullie onvoorwaardelijke liefde en steun. 
Jullie hebben mijn liefde voor wetenschap altijd gevoed met vele uitjes naar mu-
sea, het knutselen van mummies en het spelen van ‘Hoe werkt het’ en ‘Meesters 
van Macht’. Als iemand vroeg wat ik later wilde worden was het ‘Ontdekker’. 
Ik heb een fantastische jeugd gehad en ik kan altijd bij jullie terecht als ik me 
onzeker voel over hoe ik dingen moet aanpakken. Bedankt voor jullie steun en 
vertrouwen.
 Lieve Willem, het waren voor ons beiden jaren met ups en downs, met 
lastige momenten in ons werk en het verlies van Vincent. Maar we hebben ook 
veel prachtige momenten beleefd, zoals de mooie reizen die we hebben gemaakt 
en natuurlijk onze bruiloft. We worden samen steeds sterker en hechter. Met jou 
is het leven zo veel leuker en ik kan niet wachten op onze volgende avonturen. Ik 
hou van jou.

